@article {pmid41379427,
year = {2025},
author = {Salamh, P and Dilibe-Daramola, F and Flannery, A and Pollard, C and Rocha, R and Lapidow, A and Wooten, L},
title = {Incidence and characteristics among individuals developing frozen shoulder following COVID-19 vaccine administration: A systematic review.},
journal = {Physiotherapy theory and practice},
volume = {},
number = {},
pages = {1-8},
doi = {10.1080/09593985.2025.2601894},
pmid = {41379427},
issn = {1532-5040},
abstract = {PURPOSE: Perform a systematic review to determine incidence and characteristics of vaccine administration of those developing frozen shoulder (FS) following COVID-19 vaccine administration.

METHODOLOGY: Systematic review of the literature (PROSPERO number CRD42024611140). Inclusion criteria; diagnosis of frozen shoulder, published or available in the English language and onset of frozen shoulder linked to COVID-19 vaccination. Studies were excluded if FS was linked to onset outside of vaccination and if data were not separated. Relevant studies were assessed for inclusion and selected studies were identified from PubMed, EMBASE, EBSCOhost, Cochrane Library, Web of Science and CINAHL databases. The search strategy was developed by a biomedical librarian run on August 4, 2025. Data were extracted from retained studies and underwent quality assessment using The Joanna Briggs Institute Critical Appraisal Checklist.

RESULTS: The search resulted in 1,506 studies and 9 retained for appraisal. A total of 140 individuals were identified among the retained studies with past medical history being reported in 6 of these studies identifying diabetes and hypothyroidism among the most common. Vaccine manufacturer and symptom manifestation data were reported in all retained studies. Incidence could not be determined based on available data.

CONCLUSION: In addition to known risk factors associated with vaccinations, those with comorbidities associated with the etiology of FS may also be predisposed to developing FS following COVID-19 vaccination administration. Clinicians evaluating those with suspected FS should be aware of the link between vaccinations and the development of FS. Additionally, clinicians administering COVID-19 vaccinations and boosters need to be aware of potential risk factors that may predispose individuals to developing FS following as well as possible signs and symptoms to be aware of post-vaccination.},
}

@article {pmid41379362,
year = {2025},
author = {Nazarian, E and Sinnige, JS and Bos, LDJ and Smit, MR},
title = {Advances in bedside imaging: lung ultrasound.},
journal = {Intensive care medicine experimental},
volume = {13},
number = {1},
pages = {126},
pmid = {41379362},
issn = {2197-425X},
abstract = {Lung ultrasound has become an indispensable tool in the management of acute respiratory failure, offering real-time, radiation-free bedside imaging. Its portability, repeatability, and high sensitivity for detecting pulmonary abnormalities have made it particularly valuable in critical care settings, especially during the Coronavirus disease 2019 pandemic. This narrative review explores the evolving role of lung ultrasound, examining both its established clinical applications and recent advances in artificial intelligence and imaging analysis. These developments emphasize the growing importance of lung ultrasound not only as a diagnostic tool but also as a platform for innovation, with artificial intelligence-driven approaches to further enhance its clinical utility.},
}

@article {pmid41379358,
year = {2025},
author = {Gomes, P and de Menêses, AG and Silveira, RCCP and Guerra, ENS and Dos Reis, PED and Ferreira, EB},
title = {Radiation recall dermatitis in cancer patients previously undergoing radiotherapy: a scoping review.},
journal = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
volume = {34},
number = {1},
pages = {26},
pmid = {41379358},
issn = {1433-7339},
mesh = {Humans ; *Radiodermatitis/etiology/epidemiology ; *Neoplasms/radiotherapy/drug therapy ; Antineoplastic Agents/adverse effects/administration & dosage ; Female ; Radiotherapy/adverse effects ; },
abstract = {PURPOSE: To map the evidence related to radiation recall dermatitis (RRD) in cancer patients previously treated with radiotherapy.

METHODS: A scoping review was conducted following the methodology outlined by the JBI Collaboration. The search was performed in PubMed, CINAHL, LILACS, Scopus, Web of Science Core Collection, Cochrane, and grey literature using Google Scholar and ProQuest on January 28, 2025. Studies published in any language and without restrictions on publication year were included.

RESULTS: This review incorporated 210 studies on RRD in cancer patients, with a predominance of case reports and case series (84.7%). Approximately 48% of cases were reported in breast cancer patients. Among these studies, 92 primary articles documented 201 instances of RRD. A significant association was identified with antineoplastic agents (73.6%), predominantly due to chemotherapy, with docetaxel identified as the most frequently reported agent (13.5%). The radiotherapy doses administered ranged from 8 to 65 Grays, and the time intervals between radiotherapy and the onset of the RRD-triggering agent varied widely, from hours to 40 years. This condition can cause symptoms such as erythema, dry and moist desquamation, edema, itching, pain, ulceration, necrosis, and bleeding.

CONCLUSION: RRD is a significant adverse event, particularly among women with breast cancer, most commonly associated with chemotherapy involving docetaxel and doxorubicin. COVID-19 infection and vaccination have also been reported as potential new triggers of RRD. Further research is needed to clarify the underlying mechanisms and to optimize therapeutic strategies for at-risk patients.},
}

Humans
*Radiodermatitis/etiology/epidemiology
*Neoplasms/radiotherapy/drug therapy
Antineoplastic Agents/adverse effects/administration & dosage
Female
Radiotherapy/adverse effects

@article {pmid41379341,
year = {2025},
author = {Mahdizadeh, S and Hamid, KH and Roudsari, MB and Jamil, NY and Alfarttoosi, KH and Taher, SG and Alwan, M and Jawad, M and Mushtaq, H and Soleimani, M and Tabatabaei, SN},
title = {Impact of emerging and re-emerging viral infections on periodontitis progression.},
journal = {Archives of microbiology},
volume = {208},
number = {1},
pages = {59},
pmid = {41379341},
issn = {1432-072X},
mesh = {Humans ; *Periodontitis/virology/microbiology/pathology/immunology ; *COVID-19/complications/virology ; *Virus Diseases/virology/complications ; Disease Progression ; SARS-CoV-2 ; },
abstract = {Periodontitis is a chronic inflammatory disease that progressively destroys the tooth-supporting structures, including the gums, periodontal ligament, and alveolar bone. This destruction is primarily driven not by the bacteria themselves, but by the host's dysregulated immune response to a dysbiotic subgingival biofilm. Bacterial colonization in periodontal disease (PD) triggers both innate and adaptive immune responses. Furthermore, numerous viruses-including human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and herpes simplex virus (HSV)-have been linked to periodontal disorders and contribute to the etiopathogenesis of periodontitis alongside bacteria. Since its emergence in 2020, COVID-19 has posed a significant global health threat. SARS-CoV-2 infection within the periodontium may induce local inflammation, potentially exacerbating PDs. Given that viral replication and persistence in tissues are thought to increase with the severity of inflammation, the presence of these viruses may be linked to the development and progression of periodontitis. The current study is unique in its synthesis of data on a wide spectrum of viruses associated with periodontitis. This includes common viruses (EBV, HCMV, HSV, human papillomavirus (HPV), and human immunodeficiency virus (HIV)), emerging viruses (Chikungunya, Dengue), and novel viruses such as SARS-CoV-2. By providing a comprehensive overview of viral co-infections in periodontitis, this review advocates for the development of new antiviral diagnostic and therapeutic strategies that adopt a broad, virus-centric approach. We conducted a literature search across PubMed, Google Scholar, and Web of Science using keywords and Medical Subject Headings (MeSH) terms such as "viral infection," "periodontitis," and specific virus names.},
}

Humans
*Periodontitis/virology/microbiology/pathology/immunology
*COVID-19/complications/virology
*Virus Diseases/virology/complications
Disease Progression
SARS-CoV-2

@article {pmid41379191,
year = {2025},
author = {La Scaléa, ACR and Uehara, SCDSA},
title = {Pain in Long COVID: A scoping review of clinical characteristics and patterns of manifestation.},
journal = {Revista latino-americana de enfermagem},
volume = {33},
number = {},
pages = {e4777},
doi = {10.1590/1518-8345.7836.4777},
pmid = {41379191},
issn = {1518-8345},
mesh = {Humans ; *COVID-19/complications ; Female ; *Pain/etiology/diagnosis/epidemiology ; Male ; Pain Measurement ; SARS-CoV-2 ; },
abstract = {to map the available scientific evidence on the clinical characteristics and patterns of pain manifestation (location, frequency, duration, intensity, and quality) in individuals with Long COVID. a scoping review of publications from March 2020 to June 2024, indexed across four databases. Study selection was conducted by two independent, blinded reviewers. Data were extracted using a standardized instrument and analyzed descriptively. nineteen studies were included, indicating that pain affects individuals across all age groups, with higher prevalence among women, primarily involving the head, neck, shoulder, lower back, and hip. Pain frequency ranged from daily to monthly episodes, with duration exceeding one year in some cases. Intensity varied from mild to severe, and pain characteristics were diverse, with descriptors including burning, pressure, colicky, and throbbing pain. the clinical characteristics and patterns of pain manifestation in Long COVID are diverse. However, there is a paucity of studies providing detailed analyses of pain features and the influence of individual variables. These findings should guide future research and clinical practice toward a more comprehensive and contextualized assessment of pain in Long COVID.},
}

Humans
*COVID-19/complications
Female
*Pain/etiology/diagnosis/epidemiology
Male
Pain Measurement
SARS-CoV-2

@article {pmid41378159,
year = {2025},
author = {Mahamadou, D and Abdoul-Aziz, AB and Moustapha, LM and Alkassoum, I and Fils, SA and Hamsatou, B and Bachir, G and Abdourahmane, Y and Farouk, M and Lagare, A and Eric, A and Issifou, D and Hassane, N and Habibatou, I and Eholié, SP},
title = {Resurgence of epidemics in Zinder: effect of the decrease in vaccination coverage and the impacts of climate change.},
journal = {IJID regions},
volume = {17},
number = {},
pages = {100781},
pmid = {41378159},
issn = {2772-7076},
abstract = {OBJECTIVES: Several epidemic outbreaks have affected the Zinder region. These include diseases targeted by the expanded immunization program and other emerging diseases. This study aimed to analyze these epidemics.

METHODS: This is documentary research of the epidemics of meningitis, measles, cholera, COVID-19, and diphtheria, which occurred in the Zinder region from 2015 to 2023, as well as their determinants. The data collection is made from the linear list of notifiable diseases of the Regional Directorate of Health and Public Hygiene of Zinder, associated with literature review on the determinants of the appearance of these epidemics.

RESULTS: The number of meningitis cases has gradually increased in Zinder from 2019 to 2024. A total of 5019 cases were registered during these epidemics, with a mortality rate of 6.31%. Five measles epidemics have been recorded since 2015. A total of 13,887 cases were notified during these epidemics, with a mortality rate of 0.30%. Three cholera epidemics occurred: in 2021, in 2022, and in 2024. During these epidemics, 884 cases were recorded, with 24 deaths or a lethality of 2.71%. The COVID-19 epidemic occurred in 2020, with 364 cases, including 17 deaths, i.e. a mortality rate of 4.67%. Since 2022, the region has been facing a diphtheria epidemic. A total of 3310 cases has been reported, with 173 deaths. The causes of these epidemics are multifaceted; they involve the decline in vaccination coverage, migration, insecurity, the COVID-19 pandemic, and climate change.

CONCLUSIONS: The impact of epidemics on the health of the population and the socio-economic development of regions implies a greater mastery of the root causes mentioned in this study.},
}

@article {pmid41378119,
year = {2025},
author = {Shepherd, J and Leake, MC},
title = {Invention, innovation, and commercialisation in British biophysics.},
journal = {Biophysical reviews},
volume = {17},
number = {4},
pages = {1143-1156},
pmid = {41378119},
issn = {1867-2450},
abstract = {British biophysics has a tradition of scientific invention and innovation, resulting in new technologies transforming biological insight, such as rapid DNA sequencing, super-resolution and label-free microscopy, high-throughput and single-molecule bio-sensing, and bio-inspired synthetic materials. Some advances were established through democratised platforms and many have biomedical success, a key example involving the SARS-CoV-2 spike protein during the COVID-19 pandemic. Here, three UK labs made crucial contributions revealing how the spike protein targets human cells and how therapies of vaccines and neutralising nanobodies work, enabled largely through biophysical innovations of cryo-electron microscopy. Here, we discuss leading-edge innovations which resulted from discovery-led British "Physics of Life" research (capturing blends of physical-life sciences research in the UK including biophysics and biological physics) and have matured into wide-reaching sustainable commercial ventures enabling translational impact. We describe the biophysical science which led to these academic spinouts, presenting the scientific questions that were addressed through innovating new techniques and approaches. We consider these examples through the lens of opportunities and challenges for academic biophysics research in partnership with British industry. We highlight how commercial breakthroughs have emerged organically from fundamental research rather than from technology-first approaches but also discuss lessons to learn from past failures. Finally, we propose recommendations concerning future resourcing and structuring of UK biophysics research and the training and support of its researchers to ensure that UK plc punches above its weight in biophysics innovation and a need to educate the policymakers and public that an absence of basic science impoverishes innovation.},
}

@article {pmid41378112,
year = {2025},
author = {Mijangos, LRR and Harding, SE and Darton, NJ},
title = {Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment.},
journal = {Biophysical reviews},
volume = {17},
number = {4},
pages = {1013-1031},
pmid = {41378112},
issn = {1867-2450},
abstract = {The transition of immunotherapy administration from intravenous infusion to subcutaneous (SC) administration of monoclonal antibody formulations for oncology patients has garnered significant interest. SC administration offers multiple benefits, including potential for at-home administration, enhanced patient compliance, reduced hospital congestion, lowered health care costs, and improved sustainability by reducing drug wastage and minimizing environmental impact. However, for many biologics, the shift to SC administration requires the development of high-concentration monoclonal antibody products (HCmAP) due to the need for large dose volumes. Here we explore the impact of the COVID-19 pandemic on immunotherapy administration and the imperative of adopting SC administration. We discuss challenges encountered throughout the manufacturing, shipping, storage, and delivery of HCmAP. A central hurdle identified involves the biophysical instability and the large increase in viscosity of these biologics due to increased antibody concentration. Further complications can arise from "non-ideality" effects through molecular crowding or co-exclusion effects (macromolecules blocking the free movement in solution of other macromolecules) and elevated macromolecular interactions. For reducing the viscosity for a given concentration of antibody, the main excipients reported are salts and amino acids, with Arg-HCl demonstrating particularly improved formulation viscosity in an HCmAP. However, excipients with viscosity-lowering effects can also impact protein stability. The journey to discover suitable excipient strategies remains ongoing, combined with emerging approaches such as molecular engineering and computational techniques, with the ultimate aim of facilitating the successful integration of SC administration for economic savings, environmental sustainability, and social equity.},
}

@article {pmid41377933,
year = {2025},
author = {Yang, B and Liu, J and Li, Y and Liu, X},
title = {mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.},
journal = {Cancer innovation},
volume = {4},
number = {6},
pages = {e70041},
pmid = {41377933},
issn = {2770-9183},
abstract = {The groundbreaking success of messenger RNA (mRNA) vaccines during the COVID-19 pandemic has significantly accelerated their application in oncology. This review comprehensively synthesizes the recent advancements in mRNA cancer vaccine development, emphasizing three critical domains: mechanistic innovations, clinical translation, and ongoing challenges. Technologically, advancements in nucleotide modification, lipid nanoparticle (LNP) delivery systems, and AI-driven neoantigen selection have significantly improved vaccine stability, immunogenicity, and personalization. Clinically, more than 150 trials have demonstrated the synergistic efficacy of mRNA vaccines (e.g., mRNA-4157/V940, BNT122) in combination with immune checkpoint inhibitors (ICIs), particularly in melanoma, with Phase III trials currently underway. Individualized neoantigen vaccines targeting patient-specific mutations have shown unprecedented response rates (> 50% in certain cohorts), while shared-antigen vaccines are progressing for high-incidence cancers. However, several critical challenges remain: (1) overcoming immunosuppressive tumor microenvironments (TME), (2) addressing systemic toxicities and LNP-related limitations, (3) scaling up cost-effective personalized manufacturing, and (4) optimizing targeted delivery. Future research directions encompass self-amplifying mRNA constructs, novel biomaterial vectors, neoadjuvant applications, and multi-omics integration for next-generation vaccine development. With rapid industrialization and evolving regulatory frameworks, mRNA vaccines are well-positioned to revolutionize precision cancer immunotherapy despite persistent translational barriers.},
}

@article {pmid41377469,
year = {2025},
author = {Ali, A and Shariq, K and Ashok Kumar, K and Zakai, A and Mumtaz, K and Ali, Z and Akmal, M and Kailash, SJ},
title = {Analyzing global research trends in hepatology during Coronavirus Disease 2019: a bibliometric analysis.},
journal = {Annals of medicine and surgery (2012)},
volume = {87},
number = {12},
pages = {8376-8384},
pmid = {41377469},
issn = {2049-0801},
abstract = {OBJECTIVE: Analyzing global hepatology trends during Coronavirus Disease 2019 (COVID-19) to accelerate effective treatments and protocols for researchers and healthcare systems.

METHODS: The related papers to COVID-19 and hepatology were extracted from 2019 to 2023. The articles were ranked according to the number of citations and a final list of top 101 most-cited articles were shortlisted. Analysis was carried out on the following: total citation count, publication year, journal name and its Impact factor, gender and their H-index, country of origin, funding information, and content of the articles. Citations per year and citations per author were calculated for all articles.

RESULTS: Between 2019 and 2023, the top 101 cited articles covered various topics. The highest number were published in 2021 (n = 42), with the American Journal of Transplantation contributing the most (n = 23). The University of Pennsylvania had the most influential presence (n = 5). These articles came from 44 countries where the US ranked first with 35 articles. There were a total of 160 authors involved, with each paper having a median and mean of 6 and 7.3 authors, respectively. The articles were categorized into nine main topics, with therapeutic intervention being the most common (n = 26) followed by pathophysiology (n = 20). Males outnumbered females as first and senior authors. A majority (n = 55) received funding, and most (n = 81) did not declare conflicts of interest.

CONCLUSION: Top articles in our analysis focused on liver transplantation, pathophysiology, and healthcare management. It can aid researchers in assessing the effectiveness of different treatment modalities for hepatic impairment in COVID-19 patients.},
}

@article {pmid41377081,
year = {2025},
author = {Lin, L and Talib, MBA},
title = {Exploring the relationship between domain-specific self-efficacy and motivation among university students: a systematic review (2019-2024).},
journal = {Frontiers in psychology},
volume = {16},
number = {},
pages = {1702507},
pmid = {41377081},
issn = {1664-1078},
abstract = {The interplay between domain-specific self-efficacy and motivation in higher education has garnered significant attention, particularly in the context of challenges such as the COVID-19 pandemic that have profoundly altered the educational landscape. This study provides a systematic review of the literature on the relationship between domain-specific self-efficacy and motivation among university students, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. From an initial pool of 5,890 articles sourced from the Education Resources Information Centre (ERIC), Scopus, and Web of Science (WoS) databases, 31 studies published between 2019 and 2024 were analyzed. Our findings underscore a predominantly positive correlation between domain-specific self-efficacy and motivation. Higher levels of self-efficacy are consistently linked to increased motivation, suggesting that enhancing self-efficacy could be a crucial strategy for boosting student motivation and, thus, academic success. Notably, many studies focus on Asian regions, highlighting both the universality and cultural specificity of these findings. However, the presence of an outlier study that found no significant relationship between self-efficacy and motivation indicates the complexity of these constructs and the potential impact of situational factors, warranting further investigation. Additionally, this review reveals a growing academic interest in self-efficacy and motivation, particularly within social sciences and education. This trend underscores the importance of a multidisciplinary approach to understanding the intricate dynamics between self-efficacy and motivation. The documented rise in research attention reflects a growing recognition of the critical role that self-efficacy and motivation play in student learning outcomes. In conclusion, this systematic review not only highlights the significant positive impact of domain-specific self-efficacy on student motivation but also calls for more nuanced studies. Future research should explore under-represented contexts and examine the broader implications of these findings across diverse educational and cultural settings.},
}

@article {pmid41376972,
year = {2025},
author = {Soto-Feijóo, R and Landín, E and Martínez-Martínez, H and Carreiras, M and Fanego, A and Ferreiro, L and Rodríguez-Núñez, N and Toubes, ME and Valdés, L},
title = {Analyzing pleural fluid attributes in SARS-CoV-2 infection: a systematic review.},
journal = {Journal of thoracic disease},
volume = {17},
number = {11},
pages = {10510-10518},
pmid = {41376972},
issn = {2072-1439},
abstract = {BACKGROUND: The characteristics of pleural fluid (PF) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are poorly understood. During the pandemic, several cases of pleural effusion (PE) have been reported, but no clear conclusions have been reached regarding the features of this fluid. This systematic review aimed to analyze and summarize the available evidence on PF attributes in patients with SARS-CoV-2 infection.

METHODS: Systematic literature search using the PRISMA methodology of studies describing PF characteristics of SARS-CoV-2 patients and treatment of PE.

RESULTS: Eighteen articles (32 patients and 37 PF samples) were included. Median age was 61 years (range, 25-81 years), male/female ratio 5.4:1. PE was predominantly unilateral (71.4%), with no distinction between one side and the other; it usually extended over 2/3 of the hemithorax (50%) and its appearance was variable [serous (50%), hematic or serohematic (28.1%) and purulent (21.9%)]. PF was exudative in 88.9% of cases, but with PF protein and PF/serum protein ratio values less than 3 g/dL and 0.5 in 36.7% and 54.5%, respectively. The pH and glucose values were less than 7.20 and 60 mg/dL in 28.6% and 24% of cases, respectively. The percentage of neutrophils (≥50%) was higher than that of lymphocytes/monocytes [12/26 (46.2%) vs. 7/26 (26.9%), respectively]. Polymerase chain reaction (PCR) on PF was positive for SARS-CoV-2 in 6/23 cases (26.1%) and for other pathogens in 8 (5 bacteria and 3 fungi). Almost all patients underwent thoracentesis and the medical treatment received by the cases with positive PCR for SARS-CoV-2 on PF varied. Patient follow-up was provided in 25 cases and 10 cases died (40%).

CONCLUSIONS: PE from coronavirus disease 2019 (COVID-19) infection is more frequent among males aged 50-80 years, generally unilateral and large. Its appearance is variable, with features of lactate dehydrogenase (LDH)-discordant exudate, usually predominantly neutrophilic, with treatment like that of any other PE. PE from COVID-19 infection is a poor prognostic sign and associated with worse mortality.},
}

@article {pmid41376141,
year = {2025},
author = {Sucu, R and Erku, D and Filiniuk, O and Kohler, R},
title = {Establishing an independent HTA agency in Ukraine: a conceptual framework for governance, operations, and long-term sustainability.},
journal = {International journal of technology assessment in health care},
volume = {41},
number = {1},
pages = {e85},
doi = {10.1017/S0266462325103255},
pmid = {41376141},
issn = {1471-6348},
support = {AID-121-C-17-00004//United States Agency for International Development/ ; },
mesh = {Ukraine ; *Technology Assessment, Biomedical/organization & administration/legislation & jurisprudence ; Humans ; COVID-19/epidemiology ; SARS-CoV-2 ; Health Policy ; },
abstract = {OBJECTIVES: Health technology assessment (HTA) has become an integral part of Ukraine's health system since its formal introduction into national legislation in 2017. By 2020, HTA was mandated for evaluating publicly funded medicines, laying the groundwork for more evidence-based healthcare decisions. Although the creation of an independent HTA agency was initially planned for 2022, implementation was delayed due to the COVID-19 pandemic and Russia's ongoing invasion. The relevant Cabinet Resolution calls for the establishment of an autonomous agency by January 2026. This commentary outlines a strategic, evidence-informed framework to guide the agency's formation.

METHODS: Drawing on the 2018 State Strategy for Access to Medicines, the 2022 Law on Medicinal Products, and international best practices, we proposed to the Government of Ukraine a two-tier structure encompassing core business functions (HTA and appraisal, guideline development, pricing, and listing) and support business functions (data and analytics, finance and strategy, IT, human resources, legal, and communications). Each department is tasked with clear mandates and supported by performance indicators to promote transparency, accountability, and operational efficiency.

RESULTS: A phased roadmap for 2025-2027 details the legal, institutional, and financial steps required for successful implementation. Key opportunities - including international partnerships and system-wide reform - are weighed alongside risks such as funding uncertainty, workforce limitations, and geopolitical instability.

CONCLUSION: By embedding HTA into national policy processes and ensuring institutional independence, Ukraine can enhance the value of healthcare investments and build long-term resilience into its health system.},
}

Ukraine
*Technology Assessment, Biomedical/organization & administration/legislation & jurisprudence
Humans
COVID-19/epidemiology
SARS-CoV-2
Health Policy

@article {pmid41375836,
year = {2025},
author = {Stratulat-Chiriac, I and Țarcă, E and Chistol, RO and Halip, IA and Țarcă, V and Furnică, C},
title = {Association Between Congenital Gastrointestinal Malformation Outcome and Largely Asymptomatic SARS-CoV-2 Infection in Pediatric Patients-A Systematic Review.},
journal = {Journal of clinical medicine},
volume = {14},
number = {23},
pages = {},
doi = {10.3390/jcm14238533},
pmid = {41375836},
issn = {2077-0383},
abstract = {Objective. Limited evidence is available concerning the surgical outcomes of patients with congenital gastrointestinal malformations and perioperative SARS-CoV-2 infection. This study examines the scientific evidence on SARS-CoV-2 infection and congenital gastrointestinal malformations requiring surgery in children. Material and Methods. We performed a systematic review of studies reporting data on children with congenital gastrointestinal malformations and SARS-CoV-2 infection, published in international databases (PubMed and Embase) from pandemic inception up to August 2024. Studies not reporting data on the SARS-CoV-2 infection status on patients with congenital digestive malformation were excluded. We assessed the quality of the included studies according to the Joanna Institute (JBI) appraisal checklist, adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, and registered the protocol with the PROSPERO database (CRD42024550744). Results. From the 902 titles retrieved, eight observational studies met the inclusion criteria comprising 29 patients from countries with different socioeconomic statuses. Most patients were neonates (75%) with a median age of 3 days at diagnosis and male to female ratio of 2:1. In total, 18 (62%) presented upper gastrointestinal tract anomalies, including esophageal atresia ± tracheoesophageal fistula (n = 10, 34.48%), duodenal atresia (n = 3, 10.3%), and congenital hypertrophic pyloric stenosis (n = 5, 17.2%). Lower digestive tract malformations (11, 38%) included anorectal malformations (n = 6, 20.6%), intestinal atresia (n = 3, 10.3%), Hirschsprung disease (n = 1, 3.44%), and Meckel's diverticulum (n = 1, 3.44%). Surgeries were primarily emergency or urgent procedures and only pyloromyotomy (5/5) was consistently operated minimally invasively. SARS-CoV-2 infection was identified mainly on routine screening (>95%). Of 29 patients, 85% were discharged home, and no postoperative surgical mortality and significant complications directly associated with COVID-19 were identified, although routine postoperative morbidity not linked to SARS-CoV-2 was observed. Conclusions. Pediatric patients with congenital gastrointestinal malformationsand perioperative SARS-CoV-2 infection typically have mild illness and favorable surgical outcomes. SARS-CoV-2 positivity alone should not delay essential surgery when infection control measures are ensured. Standardized, multicenter studies are needed to clarify perioperative risks to and inform management of this high-risk group.},
}

@article {pmid41375650,
year = {2025},
author = {Watts, P and Deac, A and Netuveli, G},
title = {An Umbrella Review of Quality of Life Among the General Population During the COVID-19 Pandemic.},
journal = {Journal of clinical medicine},
volume = {14},
number = {23},
pages = {},
doi = {10.3390/jcm14238348},
pmid = {41375650},
issn = {2077-0383},
abstract = {Background/Objectives: The COVID-19 pandemic has had widespread effects on quality of life (QoL). This umbrella review aimed to synthesise review-level evidence on the impact of the COVID-19 pandemic on QoL across the general population, including children, adolescents, adults, and older people. Methods: A systematic search of databases (MEDLINE (PubMed); EBSCOHost; Scopus; Google Scholar) and review repositories was conducted to identify systematic reviews, meta-analyses, and scoping reviews published between 2019 and 2025. Eligible reviews (2019-2025, English, peer-reviewed) included narrative, systematic and meta-analytic syntheses of quantitative, qualitative or mixed-methods evidence examining the impact of the COVID-19 pandemic on quality of life in the general population, using validated QoL measures. The review followed Joanna Briggs Institute methodology for umbrella reviews, with data synthesised narratively by QoL domain and population group. Results: Nine reviews met the inclusion criteria, encompassing 272 primary studies. Most reported declines in QoL across psychological, physical, and social domains. Children and adolescents experienced reductions in emotional and social functioning. Working-age adults reported psychological strain linked to economic and health-related stressors, while older adults were vulnerable to isolation and reduced social QoL. Environmental and structural factors also influenced QoL. Sociodemographic disparities were observed, with lower QoL reported among women, younger individuals, and those with lower socioeconomic status. Conclusions: The COVID-19 pandemic was associated with substantial declines in QoL across population groups, shaped by psychological, social, and structural factors. Findings highlight the importance of addressing social inequalities and enhancing resilience in future public health crises.},
}

@article {pmid41375068,
year = {2025},
author = {Isidoro, C},
title = {SARS-CoV2 and Anti-COVID-19 mRNA Vaccines: Is There a Plausible Mechanistic Link with Cancer?.},
journal = {Cancers},
volume = {17},
number = {23},
pages = {},
doi = {10.3390/cancers17233867},
pmid = {41375068},
issn = {2072-6694},
abstract = {To contrast the COVID-19 pandemic brought by the corona virus SARS-CoV-2, two mRNA-based anti-COVID-19 vaccines (by Pfizer-BioNTech and Moderna) were made available relatively quickly and deployed worldwide based on an emergency approval. Being considered vulnerable and at risk of infection, cancer patients have been prioritized for COVID-19 vaccination and vaccinated repeatedly because of the short time protection provided by these vaccines. Recently, a surge in the incidence and rapid progression of cancers has been observed in many countries, which could (at least partially) represent cancers undiagnosed or untreated during the pandemic. It has also been suggested that the SARS-CoV-2 itself or even the anti-COVID-19 mRNA vaccines could have contributed to the recurrence and worse clinical outcome in cancer patients, given the high incidence of COVID-19 in hospitalized patients and that these patients have been vaccinated with priority several times and in a short period. Although it appears extremely unlikely that SARS-CoV-2 and anti-COVID-19 mRNA vaccines elicit genotoxic events and cause neo-cancerogenesis in a short time, they could still cause non-genotoxic pro-carcinogenic effects by triggering an exaggerated inflammatory reaction, compromising immune homeostasis, stimulating cell proliferation, and negatively affecting cellular stress response and damage repair machinery. This could result in the promotion of regrowth of dormant micrometastases or relapses of stable minimal residual disease. Such a harmful outcome may likely result from a synergy between the virus and the vaccine, especially in multi-vaccinated and multi-infected individuals. Here, I bring the cell pathologist's point of view and discuss the multiple possible mechanisms by which the virus and the anti-COVID-19 mRNA vaccine might favor tumorigenesis. While a causal link cannot be established at this stage, knowledge of potential carcinogenic risks could help doctors and health policymakers take the best actions to protect vulnerable patients and convince the vaccine developer to design a vaccine free from such harm.},
}

@article {pmid41374027,
year = {2025},
author = {Koliou, MP and Skalkos, D},
title = {Post-Pandemic Shifts in Sustainable Food Behavior: A Systematic Review of Emerging Consumer Trends.},
journal = {Nutrients},
volume = {17},
number = {23},
pages = {},
doi = {10.3390/nu17233737},
pmid = {41374027},
issn = {2072-6643},
mesh = {Humans ; *COVID-19/psychology/epidemiology ; *Feeding Behavior/psychology ; *Consumer Behavior ; *Food Preferences/psychology ; SARS-CoV-2 ; Pandemics ; Hunger ; Female ; Emotions ; Male ; },
abstract = {The COVID-19 pandemic and its associated economic stressors have profoundly reshaped consumer eating behaviors, presenting an urgent and underexplored challenge for the academic community. This interdisciplinary review critically examines how these disruptions have influenced both food approach and food avoidance patterns, offering a structured analysis of eight key behavioral parameters: Hunger (H), Food Responsiveness (FR), Emotional Overeating (EOE), Enjoyment of Food (EF), Satiety Responsiveness (SR), Emotional Under Eating (EUE), Food Fussiness (FF), and Slowness in Eating (SE). Drawing on recent literature, we highlight significant shifts in these traits-such as heightened hedonic hunger, age-related changes in food preferences, and gender-specific emotional-satiety dynamics-underscoring the complex interplay between emotional states, physiological cues, and behavioral tendencies. Grounded in the systematic examination of peer-reviewed studies in the post-COVID period, this review offers a robust and comprehensive synthesis of current evidence. The novelty of this work lies in its integration of findings into targeted proposition statements for each parameter, visually supported by original flow charts. These culminate in the development of a "Consumers' Eating Behavior Index"-a conceptual tool designed to guide researchers, healthcare professionals, and policymakers in understanding and responding to post-pandemic dietary transformations. By emphasizing the emotional and psychological dimensions of eating, this index offers a timely framework for designing tailored public health interventions that promote sustainable nutritional habits. This study calls for renewed academic attention to the behavioral consequences of global crises, positioning eating behavior research as a critical frontier in post-COVID recovery and resilience.},
}

Humans
*COVID-19/psychology/epidemiology
*Feeding Behavior/psychology
*Consumer Behavior
*Food Preferences/psychology
SARS-CoV-2
Pandemics
Hunger
Female
Emotions
Male

@article {pmid41373962,
year = {2025},
author = {Rosanoff, A and von Ehrlich, B and Nelson, D},
title = {A Proposed Scale to Assess Magnesium Status Using Serum Calcium and Magnesium Ratios.},
journal = {Nutrients},
volume = {17},
number = {23},
pages = {},
doi = {10.3390/nu17233671},
pmid = {41373962},
issn = {2072-6643},
mesh = {Humans ; *Magnesium/blood ; *Calcium/blood ; COVID-19/blood/mortality ; Biomarkers/blood ; *Magnesium Deficiency/blood/diagnosis ; SARS-CoV-2 ; Adult ; Female ; Male ; Middle Aged ; },
abstract = {Background/Objectives: Reliable markers of human magnesium (Mg) status are needed. Methods: Current Mg studies report ratios between serum Mg and calcium (Ca) using four interchangeable expressions (i.e., molar or weight calculations of Mg/Ca or Ca/Mg). We propose a scale using ratios of serum Mg and Ca to assess Mg status, unified for all four expressions. We explore its application for case studies and published research. Results:Case Studies (4)-the proposed serum Mg/Ca scale showed better Mg diagnostic value than serum Mg alone. Published Studies-A. The proposed Mg/Ca scale's "depleted Mg" status predicted mortality among hospitalized COVID-19 patients in ROC/AUC analyses. B. The serum Ca/Mg proposed scale, when applied to "healthy" adults with "normal" serum Mg, exposed a "seriously depleted" to "adequate" range of Mg status. C. In a study of periodontal disease, patients designated "adequate" or "mild" Mg depletion by the proposed scale showed greater 5-year improvement than those with scale's "moderate to serious" Mg depletion status. D. Finally, the proposed scale demonstrated appropriate diagnostic value of serum Ca/Mg in acute coronary syndrome patients only when "corrected Ca" was NOT used in ratio calculation. Conclusions: The proposed scale needs both total serum Ca and Mg measures in identical units, i.e., mg/dL or mg% (for weight ratios); mmol/L or mEq/L (for molar ratios). Authors/reviewers/editors need to take care when reporting units/methodology of serum Mg and Ca ratios for clear reporting as to weight or molar ratio and use of total or corrected values. Future trials and statistical testing are needed to determine whether ratios between serum Mg and Ca yield more precise measures of physiological Mg status than serum Mg alone. Our findings indicate the proposed scale is worthy of further study as a marker of Mg deficit.},
}

Humans
*Magnesium/blood
*Calcium/blood
COVID-19/blood/mortality
Biomarkers/blood
*Magnesium Deficiency/blood/diagnosis
SARS-CoV-2
Adult
Female
Male
Middle Aged

@article {pmid41373540,
year = {2025},
author = {Popa, AE and Popa, E and Dramba, T and Coman, EA and Poroch, M and Ungureanu, M and Bacusca, A and Slanina, AM and Bacoanu, G and Poroch, V},
title = {Dysregulated Resolution of Inflammation After Respiratory Viral Infections: Molecular Pathways Linking Neuroinflammation to Post-Viral Neuropathic Pain-A Narrative Review.},
journal = {International journal of molecular sciences},
volume = {26},
number = {23},
pages = {},
doi = {10.3390/ijms262311383},
pmid = {41373540},
issn = {1422-0067},
mesh = {Humans ; *Neuroinflammatory Diseases/immunology/etiology/metabolism/pathology ; *Neuralgia/immunology/etiology/virology ; *COVID-19/complications/immunology ; Animals ; *Inflammation ; SARS-CoV-2 ; Microglia/immunology/metabolism ; Mitochondria/metabolism ; Signal Transduction ; Macrophages/immunology/metabolism ; Immunity, Innate ; *Respiratory Tract Infections/complications/immunology ; },
abstract = {Post-viral neuroinflammatory syndromes, particularly those occurring after SARS-CoV-2 infection, have received increasing attention due to their complex and persistent neurological manifestations. The aim of this narrative review is to integrate current evidence on the molecular and cellular mechanisms underlying chronic neuroinflammation following viral infections, with a focus on dysregulated innate immune responses, macrophage-microglia interactions, oxidative-mitochondrial stress, and impaired inflammation resolution pathways. Our synthesis shows that prolonged activation of macrophages and glial cells promotes the continuous release of pro-inflammatory mediators, while defective phagocytosis and inadequate clearance of cellular debris maintain an inflammatory microenvironment. Mitochondrial dysfunction further amplifies immune activation by stimulating metabolic stress and reactive oxygen species production. In parallel, deficiencies in mediators specialized in inflammation resolution impede the transition from inflammation to resolution, allowing neuroimmune imbalance and nociceptive sensitization to persist long after virus clearance. Key conclusions indicate that these interconnected mechanisms collectively contribute to the long-term neurological symptoms observed in post-viral states, including cognitive impairment, neuropathic pain, and fatigue. Emerging therapeutic strategies targeting cytokine signaling, microglial reactivity, mitochondrial function, and resolution pathways are promising, but remain insufficiently validated in clinical practice. Overall, evidence suggests that post-viral neuroinflammation results from the convergence of sustained immune activation and failure of endogenous resolution mechanisms, highlighting the need for further mechanistic studies and targeted interventions.},
}

Humans
*Neuroinflammatory Diseases/immunology/etiology/metabolism/pathology
*Neuralgia/immunology/etiology/virology
*COVID-19/complications/immunology
Animals
*Inflammation
SARS-CoV-2
Microglia/immunology/metabolism
Mitochondria/metabolism
Signal Transduction
Macrophages/immunology/metabolism
Immunity, Innate
*Respiratory Tract Infections/complications/immunology

@article {pmid41373500,
year = {2025},
author = {Leonardi, R and Lo Bianco, M and Spinello, S and Betta, P and Gagliano, C and Calabrese, V and Polizzi, A and Malaguarnera, G},
title = {Resveratrol as an Adjunct Antiviral Agent in Pediatric Viral Infections: A Review on Mechanistic Insights and Gut Microbiota Modulation.},
journal = {International journal of molecular sciences},
volume = {26},
number = {23},
pages = {},
doi = {10.3390/ijms262311341},
pmid = {41373500},
issn = {1422-0067},
mesh = {Humans ; *Resveratrol/therapeutic use/pharmacology ; *Gastrointestinal Microbiome/drug effects ; *Antiviral Agents/therapeutic use/pharmacology ; Child ; *Virus Diseases/drug therapy/microbiology ; SARS-CoV-2/drug effects ; Dysbiosis/drug therapy ; COVID-19 ; Rotavirus/drug effects ; },
abstract = {Pediatric viral infections impose a heavy burden on child health, often worsened by infection-induced gut dysbiosis. Resveratrol, a natural polyphenol with antiviral, anti-inflammatory, and microbiota-modulating properties, has been proposed to interrupt this pathogenic feedback. To our knowledge, this is the first narrative review focused on resveratrol's antiviral activity in pediatric viral infections, concurrently evaluating its impact on the gut microbiota and their interrelationship. We synthetized preclinical and the limited available pediatric clinical data regarding resveratrol's effect on SARS-CoV-2, respiratory syncytial virus, influenza, rotavirus, and norovirus, extracting information on the models, routes of administration, dosages, mechanisms, and outcomes. Resveratrol interferes with viral lifecycles via diverse mechanisms (modulation of host signaling cascades, capsid or structural protein interactions, and suppression of pro-viral chaperones) while concurrently reshaping the gut microbiota (reducing opportunistic taxa and enriching beneficial genera such as Bifidobacterium and Lactobacillus) leading to improved short-chain fatty acid profiles, barrier integrity, and dampened inflammation. Intranasal resveratrol in children shows clinical benefit, while oral use is underexplored and limited by poor bioavailability; adult data hint at supportive microbiome and anti-inflammatory effects if the delivery is optimized. These dual antiviral and microbiome-directed effects position resveratrol as a promising adjunct in pediatric viral disease management, though well-powered pediatric clinical trials are needed to define dosages, delivery strategies, and the contribution of microbiota-mediated synergy.},
}

Humans
*Resveratrol/therapeutic use/pharmacology
*Gastrointestinal Microbiome/drug effects
*Antiviral Agents/therapeutic use/pharmacology
Child
*Virus Diseases/drug therapy/microbiology
SARS-CoV-2/drug effects
Dysbiosis/drug therapy
COVID-19
Rotavirus/drug effects

@article {pmid41373396,
year = {2025},
author = {Shiel, EV and Connor, Z and Downes, M and Bailey-Shaw, A and Hemingway, S and Walters, C and Kola-Palmer, S},
title = {What Evidence Exists on the Effectiveness of Psychotherapy for Trauma-Related Distress? A Scoping Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233180},
pmid = {41373396},
issn = {2227-9032},
abstract = {Background/Objectives: Trauma-related distress poses significant mental health challenges, with psychotherapy serving as a primary intervention. The Walters Method is a promising new alternative that may help where traditional methods fall short (i.e., in complex or violent cases), but before it can be implemented widely, the existing evidence on the effectiveness of other psychotherapies for trauma-related distress must be mapped to see how and where it relates to other techniques. The aim of this scoping review was to provide an overview of existing evidence on the effectiveness of psychotherapy for trauma-related distress. Methods: A scoping review was conducted to better understand the effectiveness of psychotherapies for trauma-related distress (including PTSD, acute stress disorder, or other serious mental health issues). Results: Thirty-three articles were analysed. Included articles included adults with PTSD, incarcerated women, childbirth trauma survivors, female survivors of sexual abuse, hospitalised COVID-19 patients, adults with serious mental illness, veterans and active soldiers, firefighters, and refugees. Eye Movement Desensitisation and Reprocessing and Cognitive Behavioural Therapy were the most studied and effective treatments. Prolonged Exposure and Narrative Exposure Therapy were less common but noteworthy. Other therapies, including psychodynamic approaches, are seldom studied but have proven effective when explored, highlighting knowledge gaps and potential missed opportunities. Success with these alternative approaches-especially in complex trauma cases like intimate partner violence or child loss where EMDR and CBT may be less effective-suggests they have potential, but further research is needed for validation. Conclusions: This review offers novel contributions to the field by emphasising innovative therapeutic perspectives that extend beyond traditional, more studied, evidence-based approaches such as CBT and EMDR, thereby expanding treatment options for diverse clinical presentations. Alternative therapies show promise, particularly for complex trauma cases like intimate partner violence or child loss where established approaches may be less effective; however, further research is needed to validate their efficacy across diverse populations. Selection of psychotherapy should be based on clients' goals and comfort, and the cultural and contextual compatibility between the person and intervention. Future research should prioritise underexplored therapies to address current knowledge gaps and improve treatment accessibility for varied clinical needs.},
}

@article {pmid41373324,
year = {2025},
author = {Haimi, M and Inchi, L},
title = {Bridging Distance, Delivering Care: Pediatric Tele-Nutrition in the Digital Health Era-A Narrative Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233107},
pmid = {41373324},
issn = {2227-9032},
abstract = {BACKGROUND: The emergence of telehealth has transformed healthcare delivery across multiple disciplines, with tele-nutrition representing a rapidly evolving field that addresses nutritional assessment, counseling, and management through digital platforms.

OBJECTIVE: This narrative review examines the current landscape of pediatric tele-nutrition services, exploring technological platforms, clinical applications, evidence for effectiveness, implementation considerations, and future directions.

METHODS: A comprehensive literature search was conducted across PubMed, CINAHL, Embase, and Web of Science databases from January 2010 to October 2025. A total of 114 relevant sources were selected, encompassing randomized controlled trials, observational studies, systematic reviews, implementation studies, clinical guidelines, and policy documents.

RESULTS: This review synthesized 114 sources, predominantly from the United States (54%) and European nations (21%), with evidence expansion accelerating post-COVID-19 pandemic. Evidence suggests pediatric tele-nutrition demonstrates clinical outcomes comparable to traditional in-person care across diverse populations including obesity management, diabetes, gastrointestinal disorders, feeding difficulties, metabolic conditions, and preventive nutrition services. Multiple technology platforms are utilized, with synchronous video consultations most common (60-85% of encounters). Benefits include enhanced access to specialized care, increased frequency of contact, reduced family burden, and high satisfaction rates (>80% across most studies). Challenges include limitations in physical assessment, digital equity concerns affecting vulnerable populations, variable reimbursement policies, and the need for provider training. Hybrid models combining virtual and in-person care appear optimal for many conditions.

CONCLUSIONS: Pediatric tele-nutrition represents a viable and effective care delivery model with particular advantages for families facing geographic, logistic, or access barriers. Continued attention to digital equity, provider training, regulatory frameworks, sustainable reimbursement policies, and rigorous evidence generation will optimize implementation and outcomes. Future directions include artificial intelligence applications, precision nutrition approaches, and expanded global health applications.},
}

@article {pmid41373248,
year = {2025},
author = {Alagood, J and Senn, WD and Prybutok, G},
title = {Hybrid Analysis of Videoconference Technology Use by Aging-in-Place Organizations to Promote Social Engagement for Older Adults: A Scoping Review with Latent Topic Modeling.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233031},
pmid = {41373248},
issn = {2227-9032},
abstract = {Background/Objectives: Loneliness and social isolation are common among older adults and linked to adverse health outcomes. Videoconferencing can support social connections, but the role of aging-in-place organizations (AIPOs), such as senior centers and Area Agencies on Aging, in facilitating adoption is poorly understood. This review examined how AIPOs use relational videoconferencing to promote social engagement among older adults. Methods: We applied a hybrid methodology combining a scoping review with latent topic modeling to contextualize and analyze the evidence base. Exploratory searches revealed limited literature specifically addressing AIPO involvement; therefore, we first conducted latent topic modeling of the broader literature on social videoconferencing among older adults to establish a thematic foundation for the subsequent PRISMA-guided scoping review. Thematic analysis of this broader corpus, identified through 2021 database searches, applied Latent Dirichlet Allocation (LDA) to a collection of peer-reviewed articles. Subsequent refinement of this corpus by removing non-primary research and non-AIPO records produced the narrower PRISMA subset used for the scoping review. The scoping review followed JBI guidelines and was based on database searches (EBSCOhost: MEDLINE, AgeLine, SocINDEX, Health Source: Nursing/Academic Edition, and Family & Society Studies Worldwide; ProQuest Social Science Premium Collection; and PubMed, including MEDLINE, PMC, and in-process content) for peer-reviewed studies published between 2011 and 2025. Inclusion criteria required primary research involving adults aged 65 years or older, use of videoconferencing technology for social engagement, and reference to AIPOs or analogous community-based aging services. The protocol was post-registered with the Open Science Framework. Results: The LDA analysis of 101 peer-reviewed articles identified six latent themes describing the broader research landscape: problem of isolation, character of socialization, physical health, technology as intervention, technology as social medium, and supportive environments. This thematic framework informed the scoping review, which screened 1908 records and retained 25 publications (representing 24 unique studies) explicitly referencing AIPO involvement in relational videoconferencing. Only one study predated COVID-19. Mapping these studies to the LDA-derived themes revealed the least consistent coverage to be in supportive environments and physical health, particularly among AIPOs other than senior or community centers. Conclusions: Relational videoconferencing has potential to sustain and expand older adults' social connections, but evidence mapped through the scoping review shows that documentation of how AIPOs support adoption is sparse. The hybrid approach advances understanding of videoconferencing in aging contexts and identifies priorities for documenting, comparing, and refining AIPO practices to inform future interventions and policy.},
}

@article {pmid41373238,
year = {2025},
author = {Diener, BL and Berdella, M and DeCelie-Germana, J and Stables-Carney, T and Kier, C},
title = {Transforming Care Models in Cystic Fibrosis: A Review.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233022},
pmid = {41373238},
issn = {2227-9032},
abstract = {Cystic fibrosis (CF) is a multisystemic, chronic disease that requires a large multidisciplinary team for effective treatment. Over the past 20 years, the landscape of cystic fibrosis care has evolved from an almost exclusively pediatric disease to both a pediatric and adult condition. The median age of cystic fibrosis patients is rising, and the number of adults with CF is also increasing. With new developments in cystic fibrosis care, patients' health and needs have changed, and therefore the care model of the cystic fibrosis team has also changed. The introduction of highly effective CFTR modulator therapy, the COVID-19 pandemic, and the partnership of people with CF (PwCF) and their families have catalyzed the transformation of the CF care model, which includes the growth and evolution of the CF care team given the changes in the demographics of CF patients and the incorporation of telehealth and remote patient monitoring, shared decision-making, and coproduction of care. This narrative review, focusing on the United States (US) experience, explores the transformation of CF care, highlighting demographic changes, medical breakthroughs, and systemic adaptations.},
}

@article {pmid41373226,
year = {2025},
author = {Narymbayeva, N and Kamaliev, M and Juszkiewicz, KT and Kanafyanova, K and Aliyeva, S and Aitambayeva, N and Nazarova, L and Moiynbayeva, S and Saktapov, A and Svetlanova, S},
title = {Temporal and Contextual Variations in Job Satisfaction Between Physicians and Nurses: A Systematic Review and Meta-Analysis.},
journal = {Healthcare (Basel, Switzerland)},
volume = {13},
number = {23},
pages = {},
doi = {10.3390/healthcare13233008},
pmid = {41373226},
issn = {2227-9032},
abstract = {Objectives: This systematic review and meta-analysis evaluated differences in job satisfaction scores between nurses and physicians, examining variation by (a) care setting (hospital, emergency department, outpatient, mixed), and (b) time period (pre-COVID, during COVID, post-COVID). Methods: We systematically searched PubMed, Scopus, ScienceDirect, Web of Science, and CINAHL for studies published between January 2020 and July 2025. Eligible studies reported mean and standard deviation values for job satisfaction among physicians and nurses in healthcare settings across the specified timeframes. Studies were excluded if they assessed other types of satisfaction or combined data across COVID periods. Pooled standardized mean difference (SMD) was calculated using random-effects models in R. Results: Before COVID-19, the SMD was -2.40 (95% CI -8.05 to 3.26; I[2] = 98%). During the pandemic, the estimate was 1.39 (95% CI -0.57 to 3.35; I[2] = 91.5%), and post-pandemic, it remained small (SMD = 0.29; 95% CI -1.63 to 2.22; I[2] = 95.8%). Emergency care during COVID showed a significant advantage for physicians (SMD = 0.29; 95% CI 0.05 to 0.52; I[2] = 0%). Post-COVID, mixed settings slightly favored physicians (SMD = 0.06), while primary care favored nurses (SMD = -0.30); subgroup differences were significant. Conclusions: The findings reveal that job satisfaction is not solely determined by professional role but is significantly influenced by temporal and contextual factors. Job satisfaction is shaped more by temporal and contextual factors than by professional role. While no consistent differences were observed pre-pandemic, emergency care favored physicians during COVID, and post-pandemic trends showed modest advantages for nurses in primary care and physicians in mixed settings. Due to the methodological limitations of this meta-analysis, including high heterogeneity, reliance on cross-sectional data, and very low/low certainty of evidence, these results should be interpreted with caution.},
}

@article {pmid41369839,
year = {2025},
author = {Obradovic, J and Jurisic, V},
title = {The - 216G/T polymorphism in the EGFR gene: A review focusing on Non-Small lung cancer.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {172},
pmid = {41369839},
issn = {1573-4978},
support = {Agreements No. 451-03-136/2025-03/200378//The Ministry of Science, Technological Development and Innovation, Republic of Serbia/ ; Agreements No. 451-03-137/2025-03/200111//The Ministry of Science, Technological Development and Innovation, Republic of Serbia,/ ; },
mesh = {Humans ; *Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; *Polymorphism, Single Nucleotide/genetics ; *Lung Neoplasms/genetics ; Genetic Predisposition to Disease ; Mutation ; Promoter Regions, Genetic ; },
abstract = {The epidermal growth factor receptor (EGFR) is a key regulator of cell proliferation and a well-established therapeutic target in non-small-cell lung cancer (NSCLC). Somatic mutations in the EGFR gene have been widely studied in the context of tyrosine kinase inhibitors (TKIs), but germline polymorphisms as potentially predictive biomarkers have emerged as a variants of interest over the years. Among these, the - 216G/T (rs712829) single nucleotide polymorphism (SNP), located in the EGFR promoter region, is gaining attention for its potential clinical relevance. This narrative review aims to provide a comprehensive chronological overview of the discovery, functional implications, clinical relevance, and broader oncological and non-oncological associations of the EGFR - 216G/T SNP. Relevant studies were identified from 2005 to 2025 through literature searches across publicly available databases and bibliographies of key publications. This SNP was associated to increased EGFR promotor activity, pleural metastasis, susceptibility to EGFR mutations, NSCLC risk, and different inter-individual and inter-ethnic allele frequencies. Conflicting findings regarding survival outcomes and toxicity underscore the need for further validation. Beyond NSCLC, this SNP has demonstrated relevance in colorectal cancer, glioma, breast cancer, cardiovascular disease, and even COVID-19 susceptibility. The - 216G/T polymorphism represents a promising germline biomarker for NSCLC susceptibility. However, population-specific studies and investigations integrating multi-omics data, along with machine learning models are essential to clarify its utility in precision oncology.},
}

Humans
*Carcinoma, Non-Small-Cell Lung/genetics
ErbB Receptors/genetics
*Polymorphism, Single Nucleotide/genetics
*Lung Neoplasms/genetics
Genetic Predisposition to Disease
Mutation
Promoter Regions, Genetic

@article {pmid40367274,
year = {2025},
author = {Hau, J and Chan, SCC and Hussain, I and Kelly, J and Rashid, MA},
title = {Implementation of virtual pathology teaching in health professions education: A systematic review: BEME Systematic Review No. 95.},
journal = {Medical teacher},
volume = {47},
number = {12},
pages = {1918-1926},
doi = {10.1080/0142159X.2025.2497890},
pmid = {40367274},
issn = {1466-187X},
mesh = {Humans ; *Education, Distance/organization & administration/methods ; COVID-19/epidemiology ; *Pathology/education ; *Health Occupations/education ; SARS-CoV-2 ; Education, Medical ; },
abstract = {PURPOSE: Rapid changes to learning technologies, accelerated by the COVID-19 pandemic, have led to the widespread adoption of virtual education. Pathology is an important medical science that is central to many curricula in health professions education (HPE). It has been impacted by the broader transition to virtual education. This systematic review and meta-ethnography evaluated the experiences of virtual pathology education within HPE.

METHODS: MEDLINE and EMBASE were systematically searched for peer-reviewed qualitative journal articles describing the experiences of virtual pathology in HPE. Of 1119 articles identified, 17 were synthesised using a meta-ethnographic approach.

RESULTS: The final synthesis represented a total of 2126 participants, including 1256 undergraduate medical students, 297 resident doctors, 473 senior clinicians, and 100 teaching faculty. We identified the following third-order constructs: 'Adaptability to learner's needs', 'negative human consequences', and 'uncertainty about trajectory'.

CONCLUSION: This review highlights both positive and negative impacts of transitioning pathology education to virtual delivery. The need to enhance current educational practice according to these findings is particularly pressing since the shift to virtual education in pathology looks set to accelerate in years to come.},
}

Humans
*Education, Distance/organization & administration/methods
COVID-19/epidemiology
*Pathology/education
*Health Occupations/education
SARS-CoV-2
Education, Medical

@article {pmid36922164,
year = {2023},
author = {, and , and , and , },
title = {[Expert consensus on diagnosis and treatment of COVID-19 infection related cough in children].},
journal = {Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]},
volume = {57},
number = {3},
pages = {309-317},
doi = {10.3760/cma.j.cn112150-20230120-00052},
pmid = {36922164},
issn = {0253-9624},
support = {BE2021656//Jiangsu Province Key Research and Development Program (Social Development Project)/ ; SZYJTD201806//Suzhou "Clinical Medicine Expert Team"/ ; 82070009, 82270018//National Nature Science Fundation of China/ ; },
mesh = {Child ; Humans ; *Cough/diagnosis/etiology/therapy ; *COVID-19/therapy ; SARS-CoV-2 ; Consensus ; COVID-19 Testing ; },
abstract = {An epidemic outbreak of the corona virus disease 2019(COVID-19) Omicron variant occurred in most regions of China. Children are susceptible to COVID-19 and the vast majority of them suffer from upper respiratory tract infection. Cough is one of the most common symptoms. COVID-19 infection related cough includes acute cough, persistent cough and chronic cough, and children with original chronic cough or chronic lung disease can also induce or aggravate symptom of cough after infection, which has a great impact on children's physical and mental health. The treatment for COVID-19 infection related cough vary with the etiology. Improper treatment would delay the patient's condition and increase adverse drug reaction. Currently, there is no guideline or consensus on the diagnosis and treatment of COVID-19 infection related cough in children in China, therefore this consensus is drafted. Referring to the latest international research and the diagnostic and therapeutic strategy for COVID-19 infection (Tenth Edition For Trial Implementation), and combining with clinical diagnosis and treatment experience,the consensus elaborates the pathogenesis and etiology of COVID-19 infection related cough, the use of cough relievers and expectorants, as well as the key points of diagnosis and treatment of different etiological factors. It is expected to provide specific and feasible guidance scheme for pediatricians, general practitioners and clinical pharmacists.},
}

Child
Humans
*Cough/diagnosis/etiology/therapy
*COVID-19/therapy
SARS-CoV-2
Consensus
COVID-19 Testing

@article {pmid36822865,
year = {2023},
author = {, and , and , and , },
title = {[Expert consensus on the infection prevention and control of SARS-CoV-2 Omicron variant in healthcare facilities].},
journal = {Zhonghua yi xue za zhi},
volume = {103},
number = {8},
pages = {545-558},
doi = {10.3760/cma.j.cn112137-20220929-02059},
pmid = {36822865},
issn = {0376-2491},
support = {2020-53//China National Health Development Research Center "Evidence Based Evaluation and Demonstration Base Construction Project for Medical Institutions' Sense and Control Measures"/ ; 20411950104//Emergency Science and Technology Project of Science and Technology Commission of Shanghai Municipality/ ; SHDC22021315//Shanghai Hospital Development Center Foundation/ ; 20411950104//Shanghai Committee of Science and Technology/ ; },
mesh = {Humans ; *COVID-19 ; Consensus ; SARS-CoV-2 ; Delivery of Health Care ; },
abstract = {SARS-CoV-2 has been mutating ever since COVID-19 became a global pandemic in 2020, resulting in changes in its viral characteristics. Dealing with infections due to the Omicron variant, it is important for healthcare facilities to dynamically carry out accurate and scientific prevention and control strategies. The current consensus aimed to target the most concerned aspects, including the detection, transmission, prevention and disinfection of the Omicron variant. Through reviewing the latest evidence-based literature, rounds of discussions, and multiple revisions, the panel of experts formed 22 evidence-based recommendations. This consensus provides scientific and practical guidance for the medical institutions, as well as providing reference for other professional organizations and personnel.},
}

Humans
*COVID-19
Consensus
SARS-CoV-2
Delivery of Health Care

@article {pmid36629948,
year = {2023},
author = {Ishige, T and Shimizu, T and Watanabe, K and Arai, K and Kamei, K and Kudo, T and Kunisaki, R and Tokuhara, D and Naganuma, M and Mizuochi, T and Murashima, A and Inoki, Y and Iwata, N and Iwama, I and Koinuma, S and Shimizu, H and Jimbo, K and Takaki, Y and Takahashi, S and Cho, Y and Nambu, R and Nishida, D and Hagiwara, SI and Hikita, N and Fujikawa, H and Hosoi, K and Hosomi, S and Mikami, Y and Miyoshi, J and Yagi, R and Yokoyama, Y and Hisamatsu, T},
title = {Expert consensus on vaccination in patients with inflammatory bowel disease in Japan.},
journal = {Journal of gastroenterology},
volume = {58},
number = {2},
pages = {135-157},
pmid = {36629948},
issn = {1435-5922},
support = {20316729//Ministry of Health, Labour and Welfare/ ; },
mesh = {Adult ; Pregnancy ; Female ; Humans ; Child ; Consensus ; Japan ; *COVID-19 ; *Inflammatory Bowel Diseases/drug therapy ; Vaccination/adverse effects ; },
abstract = {Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients' IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.},
}

Adult
Pregnancy
Female
Humans
Child
Consensus
Japan
*COVID-19
*Inflammatory Bowel Diseases/drug therapy
Vaccination/adverse effects

@article {pmid36599436,
year = {2023},
author = {, and , },
title = {[Expert consensus on treatment of severe COVID-19 caused by Omicron variants].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {46},
number = {2},
pages = {101-110},
doi = {10.3760/cma.j.cn112147-20221230-00994},
pmid = {36599436},
issn = {1001-0939},
support = {2022-NHLHCRF-LX-01-01//National High Level Hospital Clinical Research Funding/ ; 2022-I2M-JB-016//CAMS Innovation Fund for Medical Sciences/ ; 2022YFC2504401//National Key Research and Development Program of China/ ; 2022‑NHLHCRF‑LX‑01‑01//National High Level Hospital Clinical Research Funding/ ; 2022‑I2M‑JB‑016//CAMS Innovation Fund for Medical Sciences/ ; },
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; Consensus ; Critical Care ; China ; },
abstract = {Severe novel coronavirus infection (COVID-19) caused by Omicron variants has arisen in many places of China recently, and critical care is currently the biggest challenge for medical institutions in China. How to manage these patients in a procedural and standardized way to minimize the mortality is a problem that the medical staff with different professional backgrounds has to face. Therefore, the Chinese Thoracic Society and Chinese Association of Chest Physicians Critical Care Group jointly initiated and organized pulmonary and critical care experts to write this recommendation based on the current medical evidence and clinical practice, in order to standardize the clinical treatment of critically ill patients.},
}

Humans
*COVID-19
SARS-CoV-2
Consensus
Critical Care
China

@article {pmid36567574,
year = {2022},
author = {World Federation Of Chinese Medical Societies Emergency Committee, and World Federation Of Chinese Medical Societies Respiratory Diseases, and World Federation Of Chinese Medical Societies Heat Disease Committee, and Chinese Association Of Chinese Medicine Pulmonary Disease Chapter, and The First Aid Group Of Integrated Traditional Chinese And Western Medicine Of The Emergency Branch Of The Chinese Medical Association, and The First Aid Group Of Integrated Traditional Chinese And Western Medicine Of The Emergency Branch Of The Emergency Physician Branch Of The Chinese Medical Doctor Association, and The Emergency Branch Of The Shanghai Chinese Medical Association, and The Institute Of Emergency And Critical Care Of The Shanghai University Of Traditional Chinese Medicine, and National Health Commission's Key Laboratory Of Critical Care Medicine, },
title = {[Expert consensus on traditional Chinese medicine health management in adults with SARS-CoV-2 variant infection at home].},
journal = {Zhonghua wei zhong bing ji jiu yi xue},
volume = {34},
number = {12},
pages = {1233-1237},
doi = {10.3760/cma.j.cn121430-20221210-01079},
pmid = {36567574},
issn = {2095-4352},
mesh = {Adult ; Humans ; SARS-CoV-2 ; *COVID-19 ; Consensus ; East Asian People ; *Drugs, Chinese Herbal/therapeutic use ; China ; Medicine, Chinese Traditional ; },
abstract = {In order to more actively respond to the new situation of prevention and control of coronavirus disease 2019 (COVID-19), and to guide home health management for adults who are asymptomatic carriers or exhibit mild symptoms, the World Federation of Chinese Medical Societies Emergency Committee, World Federation of Chinese Medical Societies Respiratory Diseases, World Federation of Chinese Medical Societies Heat Disease Committee, Chinese Association of Chinese Medicine Pulmonary Disease Chapter, the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Chinese Medical Doctor Association, the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Emergency Physician Branch of the Chinese Medical Association, the Emergency Branch of the Shanghai Chinese Medical Association, the Institute of Emergency and Critical Care of the Shanghai University of Traditional Chinese Medicine, National Health Commission's Key Laboratory of Critical Care Medicine and other academic institutions have organized the medical experts at treating COVID-19 front line in China to investigate and discuss the traditional Chinese medicine (TCM) health management at home for adults infected with SARS-CoV-2 variants, and concluded the "Expert consensus on traditional Chinese medicine health management at home for adults infected with SARS-CoV-2 variants", in combination with "Guideline on SARS-CoV-2 variant infection recover at home" issued by the Joint Prevention and Control Mechanism of the State Council. The expert consensus included home environment, asymptomatic infection, infection with mild symptoms, recovery period, and TCM non-drug therapy intervention, which will provide a guidance to TCM intervention at home to adults infected with SARS-CoV-2 variants.},
}

Adult
Humans
SARS-CoV-2
*COVID-19
Consensus
East Asian People
*Drugs, Chinese Herbal/therapeutic use
China
Medicine, Chinese Traditional

@article {pmid36319453,
year = {2022},
author = {, and , },
title = {[Chinse expert consensus on issues related to the protection, treatment and management of patients with solid tumors during COVID-19 (2022 edition)].},
journal = {Zhonghua zhong liu za zhi [Chinese journal of oncology]},
volume = {44},
number = {10},
pages = {1083-1090},
doi = {10.3760/cma.j.cn112152-20220505-00309},
pmid = {36319453},
issn = {0253-3766},
mesh = {Humans ; *COVID-19 ; Pandemics ; Consensus ; *Neoplasms ; China ; },
abstract = {The new coronavirus is still in the global pandemic stage. At present, the Delta strain and the Omicron strain are the main circulating strains. The mutant strain has stronger infectivity than the original virus. In the content of COVID-19 pandemic, social public resources and medical resources may be affected, which lead to the medical treatment being delayed or interrupted in some patients with malignant tumors. Based on relevant research and clinical practice at home and abroad, the Cancer Support Therapy Committee of China Anti-Cancer Association and the Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association, in the light of China's national conditions and the availability of resources such as vaccines and antiviral drug, to formulate a consensus of Chinese experts on issues related to the prevention, treatment and management of patients with solid tumors. The main contents include the vaccination of cancer patients with COVID-19, the optimization of medical resources, and the timing of restarting anti-tumor therapy after COVID-19 infection. This article is aimed at providing reference for clinical practice.},
}

Humans
*COVID-19
Pandemics
Consensus
*Neoplasms
China

@article {pmid36152123,
year = {2022},
author = {Chen, S and Zhao, W and Li, J and Wu, D and , },
title = {Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition).},
journal = {Frontiers of medicine},
volume = {16},
number = {5},
pages = {815-826},
pmid = {36152123},
issn = {2095-0225},
mesh = {Humans ; Consensus ; *Lymphoma, B-Cell/drug therapy ; China ; },
abstract = {Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL) due to their reliable efficacy, manageable safety, high accessibility, and convenience for use. Still, no guidelines or consensus focusing on oral drug therapies for BCL is available. To provide a reference of oral agent-based treatment for mature BCL, a panel of experts from the Lymphocyte Disease Group, Chinese Society of Hematology, Chinese Medical Association conducted an extensive discussion and reached a consensus on oral drugs for Chinese BCL patients on the basis of the current application status of oral drugs in China, combined with the latest authoritative guidelines in the world and current research reports. This consensus reviewed the application of oral drugs in the treatment of BCL and the latest research and provided appropriate recommendations on the use of oral drugs for indolent or aggressive BCL patients. With the deepening of research and the development of standardized clinical applications, oral medications will bring better treatment to BCL patients, enabling more patients to benefit from them.},
}

Humans
Consensus
*Lymphoma, B-Cell/drug therapy
China

@article {pmid36103964,
year = {2022},
author = {Shang, Y and Wu, J and Liu, J and Long, Y and Xie, J and Zhang, D and Hu, B and Zong, Y and Liao, X and Shang, X and Ding, R and Kang, K and Liu, J and Pan, A and Xu, Y and Wang, C and Xu, Q and Zhang, X and Zhang, J and Liu, L and Zhang, J and Yang, Y and Yu, K and Guan, X and Chen, D and , },
title = {Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {135},
number = {16},
pages = {1913-1916},
pmid = {36103964},
issn = {2542-5641},
mesh = {Humans ; *COVID-19 ; Consensus ; SARS-CoV-2 ; China ; },
}

Humans
*COVID-19
Consensus
SARS-CoV-2
China

@article {pmid35739055,
year = {2022},
author = {Chen, X and Han, CP and Zhang, W and , },
title = {Shanghai expert consensus on clinical protocol for traditional Chinese medicine treatment of COVID-19 among the elderly population (second edition).},
journal = {Journal of integrative medicine},
volume = {20},
number = {5},
pages = {427-431},
pmid = {35739055},
issn = {2095-4964},
mesh = {Aged ; China ; Clinical Protocols ; Consensus ; Humans ; *Medicine, Chinese Traditional ; SARS-CoV-2 ; *COVID-19 Drug Treatment ; },
abstract = {This document is the revised edition of the previously issued Shanghai Expert Consensus on Clinical Protocol for Traditional Chinese Medicine Treatment of COVID-19 among the Elderly Population. Based on the clinical experience and the Protocol for Diagnosis and Treatment of COVID-19 (Trial 9th Edition), this revised edition provides treatment approaches and recommendations to proactively cope with Omicron variant and increase the therapeutic efficacy for coronavirus disease 2019 among the elderly population in Shanghai, China.},
}

Aged
China
Clinical Protocols
Consensus
Humans
*Medicine, Chinese Traditional
SARS-CoV-2
*COVID-19 Drug Treatment

@article {pmid35381631,
year = {2022},
author = {, },
title = {[Chinese expert consensus on the use of Omalizumab in allergic asthma (2021 version)].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {45},
number = {4},
pages = {341-354},
doi = {10.3760/cma.j.cn112147-20220115-00051},
pmid = {35381631},
issn = {1001-0939},
support = {82161138020, U1801286//National Natural Science Foundation of China/ ; 202102010011//Science and Technology Program of Guangzhou/ ; ZNSA-2020013, ZNSA-2020003//Zhongnanshan Medical Foundation of Guangdong Province/ ; },
mesh = {*Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; *Asthma/drug therapy ; *COVID-19 ; Consensus ; Humans ; Omalizumab/therapeutic use ; Quality of Life ; },
abstract = {As the first targeted biotherapy for asthma, Omalizumab, was officially approved in China in August 2017, and was applied in clinical practice since March, 2018. Dozens of experts in Respirology and Allergy from China fully discussed the important clinical issues on the use of Omalizumab in allergic asthma by referring to the relevant publications over the world and the first version of consensus published in March 2018. Until now, over 30, 000 allergic asthma patients have received the treatment of Omalizumab. Therefore, with the latest evidence of clinical and basic research around the world, we updated the consensus with the following issues: (1) The mechanisms and available evidence on anti-IgE treatment; (2) Selection and exclusion criteria for patients using Omalizumab; (3) Cautions on the administration of Omalizumab and highlights of the use of Omalizumab with various vaccines, including novel Coronavirus vaccines, and key points to note during a Novel Coronavirus pandemic; (4) Long-term use and safety; (5) The use of Omalizumab in specific populations; (6) Clinical applications of omalizumab with other targeted therapies and allergen-specific immunotherapy. Omalizumab, combining to the Cε3 area of IgE, reduces the free IgE level, and downregulates the expression of FcεRⅠ, which inhibits the release of inflammatory mediators of mast cell sources, and leads to reduced asthma exacerbation, decreased rate of emergency visit and hospitalization, improved symptoms and quality of life, as well as less concomitant moderate to severe asthma, poorly controlled after at least 3 months treatment of ICS/LABA, and confirmed with allergic status through skin prick test or serum total IgE or specific IgE. Conditions that exclude the use of Omalizumab include patients who are suspected to be allergic to drug ingredients. Omalizumab is administered based on dosing tables by subcutaneous injection. Omalizumab should be administered by a health care professional (doctor or nurse) in a medical institution equipped with facilities for post-injection observation and rescue treatment for anaphylactic shock. After the injection, the patient should be closely monitored whether there is an anaphylactic reaction. The duration of Omalizumab treatment should be at least 16 weeks to judge its effectiveness, after 16 weeks, Omalizumab treatment will be continued or withdrawn based on the overall asthma control evaluation. Patients should be followed every 3 months to assess the disease control and dosing adjustment. The common adverse reactions were injection sites reactions. Based on the latest evidence around the word, we focused on updating the relevant treatment course, administration method and use of specific populations, in order to guide clinicians in the use of Omalizumab. The use of Omalizumab in China still requires long-term observation and further research. With the increase of clinical evidence, this consensus will be continuously improved and supplemented.},
}

*Anti-Asthmatic Agents/therapeutic use
Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
*Asthma/drug therapy
*COVID-19
Consensus
Humans
Omalizumab/therapeutic use
Quality of Life

@article {pmid35257524,
year = {2022},
author = {Choi, JH and Moon, J and Kim, S and Bae, H and Lee, J and Choe, YJ},
title = {Expert Consensus on COVID-19 Vaccination in Korean Adolescents: A Modified Delphi Survey.},
journal = {Journal of Korean medical science},
volume = {37},
number = {9},
pages = {e69},
pmid = {35257524},
issn = {1598-6357},
support = {2021-10-023//Korea Disease Control and Prevention Agency/Korea ; },
mesh = {Adolescent ; Adult ; *COVID-19/prevention & control ; *COVID-19 Vaccines ; Child ; Consensus ; Humans ; Republic of Korea ; Vaccination ; },
abstract = {The effectiveness of coronavirus disease 2019 (COVID-19) vaccines had been shown in many studies in adult population, however, the real-world evidence in the childhood population was scarce. We aimed to organize the collective expert's opinions on adolescent vaccination against COVID-19 in Korea, therefore to guide the vaccination policy in the setting of available evidence. The Delphi panels responded that adolescents were greatly impacted by the quarantine measures, and COVID-19 is an important health problem for adolescents. Panels responded that in general, the benefits of the COVID-19 vaccine overweigh the potential risks in Korean adolescents. Continuing monitoring of available data is needed to provide the best vaccination practices in adolescents guided by the updated evidence.},
}

Adolescent
Adult
*COVID-19/prevention & control
*COVID-19 Vaccines
Child
Consensus
Humans
Republic of Korea
Vaccination

@article {pmid35125460,
year = {2022},
author = {Iyer, S and Bovonratwet, P and Samartzis, D and Schoenfeld, AJ and An, HS and Awwad, W and Blumenthal, SL and Cheung, JPY and Derman, PB and El-Sharkawi, M and Freedman, BA and Hartl, R and Kang, JD and Kim, HJ and Louie, PK and Ludwig, SC and Neva, MH and Pham, MH and Phillips, FM and Qureshi, SA and Radcliff, KE and Riew, KD and Sandhu, HS and Sciubba, DM and Sethi, RK and Valacco, M and Zaidi, HA and Zygourakis, CC and Makhni, MC},
title = {Appropriate Telemedicine Utilization in Spine Surgery: Results From a Delphi Study.},
journal = {Spine},
volume = {47},
number = {8},
pages = {583-590},
doi = {10.1097/BRS.0000000000004339},
pmid = {35125460},
issn = {1528-1159},
mesh = {*COVID-19/epidemiology ; Consensus ; Delphi Technique ; Humans ; Patient Satisfaction ; *Telemedicine ; },
abstract = {STUDY DESIGN: Delphi expert panel consensus.

OBJECTIVE: To obtain expert consensus on best practices for appropriate telemedicine utilization in spine surgery.

SUMMARY OF BACKGROUND DATA: Several studies have shown high patient satisfaction associated with telemedicine during the COVID-19 peak pandemic period as well as after easing of restrictions. As this technology will most likely continue to be employed, there is a need to define appropriate utilization.

METHODS: An expert panel consisting of 27 spine surgeons from various countries was assembled in February 2021. A two-round consensus-based Delphi method was used to generate consensus statements on various aspects of telemedicine (separated as video visits or audio visits) including themes, such as patient location and impact of patient diagnosis, on assessment of new patients. Topics with ≥75% agreement were categorized as having achieved a consensus.

RESULTS: The expert panel reviewed a total of 59 statements. Of these, 32 achieved consensus. The panel had consensus that video visits could be utilized regardless of patient location and that video visits are appropriate for evaluating as well as indicating for surgery multiple common spine pathologies, such as lumbar stenosis, lumbar radiculopathy, and cervical radiculopathy. Finally, the panel had consensus that video visits could be appropriate for a variety of visit types including early, midterm, longer term postoperative follow-up, follow-up for imaging review, and follow-up after an intervention (i.e., physical therapy, injection).

CONCLUSION: Although telemedicine was initially introduced out of necessity, this technology most likely will remain due to evidence of high patient satisfaction and significant cost savings. This study was able to provide a framework for appropriate telemedicine utilization in spine surgery from a panel of experts. However, several questions remain for future research, such as whether or not an in-person consultation is necessary prior to surgery and which physical exam maneuvers are appropriate for telemedicine.Level of Evidence: 4.},
}

*COVID-19/epidemiology
Consensus
Delphi Technique
Humans
Patient Satisfaction
*Telemedicine

@article {pmid35057603,
year = {2022},
author = {Chopra, HK and Nair, T and Ponde, CK and Kaul, S and Mehta, Y and Vora, A and Mukhopadhyay, P and Jayagopal, PB and Behera, M and Patil, R and Deshpande, M and Anantharaman, R},
title = {COVID-Inflicted Coagulopathy: Expert Consensus on Management with Novel Oral Anticoagulants in India.},
journal = {The Journal of the Association of Physicians of India},
volume = {69},
number = {12},
pages = {11-12},
pmid = {35057603},
issn = {0004-5772},
mesh = {Administration, Oral ; Anticoagulants/therapeutic use ; *COVID-19 ; Consensus ; *Heparin, Low-Molecular-Weight ; Humans ; India/epidemiology ; Pandemics ; SARS-CoV-2 ; },
abstract = {Coronavirus disease 2019 (COVID-19) is a highly hypercoagulable viral infection complicated as COVID-inflicted coagulopathy (CIC), that is associated with increased risk of morbidity and mortality. International guidelines recommend low molecular weight heparin (LMWH) to treat CIC in both in-hospital and in-home settings. However, in India, using subcutaneous LMWH may not be a feasible option for a vast majority of patients under home management. Additionally, while some evidence advocates the use of novel oral anticoagulants (NOACs), in hospitalized settings, most guidelines find no role of NOACs in hospital settings. On the other hand, the resource crunch faced in recent COVID-19 pandemic in India forced physicians to treat many patients in home settings. These patients had been usually prescribed NOACs for ease of administration and adherence. Therefore, there is a need to form a consensus on the use of NOACs to manage CIC in India.},
}

Administration, Oral
Anticoagulants/therapeutic use
*COVID-19
Consensus
*Heparin, Low-Molecular-Weight
Humans
India/epidemiology
Pandemics
SARS-CoV-2

@article {pmid34815248,
year = {2024},
author = {Dewhurst, F and Hanratty, B and Frew, K and Paes, P and Walker, R and Barnes, C and Maddock, H and Elverson, J and Byrne-Davis, L},
title = {Palliative medicine trainees be should learn about frailty: meta-synthesis and Delphi study to establish curriculum content.},
journal = {BMJ supportive & palliative care},
volume = {13},
number = {e3},
pages = {e1008-e1018},
doi = {10.1136/bmjspcare-2021-003013},
pmid = {34815248},
issn = {2045-4368},
mesh = {Aged ; Humans ; Curriculum ; Delphi Technique ; *Frailty/therapy ; Palliative Care ; *Palliative Medicine ; },
abstract = {OBJECTIVES: Frailty is common and highly associated with morbidity and mortality, a fact that has been highlighted by COVID-19. Understanding how to provide palliative care for frail individuals is an international priority, despite receiving limited mention in Palliative Medicine curricula or examinations worldwide. This study aimed to synthesise evidence and establish expert consensus on what should be included in a Palliative-Medicine Specialist Training Curriculum for frailty.

METHODS: Literature Meta-synthesis conducted by palliative medicine, frailty and education experts produced a draft curriculum with Bologna based Learning-Outcomes. A Delphi study asked experts to rate the importance of Learning-Outcomes for specialist-training completion and propose additional Learning-Outcomes. This process was repeated until 70% consensus was achieved for over 90% of Learning-Outcomes. Experts divided Learning-Outcomes into specific (for inclusion in a frailty subsection) or generic (applicable to other palliative conditions). The Delphi panel was Subject Matter Experts: Palliative-Medicine Consultants (n=14) and Trainees (n=10), representing hospital, community, hospice and care home services and including committee members of key national training organisations. A final reviewing panel of Geriatric Medicine Specialists including experts in research methodology, national training requirements and frailty were selected.

RESULTS: The meta-synthesis produced 114 Learning-Outcomes. The Delphi Study and Review by Geriatric Medicine experts resulted in 46 essential and 33 desirable Learning-Outcomes.

CONCLUSIONS: This frailty curriculum is applicable internationally and highlights the complex and unique palliative needs of frail patients. Future research is required to inform implementation, educational delivery and service provision.},
}

Aged
Humans
Curriculum
Delphi Technique
*Frailty/therapy
Palliative Care
*Palliative Medicine

@article {pmid33946120,
year = {2021},
author = {Elalamy, I and Gerotziafas, G and Alamowitch, S and Laroche, JP and Van Dreden, P and Ageno, W and Beyer-Westendorf, J and Cohen, AT and Jimenez, D and Brenner, B and Middeldorp, S and Cacoub, P and , },
title = {SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia.},
journal = {Thrombosis and haemostasis},
volume = {121},
number = {8},
pages = {982-991},
pmid = {33946120},
issn = {2567-689X},
mesh = {COVID-19/*prevention & control ; COVID-19 Vaccines/*adverse effects/therapeutic use ; Clinical Decision-Making ; Hemorrhage/etiology ; Humans ; Purpura, Thrombocytopenic, Idiopathic/*etiology ; Risk Factors ; Thrombocytopenia/etiology ; Thrombosis/*etiology ; Vaccination/adverse effects/methods ; },
abstract = {Historically, the vaccination strategies developed in the second half of the 20th century have facilitated the eradication of infectious diseases. From the onset of COVID-19 pandemic to the end of April 2021, more than 150 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, and with devastating material, physical, and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-CoV-2 pandemic. Health care professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported to provide reliable and credible information on vaccines. We need to inform, reassure, and support our patients when the prescription is made. Facing these challenges and observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a 10-point guideline for decision-making on what to do and not to do.},
}

COVID-19/*prevention & control
COVID-19 Vaccines/*adverse effects/therapeutic use
Clinical Decision-Making
Hemorrhage/etiology
Humans
Purpura, Thrombocytopenic, Idiopathic/*etiology
Risk Factors
Thrombocytopenia/etiology
Thrombosis/*etiology
Vaccination/adverse effects/methods

@article {pmid33857654,
year = {2021},
author = {Ng, YS and Ong, PH and Mah, SM and Koh, CWC and Loh, YJ and Chew, E},
title = {Rehabilitation prioritization: Development of expert consensus on essential rehabilitation during pandemics.},
journal = {Annals of physical and rehabilitation medicine},
volume = {64},
number = {6},
pages = {101512},
pmid = {33857654},
issn = {1877-0665},
mesh = {Consensus ; Humans ; *Pandemics ; },
}

Consensus
Humans
*Pandemics

@article {pmid33630471,
year = {2021},
author = {Asbun, HJ and Abu Hilal, M and Kunzler, F and Asbun, D and Bonjer, J and Conlon, K and Demartines, N and Feldman, LS and Morales-Conde, S and Pietrabissa, A and Pryor, AD and Schlachta, CM and Sylla, P and Targarona, EM and Agra, Y and Besselink, MG and Callery, M and Cleary, SP and De La Cruz, L and Eckert, P and Evans, C and Han, HS and Jones, DB and Gan, TJ and Koch, D and Lillemoe, KD and Lomanto, D and Marks, J and Matthews, B and Mellinger, J and Melvin, WS and Moreno-Paquentin, E and Navarrete, C and Pawlik, TM and Pessaux, P and Ricciardi, W and Schwaitzberg, S and Shah, P and Szokol, J and Talamini, M and Torres, R and Triboldi, A and Udomsawaengsup, S and Valsecchi, F and Vauthey, JN and Wallace, M and Wexner, SD and Zinner, M and Francis, N},
title = {International Delphi Expert Consensus on Safe Return to Surgical and Endoscopic Practice: From the Coronavirus Global Surgical Collaborative.},
journal = {Annals of surgery},
volume = {274},
number = {1},
pages = {50-56},
pmid = {33630471},
issn = {1528-1140},
mesh = {COVID-19/epidemiology/*prevention & control/transmission ; Consensus ; Delphi Technique ; *Elective Surgical Procedures ; *Endoscopy ; Humans ; Infection Control/*organization & administration ; Internationality ; Intersectoral Collaboration ; Triage ; },
abstract = {OBJECTIVE: The aim of this work is to formulate recommendations based on global expert consensus to guide the surgical community on the safe resumption of surgical and endoscopic activities.

BACKGROUND: The COVID-19 pandemic has caused marked disruptions in the delivery of surgical care worldwide. A thoughtful, structured approach to resuming surgical services is necessary as the impact of COVID-19 becomes better controlled. The Coronavirus Global Surgical Collaborative sought to formulate, through rigorous scientific methodology, consensus-based recommendations in collaboration with a multidisciplinary group of international experts and policymakers.

METHODS: Recommendations were developed following a Delphi process. Domain topics were formulated and subsequently subdivided into questions pertinent to different aspects of surgical care in the COVID-19 crisis. Forty-four experts from 15 countries across 4 continents drafted statements based on the specific questions. Anonymous Delphi voting on the statements was performed in 2 rounds, as well as in a telepresence meeting.

RESULTS: One hundred statements were formulated across 10 domains. The statements addressed terminology, impact on procedural services, patient/staff safety, managing a backlog of surgeries, methods to restart and sustain surgical services, education, and research. Eighty-three of the statements were approved during the first round of Delphi voting, and 11 during the second round. A final telepresence meeting and discussion yielded acceptance of 5 other statements.

CONCLUSIONS: The Delphi process resulted in 99 recommendations. These consensus statements provide expert guidance, based on scientific methodology, for the safe resumption of surgical activities during the COVID-19 pandemic.},
}

COVID-19/epidemiology/*prevention & control/transmission
Consensus
Delphi Technique
*Elective Surgical Procedures
*Endoscopy
Humans
Infection Control/*organization & administration
Internationality
Intersectoral Collaboration
Triage

@article {pmid33484264,
year = {2021},
author = {Ma, B and Fan, X and Kong, W and Xiao, S and Zhu, S and Yao, M and Liu, Y and Zhu, W and Wang, J and Zeng, Y and Zhao, Y and Su, B and Xu, S and Dong, Z and Gu, H and Li, W and Jiang, Y and Gu, D and Xia, Z},
title = {Expert Consensus on Clinical Practice of Burn Units in Shanghai During the COVID-19 Epidemic.},
journal = {Journal of burn care & research : official publication of the American Burn Association},
volume = {42},
number = {4},
pages = {642-645},
doi = {10.1093/jbcr/irab010},
pmid = {33484264},
issn = {1559-0488},
support = {81930057//National Natural Science Foundation of China/ ; 2019-I2M-5-076//CAMS Innovation Fund for Medical Sciences/ ; },
mesh = {Burn Units/*organization & administration ; Burns/epidemiology/*therapy ; COVID-19/*epidemiology/therapy ; China/epidemiology ; *Consensus ; Critical Care/*organization & administration ; Humans ; Infection Control/organization & administration ; },
abstract = {In response to coronavirus disease 2019 (COVID-19), the Shanghai Burn Clinical Quality Control Center organized experts to formulate and implement a set of rapid, simple, and effective prevention and control measures, and there have not been any cases of health care professionals or inpatients in burn units suspected or confirmed with COVID-19. This article elaborates on the specific measures in burn units in response to the epidemic, including the implementation of standardized procedures, remote consultations, strengthened follow-up, exchange of experience, and popular science, among others. We share experience from Shanghai to benefit related disciplines in other countries and regions.},
}

Burn Units/*organization & administration
Burns/epidemiology/*therapy
COVID-19/*epidemiology/therapy
China/epidemiology
*Consensus
Critical Care/*organization & administration
Humans
Infection Control/organization & administration

@article {pmid33394078,
year = {2021},
author = {Lan, X and Long, Y and Shao, F and Song, Y},
title = {Expert consensus on the safety prevention and control of nuclear medicine diagnosis and treatment during the outbreak of COVID-19 (1st edition): (translated from Chinese version).},
journal = {European journal of nuclear medicine and molecular imaging},
volume = {48},
number = {4},
pages = {1134-1143},
pmid = {33394078},
issn = {1619-7089},
mesh = {COVID-19/*prevention & control ; China/epidemiology ; Consensus ; Disease Outbreaks/*prevention & control ; Humans ; Nuclear Medicine/*trends ; SARS-CoV-2 ; },
abstract = {In December 2019, an infectious disease caused by a new type of coronavirus infection was prevalent in Wuhan and across the country. On January 20, 2020, the National Health Commission of the People's Republic of China issued No.1 Announcement, which incorporated the novel coronavirus pneumonia into the Class B infectious disease according to the Law on Prevention and Control of Infectious Disease, but the disease should be adopted in the management of Class A infectious disease. In order to effectively control the source of infection, cut off the transmission route, protect the susceptible population, ensure the medical quality and medical safety, perform epidemic prevention and control, and comprehensively guarantee the life safety and physical health of medical staff, patients, and family members, it is very important to organize and carry out nuclear medicine diagnosis and treatment scientifically and safely. According to the national prevention and control policy, Chinese Society of Nuclear Medicine and editorial board of the Chinese Journal of Nuclear Medicine and Molecular Imaging organized professionals to formulate the expert consensus on the safety prevention process of nuclear medicine imaging and nuclide therapy during the period of new coronavirus infection.},
}

COVID-19/*prevention & control
China/epidemiology
Consensus
Disease Outbreaks/*prevention & control
Humans
Nuclear Medicine/*trends
SARS-CoV-2

@article {pmid33323819,
year = {2020},
author = {Sun, TW and Zhang, XJ and Yu, Z and Shang, Y},
title = {Chinese expert consensus on the diagnosis and treatment of severely and critically ill patients with coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {133},
number = {24},
pages = {2963-2965},
pmid = {33323819},
issn = {2542-5641},
mesh = {COVID-19/diagnosis/*therapy ; Consensus ; Critical Illness ; Humans ; *SARS-CoV-2 ; },
}

COVID-19/diagnosis/*therapy
Consensus
Critical Illness
Humans
*SARS-CoV-2

@article {pmid33272328,
year = {2020},
author = {Chan, Y and Banglawala, SM and Chin, CJ and Côté, DWJ and Dalgorf, D and de Almeida, JR and Desrosiers, M and Gall, RM and Gevorgyan, A and Hassan Hassan, A and Janjua, A and Lee, JM and Leung, RM and Mechor, BD and Mertz, D and Monteiro, E and Nayan, S and Rotenberg, B and Scott, J and Smith, KA and Sommer, DD and Sowerby, L and Tewfik, MA and Thamboo, A and Vescan, A and Witterick, IJ},
title = {CSO (Canadian Society of Otolaryngology - Head & Neck Surgery) position paper on rhinologic and skull base surgery during the COVID-19 pandemic.},
journal = {Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale},
volume = {49},
number = {1},
pages = {81},
pmid = {33272328},
issn = {1916-0216},
mesh = {*COVID-19/diagnosis/epidemiology/prevention & control ; *COVID-19 Testing ; Disease Transmission, Infectious/prevention & control ; Humans ; Nose/*surgery ; Otolaryngology/methods/*standards ; Otorhinolaryngologic Diseases/surgery ; Otorhinolaryngologic Surgical Procedures/*standards ; *Pandemics ; Personal Protective Equipment/*standards ; Postoperative Care/standards ; Preoperative Care/methods/*standards ; Skull Base/*surgery ; },
abstract = {Healthcare services in many countries have been partially or completely disrupted by the Coronavirus (COVID-19) pandemic since its onset in the end of 2019. Amongst the most impacted are the elective medical and surgical services in order to conserve resources to care for COVID-19 patients. As the number of infected patients decrease across Canada, elective surgeries are being restarted in a staged manner. Since Otolaryngologists - Head & Neck Surgeons manage surgical diseases of the upper aerodigestive tract where the highest viral load reside, it is imperative that these surgeries resume in a safe manner. The aim of this document is to compile the current best evidence available and provide expert consensus on the safe restart of rhinologic and skull base surgeries while discussing the pre-operative, intra-operative, and post-operative care and tips. Risk assessment, patient selection, case triage, and pre-operative COVID-19 testing will be analyzed and discussed. These guidelines will also consider the optimal use of personal protective equipment for specific cases, general and specific operative room precautions, and practical tips of intra-operative maneuvers to optimize patient and provider safety. Given that the literature surrounding COVID-19 is rapidly evolving, these recommendations will serve to start our specialty back into elective rhinologic surgeries over the next months and they may change as we learn more about this disease.},
}

*COVID-19/diagnosis/epidemiology/prevention & control
*COVID-19 Testing
Disease Transmission, Infectious/prevention & control
Humans
Nose/*surgery
Otolaryngology/methods/*standards
Otorhinolaryngologic Diseases/surgery
Otorhinolaryngologic Surgical Procedures/*standards
*Pandemics
Personal Protective Equipment/*standards
Postoperative Care/standards
Preoperative Care/methods/*standards
Skull Base/*surgery

@article {pmid33213540,
year = {2021},
author = {Khan, S and Tsang, KK and Mertz, D and Dolovich, M and Tunks, M and Demers, C and Hassall, K and Maharaj, N and Margallo, K and Cividino, M and Chagla, Z and Duong, M},
title = {A regional Canadian expert consensus on recommendations for restoring exercise and pulmonary function testing in low and moderate-to-high community prevalence coronavirus disease 2019 (COVID-19) settings.},
journal = {Infection control and hospital epidemiology},
volume = {42},
number = {12},
pages = {1535-1537},
pmid = {33213540},
issn = {1559-6834},
mesh = {*COVID-19 ; Canada/epidemiology ; Consensus ; Humans ; Prevalence ; SARS-CoV-2 ; },
}

*COVID-19
Canada/epidemiology
Consensus
Humans
Prevalence
SARS-CoV-2

@article {pmid33089297,
year = {2020},
author = {Zhu, L and Wang, JB and Yu, Q and Huang, ZW and Han, FK and Li, SJ and Sha, Y and Shi, HM and Tao, XF},
title = {[Shanghai municipal expert consensus on standardized prevention and control of COVID-19 during procedures of oral radiology].},
journal = {Shanghai kou qiang yi xue = Shanghai journal of stomatology},
volume = {29},
number = {4},
pages = {431-434},
pmid = {33089297},
issn = {1006-7248},
mesh = {Betacoronavirus ; COVID-19 ; China ; Consensus ; *Coronavirus Infections ; Humans ; *Pandemics ; *Pneumonia, Viral ; *Radiography, Dental ; SARS-CoV-2 ; },
abstract = {The announcement of National Health Commission on January 20, 2020 (No.1 of 2020) has included novel coronavirus pneumonia into the B class infectious diseases according to the law of the People's Republic of China on the prevention and control of infectious diseases, and has been managed as A class infectious diseases. People's governments at all levels and health administration departments have been paying high attention to it. With the alleviation of COVID-19 nationwide, dental clinics gradually resume to work. The main transmission routes of COVID-19 are respiratory droplets and contact transmission, hence oral radiological examination is kind of a high-risk operation. Standardized radiologic process is of great significance to reduce the risk of COVID-19 transmission. In accordance with the national and Shanghai epidemic prevention requirements, and in combination with the actual situation of various medical institutions, Oral and Maxillofacial Radiology Committee of Shanghai Stomatological Association formulated the expert consensus on standardized prevention and control of COVID-19 for clinical reference. This recommendation will be updated according to the situation of epidemic prevention and control in China and the new relevant diagnosis and treatment plans.},
}

Betacoronavirus
COVID-19
China
Consensus
*Coronavirus Infections
Humans
*Pandemics
*Pneumonia, Viral
*Radiography, Dental
SARS-CoV-2

@article {pmid32852385,
year = {2020},
author = {Yang, XH and Hu, B and Shang, Y and Liu, J and Zhong, M and Shang, XL and Wu, ZX and Yu, Z and Sun, RH and Wang, HL and Zhao, MY and Meng, M and Xu, QH and Zheng, X and Chen, DC},
title = {Expert consensus on management of analgesia and sedation for patients with severe coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {133},
number = {18},
pages = {2186-2188},
doi = {10.1097/CM9.0000000000001034},
pmid = {32852385},
issn = {2542-5641},
mesh = {Analgesia/*methods ; *Betacoronavirus ; COVID-19 ; Conscious Sedation/*methods ; Consensus ; Coronavirus Infections/*complications ; Humans ; Pandemics ; Pneumonia, Viral/*complications ; SARS-CoV-2 ; },
}

Analgesia/*methods
*Betacoronavirus
COVID-19
Conscious Sedation/*methods
Consensus
Coronavirus Infections/*complications
Humans
Pandemics
Pneumonia, Viral/*complications
SARS-CoV-2

@article {pmid32794674,
year = {2020},
author = {Bone Circulation And Osteonecrosis Professional Committee Shockwave Medical Specialty Committee Of Chinese Research Hospital Association, },
title = {[Expert consensus on prevention and treatment strategies for osteonecrosis of femoral head during the prevention and control of novel coronavirus pneumonia (2020)].},
journal = {Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery},
volume = {34},
number = {8},
pages = {1031-1035},
pmid = {32794674},
issn = {1002-1892},
mesh = {Betacoronavirus ; COVID-19 ; Consensus ; Coronavirus Infections/*epidemiology ; Femur Head/pathology ; Femur Head Necrosis/*prevention & control/*therapy ; Humans ; Osteonecrosis/*prevention & control/*therapy ; Pandemics ; Pneumonia, Viral/*epidemiology ; SARS-CoV-2 ; },
abstract = {Novel coronavirus pneumonia is a new type of respiratory infectious disease that has rapidly spread in many countries or regions around the world. The World Health Organization (WHO) named it "coronavirus disease 2019 (COVID-19)". Glucocorticoids (GC) have certain application value in patients with COVID-19, but they need to be used with caution and strict indications and dosage. Application of large doses of GC can also cause osteonecrosis of femoral head (ONFH). On the basis of the latest literature and evidence-based medical evidence on the fight against COVID-19 epidemic and steroid ONFH diagnosis and treatment, the Bone Circulation and Osteonecrosis Professional Committee, Shockwave Medical Specialty Committee of Chinese Research Hospital Association organized Chinese bone necrosis related experts to jointly write this consensus, focusing on the prevention strategy and the protective management measures in the ONFH diagnosis and treatment process during the prevention and control of COVID-19, which can provide reference for hospitals at all levels to carry out early prevention and treatment of ONFH.},
}

Betacoronavirus
COVID-19
Consensus
Coronavirus Infections/*epidemiology
Femur Head/pathology
Femur Head Necrosis/*prevention & control/*therapy
Humans
Osteonecrosis/*prevention & control/*therapy
Pandemics
Pneumonia, Viral/*epidemiology
SARS-CoV-2

@article {pmid32641446,
year = {2020},
author = {Wang, F and Liu, J and Zhang, P and Jiang, W and Zhang, L and Zhang, M and Teng, J and Wang, J and Xie, X and Cao, J and Li, W and Wu, Y and Zhou, H and Su, Y and Pan, S and Liu, L},
title = {Expert consensus on prevention and control of COVID-19 in the neurological intensive care unit (first edition).},
journal = {Stroke and vascular neurology},
volume = {5},
number = {3},
pages = {242-249},
pmid = {32641446},
issn = {2059-8696},
mesh = {Betacoronavirus/*pathogenicity ; COVID-19 ; Consensus ; Coronavirus Infections/diagnosis/*prevention & control/transmission/virology ; Critical Illness ; Cross Infection/diagnosis/*prevention & control/transmission/virology ; Host-Pathogen Interactions ; Humans ; Infection Control/*standards ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Intensive Care Units/*standards ; Nervous System Diseases/diagnosis/*therapy ; Neurology/*standards ; Occupational Health ; Pandemics/*prevention & control ; Patient Safety ; Pneumonia, Viral/diagnosis/*prevention & control/transmission/virology ; Risk Assessment ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome ; },
abstract = {During the COVID-19 epidemic, the treatment of critically ill patients has been increasingly difficult and challenging. During the epidemic, some patients with neurological diseases also have COVID-19, which could be misdiagnosed and cause silent transmission and nosocomial infection. Such risk is high in a neurological intensive care unit (NCU). Therefore, prevention and control of epidemic in critically ill patients is of utmost importance. The principle of NCU care should include comprehensive screening and risk assessment, weighing risk against benefits and reducing the risk of COVID-19 transmission while treating patients as promptly as possible.},
}

Betacoronavirus/*pathogenicity
COVID-19
Consensus
Coronavirus Infections/diagnosis/*prevention & control/transmission/virology
Critical Illness
Cross Infection/diagnosis/*prevention & control/transmission/virology
Host-Pathogen Interactions
Humans
Infection Control/*standards
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Intensive Care Units/*standards
Nervous System Diseases/diagnosis/*therapy
Neurology/*standards
Occupational Health
Pandemics/*prevention & control
Patient Safety
Pneumonia, Viral/diagnosis/*prevention & control/transmission/virology
Risk Assessment
Risk Factors
SARS-CoV-2
Treatment Outcome

@article {pmid32627963,
year = {2020},
author = {Corona-Cruz, J and Alba, EG and Iñiguez-García, M and López-Saucedo, R and Olivares-Torres, C and Rodriguez-Cid, J and Salazar-Otaola, G and Martínez-Said, H and Flores, RM and Arrieta, O},
title = {Surgical care of thoracic malignancies during the COVID-19 pandemic in México: An expert consensus guideline from the Sociedad Mexicana de Oncología (SMeO) and the Sociedad Mexicana de Cirujanos Torácicos Generales (SMCTG).},
journal = {Thoracic cancer},
volume = {11},
number = {8},
pages = {2370-2375},
pmid = {32627963},
issn = {1759-7714},
mesh = {COVID-19/complications/*epidemiology/virology ; Guidelines as Topic ; Humans ; Lung Neoplasms/complications/*epidemiology/surgery/virology ; Medical Oncology/trends ; Mexico/epidemiology ; *Pandemics ; SARS-CoV-2/pathogenicity ; Thoracic Neoplasms/complications/*epidemiology/surgery/virology ; Triage ; },
abstract = {To date, the impact, timeline and duration of COVID-19 pandemic remains unknown and more than ever it is necessary to provide safe pathways for cancer patients. Multiple triage systems for nonemergent surgical procedures have been published, but potentially curative cancer procedures are essential surgery rather than elective surgery. In the present and future scenario of our country, thoracic oncology teams may have the difficult decision of weighing the utility of surgical intervention against the risk for inadvertent COVID-19 exposure for patients and medical staff. In consequence, traditional pathways of surgical care must be adjusted to reduce the risk of infection and the use of resources. It is recommended that all thoracic cancer patients should be offered treatment according to the accepted standard of care until shortage of services require a progressive reduction in surgical cases. Here, we present a consensus of recommendations discussed by a multidisciplinary panel of experts on thoracic oncology and based on the best available evidence, and hope it will provide a modifiable framework of guidance for local strategy planners in thoracic cancer care services in Mexico. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: This article provides recommendations to guarantee the continuity of surgical care for thoracic oncology cases during COVID-19 pandemic, whilst maintaining the safety of patients and medical staff. WHAT THIS STUDY ADDS: This guideline is the result of an expert consensus on thoracic surgical oncology with recommendations adapted to medical, economic and social realities of Mexico.},
}

COVID-19/complications/*epidemiology/virology
Guidelines as Topic
Humans
Lung Neoplasms/complications/*epidemiology/surgery/virology
Medical Oncology/trends
Mexico/epidemiology
*Pandemics
SARS-CoV-2/pathogenicity
Thoracic Neoplasms/complications/*epidemiology/surgery/virology
Triage

@article {pmid32521580,
year = {2020},
author = {, and , },
title = {[Expert consensus on special blood purification technics in patients with corona virus disease 2019].},
journal = {Zhonghua nei ke za zhi},
volume = {59},
number = {11},
pages = {847-853},
doi = {10.3760/cma.j.cn112138-20200306-00202},
pmid = {32521580},
issn = {0578-1426},
mesh = {Betacoronavirus ; COVID-19 ; China ; Consensus ; Coronavirus Infections/*blood ; *Hemofiltration ; *Hemoperfusion ; Humans ; Pandemics ; *Plasma Exchange ; Pneumonia, Viral/*blood ; SARS-CoV-2 ; },
abstract = {The outbreak of corona virus disease 2019 (COVID-19) has spread to more than 70 countries worldwide and there was a higher mortality in those who developed serious illness.Cytokine storm syndrome is an important pathophysiological basis for COVID-19 patients developing into severe or critical conditions. It was indicated in the diagnosis and treatment scheme, by the National Health Commission of the People's Republic of China, that blood purifications such as plasma exchange, plasma adsorption, hemoperfusion, hemofiltration and plasmafiltration could be considered for use in the critical patients with cytokine storm syndrome. This expert consensus, proposed by the Chinese Society of Nephrology and the Nephrology Committee of Chinese Research Hospital Association, is to guide and standardize the clinical application of blood purifications in the treatment of severe or critical patients with COVID-19.},
}

Betacoronavirus
COVID-19
China
Consensus
Coronavirus Infections/*blood
*Hemofiltration
*Hemoperfusion
Humans
Pandemics
*Plasma Exchange
Pneumonia, Viral/*blood
SARS-CoV-2

@article {pmid32358326,
year = {2020},
author = {Tang, PF and Hou, ZY and Wu, XB and Zhang, CQ and Wang, JW and Xing, X and Shao, ZW and Yu, AX and Wang, G and Chen, B and Zhang, P and Hu, YJ and Wang, BW and Guo, XD and Tang, X and Zhou, DS and Liu, F and Chen, AM and Zhang, K and Li, KN and Zhu, YB and , },
title = {Expert consensus on management principles of orthopedic emergency in the epidemic of coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {133},
number = {9},
pages = {1096-1098},
pmid = {32358326},
issn = {2542-5641},
mesh = {*Betacoronavirus ; COVID-19 ; Consensus ; *Coronavirus Infections/complications/epidemiology/prevention & control ; Epidemics ; Humans ; Minimally Invasive Surgical Procedures ; *Musculoskeletal Diseases/complications/therapy ; *Pandemics/prevention & control ; *Pneumonia, Viral/complications/epidemiology/prevention & control ; SARS-CoV-2 ; },
}

*Betacoronavirus
COVID-19
Consensus
*Coronavirus Infections/complications/epidemiology/prevention & control
Epidemics
Humans
Minimally Invasive Surgical Procedures
*Musculoskeletal Diseases/complications/therapy
*Pandemics/prevention & control
*Pneumonia, Viral/complications/epidemiology/prevention & control
SARS-CoV-2

@article {pmid32307014,
year = {2020},
author = {Song, JC and Wang, G and Zhang, W and Zhang, Y and Li, WQ and Zhou, Z and , },
title = {Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.},
journal = {Military Medical Research},
volume = {7},
number = {1},
pages = {19},
pmid = {32307014},
issn = {2054-9369},
mesh = {Aged ; Anticoagulants/therapeutic use ; *Betacoronavirus ; Blood Coagulation Disorders/*diagnosis/drug therapy/virology ; COVID-19 ; China ; Consensus ; Coronavirus Infections/*complications ; Humans ; Middle Aged ; Pandemics ; Pneumonia, Viral/*complications ; SARS-CoV-2 ; },
abstract = {Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.},
}

Aged
Anticoagulants/therapeutic use
*Betacoronavirus
Blood Coagulation Disorders/*diagnosis/drug therapy/virology
COVID-19
China
Consensus
Coronavirus Infections/*complications
Humans
Middle Aged
Pandemics
Pneumonia, Viral/*complications
SARS-CoV-2

@article {pmid32295323,
year = {2020},
author = {, and , },
title = {[Expert consensus on sleep study and non-invasive positive airway pressure therapy during the epidemic of coronavirus disease 2019].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {6},
pages = {490-495},
doi = {10.3760/cma.j.cn112147-20200309-00283},
pmid = {32295323},
issn = {1001-0939},
mesh = {Betacoronavirus ; COVID-19 ; China ; Consensus ; *Coronavirus ; Coronavirus Infections/epidemiology/*therapy ; Humans ; Noninvasive Ventilation/*methods ; Pandemics ; Pneumonia, Viral/epidemiology/*therapy ; Respiratory Insufficiency/*prevention & control ; SARS-CoV-2 ; Sleep/*physiology ; },
abstract = {Coronavirus disease (COVID-19) is mainly transmitted through respiratory droplets, close unprotected contact, and intense aerosols-generating procedures. Sleep study and non-invasive positive airway pressure (NIPAP) therapy can increase the risk of exposure and transmission of new coronaviruses to medical staff and patients. China's national epidemic control has entered a critical stage of overall prevention and control together with the restoration of normal medical care delivery. Based on the characteristics of sleep-disordered breathing, this consensus elaborates on the recommendations from the following four aspects that include patient and medical staff education, optimization of diagnostic and treatment protocols, sterilization of medical devices and the environment, and control of hospital-acquired infection. It is emphasized that the indications for sleep study and NIPAP should be strictly defined according to the local epidemic situation. Portable home sleep study and auto-titration positive airway pressure is recommended. The applications of disposable nasal pressure transducer for sleep study and disposable or personal masks and ventilator tubing for NIPAP are strongly suggested. Moreover, it is necessary to standardize the procedure of NIPAP, to separate the functional divisions in sleep lab, to comply with the protection regulations for medical personnel, and to strengthen the cleaning and disinfection management.},
}

Betacoronavirus
COVID-19
China
Consensus
*Coronavirus
Coronavirus Infections/epidemiology/*therapy
Humans
Noninvasive Ventilation/*methods
Pandemics
Pneumonia, Viral/epidemiology/*therapy
Respiratory Insufficiency/*prevention & control
SARS-CoV-2
Sleep/*physiology

@article {pmid32294813,
year = {2020},
author = {, },
title = {[Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {4},
pages = {288-296},
doi = {10.3760/cma.j.cn112147-20200304-00239},
pmid = {32294813},
issn = {1001-0939},
mesh = {Betacoronavirus ; Bronchoscopy ; COVID-19 ; Consensus ; Coronavirus Infections/*prevention & control/*therapy/transmission ; Critical Illness ; Cross Infection/*prevention & control/virology ; Filtration ; Humans ; Masks ; Pandemics/*prevention & control ; Pneumonia, Viral/*prevention & control/*therapy/transmission ; Respiratory Therapy/*standards ; SARS-CoV-2 ; Ventilators, Mechanical ; },
abstract = {Definite evidence has shown that the novel coronavirus (COVID-19) could be transmitted from person to person, so far more than 1 700 bedside clinicians have been infected. A lot of respiratory treatments for critically ill patients are deemed as high-risk factors for nosocomial transmission, such as intubation, manual ventilation by resuscitator, noninvasive ventilation, high-flow nasal cannula, bronchoscopy examination, suction and patient transportation, etc, due to its high possibility to cause or worsen the spread of the virus. As such, we developed this consensus recommendations on all those high-risk treatments, based on the current evidence as well as the resource limitation in some areas, with the aim to reduce the nosocomial transmission and optimize the treatment for the COVID-19 pneumonia patients. Those recommendations include: (1)Standard prevention and protection, and patient isolation; (2)Patient wearing mask during HFNC treatment; (3)Using dual limb ventilator with filters placed at the ventilator outlets, or using heat-moisture exchanger (HME) instead of heated humidification in single limb ventilator with HME placed between exhalation port and mask; avoid using mask with exhalation port on the mask; (4)Placing filter between resuscitator and mask or artificial airway; (5)For spontaneous breathing patients, placing mask for patients during bronchoscopy examination; for patients receiving noninvasive ventilation, using the special mask with bronchoscopy port to perform bronchoscopy; (6)Using sedation and paralytics during intubation, cuff pressure should be maintained between 25-30 cmH(2)O(1 cmH(2)O=0.098 kPa); (7)In-line suction catheter is recommended and it can be used for one week; (8)Dual-limb heated wire circuits are recommended and only changed with visible soiled; (9)For patients who need breathing support during transportation, placing an HME between ventilator and patient; (10)PSV is recommended for implementing spontaneous breathing trial (SBT), avoid using T-piece to do SBT. When tracheotomy patients are weaned from ventilator, HME should be used, avoid using T-piece or tracheostomy mask. (11)Avoid unnecessary bronchial hygiene therapy; (12) For patients who need aerosol therapy, dry powder inhaler metered dose inhaler with spacer is recommended for spontaneous breathing patients; while vibrating mesh nebulizer is recommended for ventilated patients and additional filter is recommended to be placed at the expiratory port of ventilation during nebulization.},
}

Betacoronavirus
Bronchoscopy
COVID-19
Consensus
Coronavirus Infections/*prevention & control/*therapy/transmission
Critical Illness
Cross Infection/*prevention & control/virology
Filtration
Humans
Masks
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control/*therapy/transmission
Respiratory Therapy/*standards
SARS-CoV-2
Ventilators, Mechanical

@article {pmid32268984,
year = {2020},
author = {He, Y and Wei, J and Bian, J and Guo, K and Lu, J and Mei, W and Ma, J and Xia, Z and Xu, M and Yan, F and Yu, C and Wang, E and Wang, W and Zeng, N and Wang, S and Xu, J and Huang, Y and Huang, J},
title = {Chinese Society of Anesthesiology Expert Consensus on Anesthetic Management of Cardiac Surgical Patients With Suspected or Confirmed Coronavirus Disease 2019.},
journal = {Journal of cardiothoracic and vascular anesthesia},
volume = {34},
number = {6},
pages = {1397-1401},
pmid = {32268984},
issn = {1532-8422},
mesh = {Anesthesiology/methods ; Anesthetics/*therapeutic use ; COVID-19 ; Cardiovascular Diseases/surgery/virology ; Cardiovascular Surgical Procedures ; Cardiovascular System/virology ; China/epidemiology ; *Consensus ; Coronavirus Infections/*drug therapy/epidemiology ; Disease Outbreaks ; Humans ; Pandemics ; Pneumonia, Viral/*drug therapy/epidemiology ; Practice Guidelines as Topic ; Renin-Angiotensin System/physiology ; },
abstract = {The outbreak of a new coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) in China in December 2019 has brought serious challenges to disease prevention and public health. Patients with severe coronavirus disease 2019 (COVID-19) who undergo cardiovascular surgery necessitate extremely high demands from anesthesia personnel, and face high risks of mortality and morbidity. Based on the current understanding of COVID-19 and the clinical characteristics of cardiovascular surgical patients, the authors provide anesthesia management guidelines for cardiovascular surgery along with the prevention and control of COVID-19.},
}

Anesthesiology/methods
Anesthetics/*therapeutic use
COVID-19
Cardiovascular Diseases/surgery/virology
Cardiovascular Surgical Procedures
Cardiovascular System/virology
China/epidemiology
*Consensus
Coronavirus Infections/*drug therapy/epidemiology
Disease Outbreaks
Humans
Pandemics
Pneumonia, Viral/*drug therapy/epidemiology
Practice Guidelines as Topic
Renin-Angiotensin System/physiology

@article {pmid32234175,
year = {2020},
author = {, and , },
title = {[Expert consensus on principal of clinical management of patients with severe emergent cardiovascular diseases during the epidemic period of COVID-19].},
journal = {Zhonghua xin xue guan bing za zhi},
volume = {48},
number = {3},
pages = {189-194},
doi = {10.3760/cma.j.cn112148-20200210-00066},
pmid = {32234175},
issn = {0253-3758},
mesh = {*Betacoronavirus ; COVID-19 ; *Cardiovascular Diseases/complications ; Consensus ; Coronavirus Infections/*complications/epidemiology ; Epidemics ; Humans ; Pandemics ; Pneumonia, Viral/*complications/epidemiology ; SARS-CoV-2 ; },
}

*Betacoronavirus
COVID-19
*Cardiovascular Diseases/complications
Consensus
Coronavirus Infections/*complications/epidemiology
Epidemics
Humans
Pandemics
Pneumonia, Viral/*complications/epidemiology
SARS-CoV-2

@article {pmid32219814,
year = {2020},
author = {Specialized Committee Of Neurogenetics Neurophysician Branch Of Chinese Medical Doctor Association, and Jiang, H and Tang, B},
title = {[Expert consensus on the management strategy of patients with hereditary ataxia during prevention and control of novel coronavirus pneumonia epidemic].},
journal = {Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics},
volume = {37},
number = {4},
pages = {359-366},
doi = {10.3760/cma.j.issn.1003-9406.2020.04.001},
pmid = {32219814},
issn = {1003-9406},
mesh = {Betacoronavirus ; COVID-19 ; China/epidemiology ; Consensus ; Coronavirus Infections/complications/*epidemiology ; Epidemics ; Health Status ; Humans ; Mental Health ; Nervous System Diseases/virology ; Pandemics ; Pneumonia, Viral/complications/*epidemiology ; SARS-CoV-2 ; *Spinocerebellar Degenerations/complications/diagnosis/prevention & control/therapy ; },
abstract = {Since December 2019, a series of highly infectious cases of unexplained pneumonia have been discovered in Wuhan, Hubei Province, which have been confirmed as '2019 corona virus disease' caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 virus can invade many human systems including the lungs. Patients with central nervous system involvement may show a series of neurological symptoms, which is easy to be misdiagnosed and neglected, thereby increasing the risk of SARS-CoV-2 transmission. Hereditary ataxia is a large group of neurodegenerative diseases with great clinical and genetic heterogeneity and high mortality and disability. In view of the seriousness of the COVID-19 epidemic, a series of prevention and control measures adopted by the government have restricted the follow-up, diagnosis and treatment of patients by the hospitals, which has a great impact on their mental and physical health. In order to standardize the management of patients during the prevention and control of COVID-19 epidemic, the Specialized Committee of Neurogenetics of the Neurophysician Branch of Chinese Medical Doctor Association has formulated this consensus, with an aim to help patients to overcome the difficulties and pass the epidemic prevention period safely.},
}

Betacoronavirus
COVID-19
China/epidemiology
Consensus
Coronavirus Infections/complications/*epidemiology
Epidemics
Health Status
Humans
Mental Health
Nervous System Diseases/virology
Pandemics
Pneumonia, Viral/complications/*epidemiology
SARS-CoV-2
*Spinocerebellar Degenerations/complications/diagnosis/prevention & control/therapy

@article {pmid32164085,
year = {2020},
author = {, },
title = {[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {3},
pages = {185-188},
doi = {10.3760/cma.j.issn.1001-0939.2020.03.009},
pmid = {32164085},
issn = {1001-0939},
support = {2020B111113001//Emergency program for major public health event of Ministry of Science and Technology, Department of Science and Technology of Guangdong Province/ ; 2020GZR110106003//Guangzhou Regenerative Medicine and Health Guangdong Laboratory: Evaluation of clinical efficacy of chloroquine on 2019 novel coronavirus pneumonia/ ; },
mesh = {Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage ; COVID-19 ; China ; Chloroquine/administration & dosage/*analogs & derivatives ; Consensus ; Coronavirus Infections/*complications ; Drug Administration Schedule ; Humans ; Length of Stay ; Pneumonia, Viral/*complications/drug therapy/etiology ; Practice Guidelines as Topic ; },
abstract = {At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.},
}

Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
COVID-19
China
Chloroquine/administration & dosage/*analogs & derivatives
Consensus
Coronavirus Infections/*complications
Drug Administration Schedule
Humans
Length of Stay
Pneumonia, Viral/*complications/drug therapy/etiology
Practice Guidelines as Topic

@article {pmid32164084,
year = {2020},
author = {Zhao, JP and Hu, Y and Du, RH and Chen, ZS and Jin, Y and Zhou, M and Zhang, J and Qu, JM and Cao, B},
title = {[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {3},
pages = {183-184},
doi = {10.3760/cma.j.issn.1001-0939.2020.03.008},
pmid = {32164084},
issn = {1001-0939},
mesh = {Adrenal Cortex Hormones/*therapeutic use ; *Betacoronavirus ; COVID-19 ; Consensus ; Coronavirus Infections/*drug therapy ; Humans ; Pneumonia, Viral/*drug therapy ; SARS-CoV-2 ; COVID-19 Drug Treatment ; },
}

Adrenal Cortex Hormones/*therapeutic use
*Betacoronavirus
COVID-19
Consensus
Coronavirus Infections/*drug therapy
Humans
Pneumonia, Viral/*drug therapy
SARS-CoV-2
COVID-19 Drug Treatment

@article {pmid32129580,
year = {2020},
author = {, and , },
title = {[Expert consensus on pulmonary function testing during the epidemic of coronavirus disease 2019].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {43},
number = {4},
pages = {302-307},
doi = {10.3760/cma.j.cn112147-20200225-00175},
pmid = {32129580},
issn = {1001-0939},
support = {2018YFC1311900, 2016YFC1304603//National Key Research and Develop Program of China/ ; 2015BAI12B10//National Science and Technology Support Plan/ ; },
mesh = {Betacoronavirus ; COVID-19 ; Consensus ; Coronavirus Infections/*prevention & control ; Disinfection ; Humans ; Infection Control/*methods ; Pandemics/*prevention & control ; Pneumonia, Viral/*prevention & control ; Respiratory Function Tests/*standards ; SARS-CoV-2 ; },
abstract = {Coronavirus disease 2019 (COVID-19) is transmitted mainly by respiratory droplets and close contact, probably by aerosol. Pulmonary function testing procedures have been associated with an increasing risk of COVID-19 transmission among patients/subjects and medical staffs. Effective prevention and control strategies must be compulsorily implemented to prevent nosocomial infection. This recommendation is intended to be followed by healthcare workers (HCWs) of pulmonary function testing laboratory when COVID-19 is in epidemic. Based on the features of pulmonary function testing, precaution principles and considerations are developed in three aspects of management for HCWs, operating procedure, environment and equipment. Indications of pulmonary function testing should be followed strictly. It is strongly recommended to suspend the test for the confirmed or suspected cases of COVID-19 during the contagious stage, and to postpone the test for other patients if it is not imperative. Medical personnel should mandatorily adhere to the standard stratification of precaution measures. Patients/Subjects should be isolated in a separate area for testing. Disposable in-line filters must be used during pulmonary function testing. Cleaning and disinfection procedures for environment and equipment in pulmonary function testing laboratory should be paid more attention.},
}

Betacoronavirus
COVID-19
Consensus
Coronavirus Infections/*prevention & control
Disinfection
Humans
Infection Control/*methods
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Respiratory Function Tests/*standards
SARS-CoV-2

@article {pmid32028773,
year = {2020},
author = {, },
title = {Fighting the novel coronavirus: the publication of the Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition).},
journal = {Annals of palliative medicine},
volume = {9},
number = {2},
pages = {524-525},
doi = {10.21037/apm.2020.02.02},
pmid = {32028773},
issn = {2224-5839},
mesh = {Betacoronavirus ; COVID-19 ; China ; *Consensus ; Coronavirus Infections/*prevention & control/therapy ; Female ; Humans ; Infant Care/standards ; Infant Welfare/*prevention & control ; Infant, Newborn ; Mass Screening/standards ; Pandemics/*prevention & control ; Perinatal Care/*standards ; Pneumonia, Viral/*prevention & control/therapy ; Practice Guidelines as Topic ; Pregnancy ; SARS-CoV-2 ; },
}

Betacoronavirus
COVID-19
China
*Consensus
Coronavirus Infections/*prevention & control/therapy
Female
Humans
Infant Care/standards
Infant Welfare/*prevention & control
Infant, Newborn
Mass Screening/standards
Pandemics/*prevention & control
Perinatal Care/*standards
Pneumonia, Viral/*prevention & control/therapy
Practice Guidelines as Topic
Pregnancy
SARS-CoV-2

@article {pmid41369685,
year = {2025},
author = {Mohammadi, R and Morovati, H and Safari, F},
title = {The human mycobiome: a critical yet understudied component of health and disease.},
journal = {Microbiology (Reading, England)},
volume = {171},
number = {12},
pages = {},
doi = {10.1099/mic.0.001631},
pmid = {41369685},
issn = {1465-2080},
mesh = {Humans ; *Mycobiome ; *Fungi/genetics/classification/isolation & purification/physiology ; COVID-19/microbiology/complications ; Dysbiosis/microbiology ; SARS-CoV-2 ; Metagenomics ; Neoplasms/microbiology ; },
abstract = {The human body hosts a complex and dynamic microbial community that is crucial for maintaining health. While bacteria dominate this system, fungal communities, collectively called the mycobiome, are increasingly recognized as vital contributors. However, fungi remain understudied due to challenges in culturing many species, limiting our understanding of their roles, interactions and effects on human biology. Advances in next-generation sequencing have transformed mycobiome research, revealing fungal diversity and its impact on health and disease. This review examines the mycobiome's composition and function across major body sites, including the gut, mouth, lungs, reproductive tract and skin. It also explores connections between fungal imbalances (dysbiosis) and diseases such as neurological disorders, cancer and post-COVID-19 complications. Despite progress, challenges persist, including the need for better culture-independent diagnostic tools and standardized research methods. Combining culturomics and metagenomics could help overcome these limitations and identify new treatment targets. By summarizing current knowledge and highlighting research gaps, this review aims to guide future studies on the mycobiome's role in human health.},
}

Humans
*Mycobiome
*Fungi/genetics/classification/isolation & purification/physiology
COVID-19/microbiology/complications
Dysbiosis/microbiology
SARS-CoV-2
Metagenomics
Neoplasms/microbiology

@article {pmid41369389,
year = {2025},
author = {Niedzielska, A and Bossowska-Nowicka, M and Biernacka, Z and Gregorczyk-Zboroch, K and Toka, FN and Szulc-Dąbrowska, L},
title = {Shaping the Immune Response: Cathepsins in Virus-Dendritic Cell Interactions.},
journal = {Cells},
volume = {14},
number = {23},
pages = {},
doi = {10.3390/cells14231900},
pmid = {41369389},
issn = {2073-4409},
support = {UMO-2020/39/O/NZ6/03252//National Science Centre/ ; //Science Development Fund of the Warsaw University of Life Sciences-SGGW/ ; },
mesh = {Humans ; *Dendritic Cells/immunology/virology/metabolism ; *Cathepsins/metabolism/immunology ; Animals ; *Virus Diseases/immunology ; SARS-CoV-2/immunology ; },
abstract = {Dendritic cells (DCs) are among the first immune cells to detect viral invasion and play a central role in initiating and shaping antiviral immune responses. Many innate and adaptive immune functions of DCs are regulated by cathepsins, proteolytic enzymes primarily found in acidic endolysosomal compartments. Different DC subsets exhibit distinct cathepsin expression patterns, influencing their functional capacities and interactions with viruses. In DCs, cathepsins contribute to virus sensing through innate receptors, regulate cytokine production and DC migration, and are essential for viral antigen degradation and loading onto MHC molecules for T-cell activation. Many viruses, however, have evolved mechanisms to alter cathepsin expression and activity, thereby subverting DC function and promoting their own persistence. Indeed, cathepsins can facilitate viral entry into DCs, promote viral replication, and support immune evasion strategies. In this review, we summarize recent advances in understanding the role of cathepsins in DC-virus interactions, emphasizing both how DCs exploit cathepsins to generate protective immune responses and how viruses manipulate cathepsin activity to their advantage. We particularly focus on clinically relevant viral pathogens, including HIV, influenza virus, hepatitis C virus, human cytomegalovirus, Ebola virus, and SARS-CoV-2, to illustrate the multifaceted influence of cathepsins on DC biology during viral infection.},
}

Humans
*Dendritic Cells/immunology/virology/metabolism
*Cathepsins/metabolism/immunology
Animals
*Virus Diseases/immunology
SARS-CoV-2/immunology

@article {pmid41368891,
year = {2025},
author = {Pinero, S and Li, X and Zhang, J and Winter, M and Lee, SH and Nguyen, T and Liu, L and Li, J and Le, TD},
title = {Omics-based computational approaches for biomarker identification, prediction, and treatment of Long COVID.},
journal = {Critical reviews in clinical laboratory sciences},
volume = {},
number = {},
pages = {1-27},
doi = {10.1080/10408363.2025.2583083},
pmid = {41368891},
issn = {1549-781X},
abstract = {Long COVID, or post-acute sequelae of COVID-19 (PASC), is a major global health problem, with cumulative estimates suggesting that around 400 million people worldwide have been affected. It is characterized by persistent or new symptoms such as fatigue, cognitive impairment, and breathlessness lasting beyond four weeks after acute infection. Diverse clinical manifestations, chronic course, and incompletely understood pathophysiology-including hypotheses involving viral persistence, immune dysregulation, autoimmunity, endothelial dysfunction, and metabolic reprogramming-impede the development of diagnostic criteria, biomarkers, and targeted therapies. We conducted a critical review of 101 Long COVID omics studies, focusing on the computational methods used and their methodological quality. Using standardized criteria, we evaluated study design, statistical rigor, reproducibility, and clinical relevance across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and multiomics integration, and mapped these findings onto regulatory and translational frameworks. Despite substantial methodological heterogeneity, convergent biological signals emerged. Genomic studies implicate risk loci in immune and cardiopulmonary pathways. Epigenomic analyses identify differentially methylated regions in immune and circadian genes. Transcriptomic studies reveal persistent dysregulation of innate immune and coagulation pathways, as well as reproducible molecular endotypes. Proteomic studies consistently show abnormalities in the complement cascade and coagulation, with a small panel of complement proteins showing highly reproducible changes across independent cohorts. Metabolomic studies demonstrate sustained mitochondrial dysfunction and altered cellular bioenergetics for up to two years after infection. Multiomics integration supports at least two major endotypes, characterized by predominant inflammatory versus metabolic dysregulation, and provides a basis for patient stratification and computational treatment discovery. Machine learning models frequently achieve high classification performance, but are rarely externally validated. Critical limitations restrict clinical translation. Most studies are underpowered relative to analytical complexity, use heterogeneous case definitions and controls, and report platform-specific signatures with limited overlap. External validation, preregistered analysis plans, and regulatory-aligned assay development are uncommon. To date, no regulatory-approved diagnostic assay or evidence-based therapeutic intervention has directly emerged from these computational findings. Future progress requires harmonized phenotyping protocols, adequately powered longitudinal cohorts with external validation, integration of spatial omics and explainable artificial intelligence, and early engagement with regulatory and health-technology assessment pathways. This review provides a critical assessment and a translational roadmap, outlining how methodologically robust computational omics can be advanced toward clinically actionable tools for Long COVID.},
}

@article {pmid41317559,
year = {2025},
author = {Angeloni, NA and Adhikari, NK and Lamontagne, F},
title = {A Practical Review of Adaptive Platform Trials.},
journal = {Transfusion medicine reviews},
volume = {39},
number = {4},
pages = {150935},
doi = {10.1016/j.tmrv.2025.150935},
pmid = {41317559},
issn = {1532-9496},
mesh = {Humans ; *COVID-19/therapy/epidemiology ; *SARS-CoV-2 ; Bayes Theorem ; *Randomized Controlled Trials as Topic/methods ; *Adaptive Clinical Trials as Topic/methods ; Research Design ; Pandemics ; },
abstract = {Traditional randomized controlled trials (RCTs) can provide rigorous evidence but are often slow and resource-intensive, requiring separate trials for each intervention. Adaptive platform trials (APTs) have been promoted as a solution, offering a framework that tests multiple therapies under a single protocol, with arms added or dropped as evidence accumulates. However, their advantages come with trade-offs that warrant scrutiny. In this review, we critically appraise 3 landmark APTs. The I-SPY2 trial accelerated Phase II oncology research by utilizing Bayesian adaptive randomization and surrogate endpoints; however, much of its efficiency stemmed from relying on intermediate outcomes, which may not reliably predict survival. RECOVERY demonstrated the power of scale on a pragmatic UK-wide platform, but its success reflected health system infrastructure, political leadership, and the unique circumstances of the COVID-19 pandemic as much as its design. REMAP-CAP, a perpetual platform trial for pneumonia, rapidly switched to pandemic mode in 2020 and tested COVID-19 therapies using Bayesian models and response-adaptive randomization (RAR); however, the RAR amplified random noise in some domains, exposing patients to interventions later shown to be ineffective. A recent systematic review confirmed wide heterogeneity in APTs and suboptimal reporting. APTs are not inherently better than classical RCTs. Gains in speed may depend on less rigorous endpoints, complex adaptive methods, or streamlined oversight, each of which introduces new risks of error. As APTs spread to new fields such as transfusion medicine, clinicians and researchers must learn to recognize both the potential benefits and the pitfalls of this design.},
}

Humans
*COVID-19/therapy/epidemiology
*SARS-CoV-2
Bayes Theorem
*Randomized Controlled Trials as Topic/methods
*Adaptive Clinical Trials as Topic/methods
Research Design
Pandemics

@article {pmid40866234,
year = {2025},
author = {Chen, G and Yuan, J and Wei, Y and Wu, Y and Zhang, Q and Li, X and Fu, L and Gao, Y and Zheng, Y and Sun, H and Weng, W and Chen, J and Chong, Y and Wu, T and Wu, G and Gong, Z and Deng, X and Mao, L and Huang, C and Qu, Z and Qin, B and Jiang, Y and Lin, F and Lin, B and Liu, X and Xu, K and Peng, J and Wu, Z and Liu, C and Li, W and Qiao, K and Yang, L and Ye, C and Huang, J and Xu, Y and Zhang, J and Sun, Y and Lai, X and Liu, B and Qian, W and Li, X and Yu, H and Yang, X and Hu, Z and Lu, H and , },
title = {Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection.},
journal = {Bioscience trends},
volume = {19},
number = {5},
pages = {484-494},
doi = {10.5582/bst.2025.01244},
pmid = {40866234},
issn = {1881-7823},
mesh = {Humans ; *Antiviral Agents/therapeutic use/administration & dosage ; *COVID-19 Drug Treatment ; SARS-CoV-2/drug effects ; China ; Drug Therapy, Combination ; Ritonavir/therapeutic use ; Consensus ; COVID-19 ; East Asian People ; },
abstract = {The persistent mutation of the novel coronavirus (SARS-CoV-2) not only remains a threat to human health but also continues to challenge existing antiviral therapeutic strategies. In current clinical practice, the resistance of novel coronavirus to antivirals, the rebound of viral load after treatment with drugs such as nirmatrelvir/ritonavir (NTV/r), and the urgent need for rapid clearance of the virus in the management of critically and emergently ill patients suggest that the existing single-drug regimens may have limitations and that the intensity of suppression may be insufficient in some cases. In clinical practice, we have observed that a combination of antivirals with different mechanisms of action can result in better efficacy and not significantly increase adverse drug reactions (ADRs). For some immunosuppressed, post-transplantation, or other special patients in particular, such as those in whom COVID-19 nucleic acids tended not to be negative after conventional treatment, when virus clearance is still the main goal, the combination of small-molecule antivirals can help to clear the virus as early as possible and attempt to improve the success rate of salvage. Based on evidence-based medicine and in light of the current situation of China, we assembled experts from disciplines such as infectious diseases, respiratory medicine, critical care medicine, and clinical pharmacy into a group to carry out a systematic literature search and identify key issues and to put forward relevant recommendations to reach an Expert Consensus on Combined Use of Oral Small-molecule Antivirals to Treat COVID-19, which is intended to serve as a reference for clinical practice.},
}

Humans
*Antiviral Agents/therapeutic use/administration & dosage
*COVID-19 Drug Treatment
SARS-CoV-2/drug effects
China
Drug Therapy, Combination
Ritonavir/therapeutic use
Consensus
COVID-19
East Asian People

@article {pmid40850755,
year = {2025},
author = {Chen, G and Lu, H},
title = {Expert consensus on combination antiviral therapy for high-risk COVID-19 patients: A timely call to action.},
journal = {Bioscience trends},
volume = {19},
number = {5},
pages = {479-483},
doi = {10.5582/bst.2025.01254},
pmid = {40850755},
issn = {1881-7823},
mesh = {Humans ; *Antiviral Agents/therapeutic use/administration & dosage ; *COVID-19 Drug Treatment ; Consensus ; COVID-19 ; SARS-CoV-2 ; Drug Therapy, Combination ; China/epidemiology ; },
abstract = {On May 5, 2023, the WHO declared that the COVID-19 pandemic no longer constitutes a public health emergency of international concern (PHEIC), but SARS-CoV-2 continues to spread and evolve on a global scale. The WHO reported that COVID-19 still poses a threat to humanity, and especially in some areas with large numbers of infected people. For some high-risk COVID-19 patients, such as those with underlying conditions, elderly patients, patients who need long-term immunosuppressive therapy after organ transplantation, patients with immunosuppressive diseases, patients who tend not to test negative for SARS-CoV-2 despite standard antiviral therapy, and cancer patients, special attention is still required after infection with SARS-CoV-2. How to clear SARS-CoV-2 in a timely manner is the key to treating such patients. Based on the demands of clinical practice and medical evidence, the National Center for Infectious Diseases of China assembled experts from relevant disciplines to reach the Chinese expert consensus on the combined use of antivirals to treat COVID-19, providing timely suggestions to resolve the medication issues that have been plaguing clinical practice. The consensus suggests that for special patients, combined medication can promptly eliminate the virus without increasing the risk to patient safety.},
}

Humans
*Antiviral Agents/therapeutic use/administration & dosage
*COVID-19 Drug Treatment
Consensus
COVID-19
SARS-CoV-2
Drug Therapy, Combination
China/epidemiology

@article {pmid40205292,
year = {2025},
author = {Unni, EJ and Schougaard, LMV and Aiyegbusi, OL and Mate, KKV and Austin, EJ and Greffin, K and Roberts, N and Grove, BE and Muehlan, H and , },
title = {Expert consensus on implementing patient-reported outcomes in telehealth: findings from an international Delphi study.},
journal = {Journal of patient-reported outcomes},
volume = {9},
number = {1},
pages = {40},
pmid = {40205292},
issn = {2509-8020},
mesh = {Humans ; *Telemedicine ; Delphi Technique ; *Patient Reported Outcome Measures ; Consensus ; *COVID-19/epidemiology ; SARS-CoV-2 ; Pandemics ; },
abstract = {BACKGROUND: Using Patient Reported Outcomes (PROs) in clinical care can reduce healthcare service utilization by improving the quality of care. Telehealth, defined by WHO, as the use of "telecommunications and virtual technology to deliver healthcare outside of traditional healthcare facilities", can facilitate a dynamic dialogue between patients and healthcare providers for timely interventions. With the increased use of telehealth facilitated by the infrastructure development during the COVID-19 pandemic, there is an opportunity to utilize telehealth for PRO implementation and a need for guidelines for using PROs via telehealth. This study aimed to generate expert consensus on the utilization of PROs in telehealth.

METHODS: Delphi methodology was used to achieve consensus among international experts with a predetermined consensus threshold of 70%. Experts were mainly identified through the ISOQOL Clinical Practice SIG. Surveys asked a combination of structured and open-ended questions about the conceptualization of PROs in telehealth, its applicability, target population, implementation challenges and successful strategies, evaluation approaches, and the essential stakeholders. Data from each round were iteratively analyzed using descriptive statistics (quantitative data) and content analysis (qualitative data).

RESULTS: Out of 24 invitations sent, 17 completed the first round, and 11 completed all three rounds. Respondents were equally distributed between clinicians and researchers and 70% had used PROs via telehealth before the pandemic. Consensus was achieved and some of the relevant aspects are monitoring patients for applicability; individuals with chronic diseases as the target population; resources, staff buy-in, and clinical workflow as the implementation challenges and strategies; utilization metrics for evaluation; and clinicians and patients as essential stakeholders. Though consensus was not reached for the conceptualization of PROs using telehealth, the modified FDA definition of telehealth with the addition of its purpose, and the mode of administration was the most acceptable version. See attached table.

CONCLUSION: The expert consensus achieved provides important insights from an international perspective on how PROs are currently used via telehealth and the needed implementation support to advance their expansion in research and practice. Lack of consensus on the definition of PROs in telehealth signals the continued rapid evolution of their use and the need for additional research.},
}

Humans
*Telemedicine
Delphi Technique
*Patient Reported Outcome Measures
Consensus
*COVID-19/epidemiology
SARS-CoV-2
Pandemics

@article {pmid40108925,
year = {2025},
author = {Sinha, V and Roy, S and Shinde, S and Mondal, D and Dixit, V and Dwivedi, D and Pandey, SK and Gupta, RK and Vishwakarma, NK and Shukla, D},
title = {Navigating Cardiovascular Challenges of Obesity: Exploring Preventive Approaches.},
journal = {Endocrine, metabolic & immune disorders drug targets},
volume = {25},
number = {12},
pages = {918-940},
pmid = {40108925},
issn = {2212-3873},
mesh = {Humans ; *Obesity/epidemiology/therapy/complications ; *Cardiovascular Diseases/prevention & control/epidemiology/etiology ; *COVID-19/epidemiology/prevention & control ; SARS-CoV-2 ; Risk Factors ; Life Style ; },
abstract = {The global prevalence of obesity has surged to epidemic proportions, posing a significant threat to public health in the twenty-first century. Beyond its established association with metabolic diseases, obesity profoundly impacts cardiovascular health, serving as a major risk factor for various cardiovascular illnesses (CVDs), including coronary artery disease, heart failure, hypertension, and stroke. Mechanistically, obesity triggers a cascade of pathophysiological processes, including chronic inflammation and insulin resistance, exacerbating atherosclerosis and endothelial dysfunction. Moreover, obesity correlates with metabolic abnormalities that further elevate the risk of cardiovascular events. As global community has faced the COVID-19 pandemic, and thus, the aftereffects of the pandemic might pose a spectrum of post-viral complications, including cardiovascular sequelae such as myocarditis and arrhythmias. Considering the intersectionality of obesity, COVID-19, and cardiovascular health are imperative, particularly as obese individuals face heightened risks of severe post-COVID-19 effects and subsequent cardiovascular complications. Lifestyle management emerges as a cornerstone in preventing and managing obesity-related cardiovascular risks, encompassing dietary modifications, physical activity, behavioural therapies, and patient education. Embracing innovative approaches, including modulation of gut microbiota and novel drug developments, holds promise in addressing the intricate nexus between obesity and cardiovascular diseases. This review underscores the paramount importance of lifestyle interventions over pharmacological measures, advocating for a comprehensive approach involving healthcare practitioners, researchers, and policymakers to mitigate the long-term cardiovascular consequences of obesity and COVID-19.},
}

Humans
*Obesity/epidemiology/therapy/complications
*Cardiovascular Diseases/prevention & control/epidemiology/etiology
*COVID-19/epidemiology/prevention & control
SARS-CoV-2
Risk Factors
Life Style

@article {pmid40059678,
year = {2025},
author = {, and , and , },
title = {[Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2025)].},
journal = {Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
volume = {46},
number = {1},
pages = {18-30},
pmid = {40059678},
issn = {0253-2727},
mesh = {Humans ; Consensus ; COVID-19/prevention & control ; Evidence-Based Medicine ; *Hematologic Neoplasms/therapy/drug therapy/complications ; *Immunotherapy ; *Molecular Targeted Therapy/adverse effects ; SARS-CoV-2 ; China ; East Asian People ; },
abstract = {As novel therapeutic agents continue to emerge, immunotherapy and molecular-targeted drugs demonstrate expanding application prospects in hematological malignancy treatment. This expert consensus revision incorporates the latest evidence-based medicine from domestic and international sources, updating recommendations for infection diagnosis, prevention, and treatment. The document integrates recommendations for recently launched or imminent antibodies and small molecule targeted compounds, including COVID-19 considerations. This format of recommendations is modified according to the levels of evidence of The Oxford Centre for Evidence-Based Medicine (CEBM).},
}

Humans
Consensus
COVID-19/prevention & control
Evidence-Based Medicine
*Hematologic Neoplasms/therapy/drug therapy/complications
*Immunotherapy
*Molecular Targeted Therapy/adverse effects
SARS-CoV-2
China
East Asian People

@article {pmid39865009,
year = {2025},
author = {, },
title = {[Expert consensus on flow cytometry-based assays for SARS-CoV-2-specific T cells and related operating procedure].},
journal = {Zhonghua yi xue za zhi},
volume = {105},
number = {4},
pages = {261-270},
doi = {10.3760/cma.j.cn112137-20240923-02164},
pmid = {39865009},
issn = {0376-2491},
support = {EKPG21-30-3//Emergency Key Program of Guangzhou Laboratory/ ; },
mesh = {Humans ; *Flow Cytometry/methods ; *SARS-CoV-2/immunology ; Consensus ; COVID-19/immunology ; *T-Lymphocytes/immunology ; },
abstract = {T-cell immune response is an important component of antiviral immunity, it is of great significance to determine their absolute counts, relative frequencies and functionalities for evaluating protective immunity in individuals and population. However, there is a lack of guidelines or a consensus on assays for antigen-specific T cells. It is necessary to evaluate the SARS-CoV-2-specific T cells in population during and after COVID-19 epidemic. To standardize the detection method for SARS-CoV-2-specific T cells, the Chinese Society for Immunology organized experts and reached a consensus on the detection method, biomarker combination scheme, technical points of SOP, quality control, data analysis and interpretation of results, personnel training, etc. The consensus is of guiding significance to establish standard detection methods and operating procedures for SARS-CoV-2-specific T cells, which is beneficial for the consistency and comparability of results from different laboratories, and also provides reference for antigen-specific T cell standard detection methods for other pathogens (such as influenza) infection.},
}

Humans
*Flow Cytometry/methods
*SARS-CoV-2/immunology
Consensus
COVID-19/immunology
*T-Lymphocytes/immunology

@article {pmid39757093,
year = {2025},
author = {, },
title = {[Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition)].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {48},
number = {1},
pages = {18-34},
doi = {10.3760/cma.j.cn112147-20240611-00328},
pmid = {39757093},
issn = {1001-0939},
support = {2023YFC0872500//National Key Research and Development Program Sponsored by the Ministry of Science and Technology of the People's Republic of China/ ; 2022YFC2303200//National Key Research and Development Program Sponsored by the Ministry of Science and Technology of the People's Republic of China/ ; },
mesh = {Humans ; *Pneumonia/diagnosis/therapy ; Aged ; China/epidemiology ; *Consensus ; Quality of Life ; East Asian People ; },
abstract = {China is experiencing a demographic shift as its population ages. The elderly population becomes increasingly susceptible to pneumonia. Pneumonia in the elderly is characterized by its insidious onset, rapid progression, multiple comorbidities, poor prognosis, and high morbidity and mortality. Physicians need to pay attention to developing more comprehensive diagnostic evaluations and treatment strategies, and ensuring personalized care to the greatest extent. In order to improve the prevention and management of pneumonia in elderly, this consensus incorporates the latest guidelines and consensus from both domestic and international sources. The latest progress in this research field is also included. The document addresses 17 clinical issues in a question-and-answer format and provides 13 recommendations on the etiology, pathogenesis, clinical diagnosis, treatment, and prevention of pneumonia in older adults. It provides reference for the prevention and treatment of pneumonia in elderly, improving their quality of life, reducing hospitalization and mortality, and promoting healthy aging. The specific recommendations are as follows.Recommendation 1:The main risk factors for pneumonia in the elderly include age (Recommended Level ⅠA), age-related systemic factors (such as poor physical condition, underlying diseases, and concomitant medications), and specific factors (specifically dysphagia and aspiration). The risk increases progressively with age (Recommended Level Ⅱ-1A).Recommendation 2:Pneumonia in elderly individuals often presents with an insidious onset and atypical respiratory symptoms, especially in super-elderly patients. Initially, symptoms may include fatigue, loss of appetite, and disturbance of consciousness. Moreover, elderly patients often have underlying conditions such as pulmonary, cardiovascular, and neurological disorders, which can lead to rapid deterioration, multiple complications and sequelae. Pneumonia-related laboratory parameters in the elderly lack typical characteristic changes (Recommended Level ⅢA). The high proportion of comorbidities significantly increases the risk of pneumonia, especially pneumonia caused by drug-resistant bacteria, and the likelihood of a worse prognosis in elderly patients (Recommended Level Ⅱ-2A). Neurological or psychiatric disorders and therapeutic drugs such as antipsychotic drugs increase the risk of pneumonia including aspiration pneumonia, necrotizing pneumonia, lung abscess, hypostatic pneumonia and atelectasis in elderly patients (Recommended Level Ⅱ-2B).Recommendation 3:For elderly patients with suspected pneumonia, chest CT should be performed as early as possible in cases of long-term bed-ridden patients, aspiration pneumonia, or viral pneumonia (Recommended Level ⅢA). If conventional tests fails to identify the pathogen and empirical treatment proves to be ineffective, or if special pathogen infection such as viruses, severe or complex infection, or immunosuppression is suspected, it is advised to use invasive procedures to obtain bronchoalveolar lavage fluid (BALF), pleural effusion, or lung biopsy, and to conduct molecular biology testing (PCR, mNGS, tNGS, etc.) concurrently with conventional pathogen tests (Recommended Level ⅢA).Recommendation 4:The pharmacokinetics (PK) changes of antimicrobial drugs in elderly patients and necessity of dosage reduction should be evaluated according to the unique physiological characteristics of the elderly, such as declining body function, the presence of multiple diseases, and potential medication interactions. It is recommended to combine the PK/PD characteristics of antimicrobial drugs and therapeutic drug monitoring (TDM) methods to guide the individualized and precise prescription for elderly patients with pneumonia. This approach aims to ensure efficacy, minimizing the risk of bacterial resistance, and reduce the incidence of adverse reactions (Recommended Level Ⅱ-2B).Recommendation 5:Timing of treatment: Empiric antimicrobial therapy should be initiated as soon as the diagnosis is made. Except for outpatient clinic visitors with mild symptoms, properly collected respiratory secretions and blood samples should be sent without delay for pathogenic microorganisms testing. During the influenza season, timely empiric antiviral therapy should be initiated without positive result (Recommended Level Ⅱ-1A).Recommendation 6:Coverage of possible pathogens: Due to the increased detection rate of various pathogens such as gram-negative bacteria, anaerobic bacteria, fungi, etc., the initial treatment should cover the possible pathogens. Individualized treatment should be started according to the estimation of drug resistance risk, the of PK/PD principle, and potential drug side effects (Recommended Level Ⅱ-1A).Recommendation 7:Appropriate treatments for promoting sputum drainage and airway clearance in elderly pneumonia patients should be chosen after a comprehensive evaluation of the patient's condition. It is crucial to assess the patient's coughing efficacy to avoid asphyxia (Recommended Level ⅢA).Recommendation 8:We recommend cautious use of glucocorticoids in elderly pneumonia patients. When it is indeed necessary to use glucocorticoids in severe pneumonia cases accompanied by septic shock and hemodynamic instability, it's crucial to tailor drug regimens carefully, monitor closely for adverse reactions, and avoid excessive or prolonged glucocorticoid use (Recommended Level ⅢB).Recommendation 9:Assessing the swallowing abilities of elderly patients is important, and individuals with dysphagia should undergo swallowing rehabilitation. These measures can help reduce the risk of aspiration pneumonia, such as adopting a semi-recumbent posture, thickened fluids and soft foods, proper dental care, tube feeding, and discontinuing medications that increase the risk of aspiration pneumonia in older patients (Recommended Level ⅡA).Recommendation 10:We recommend that elderly individuals get an annual influenza virus vaccine (Recommended Level ⅠA), 23-valent pneumococcal polysaccharide vaccine (PPV 23) or the 13-valent pneumococcal conjugate vaccine (PCV 13) to prevent CAP (Recommended Level ⅠB), and COVID-19 vaccine should also be recommended in accordance with national guidelines (Recommended Level ⅠA).Recommendation 11:Older individuals should quit smoking, limit alcohol intake, participate in moderate-intensity physical activity (Recommended Level Ⅱ-1A), have regular dental examinations, maintain good nutritional status and personal hygiene, and avoid close contact with children with acute viral respiratory infections (Recommended Level Ⅱ-2A).Recommendation 12:The super-elderly are more likely to experience geriatric syndromes, particularly sarcopenia and frailty, which are closely associated with the occurrence of aspiration pneumonia. Preventing and improving sarcopenia and weakness through nutrition supplement, exercise, cognitive training, etc., can effectively reduce the incidence of pneumonia (Recommended Level ⅢA).Recommendation 13:We recommend that older adults with chronic underlying medical conditions, who are at increased risk of developing pneumonia, should receive personalized management and comprehensive preventive measures to strengthen the management of underlying diseases. Perioperative care for older patients should be optimized to reduce the risk of postoperative pneumonia (Recommended Level ⅢA).},
}

Humans
*Pneumonia/diagnosis/therapy
Aged
China/epidemiology
*Consensus
Quality of Life
East Asian People

@article {pmid38832476,
year = {2024},
author = {Kang, CR and Ahn, B and Choe, YJ and Lim, SY and Kim, HW and Kang, HM and Park, JY and Lee, H and Lee, S and Jeong, S and Kwon, S and Choi, EH},
title = {Expert Consensus on the Structure, Role, and Procedures of the Korea Expert Committee on Immunization Practices.},
journal = {Journal of Korean medical science},
volume = {39},
number = {21},
pages = {e166},
pmid = {38832476},
issn = {1598-6357},
support = {2023-10-019/KDCA/Korea Disease Control and Prevention Agency/Korea ; },
mesh = {Humans ; Republic of Korea ; *COVID-19/prevention & control ; Surveys and Questionnaires ; *Consensus ; Immunization ; Advisory Committees ; SARS-CoV-2 ; Health Policy ; COVID-19 Vaccines ; },
abstract = {BACKGROUND: The Korea Expert Committee on Immunization Practices (KECIP) is a key advisory body the government to develop guidelines and provide technical advisory activities on immunization policies in Korea. A recent policy study, inspired by global best practices, aims to enhance KECIP's functionality for providing timely and transparent recommendations in the face of evolving vaccine science and emerging infectious diseases like COVID-19.

METHODS: This study reviewed the current status of KECIP and collected expert opinions through surveys and consultations. Among the 40 panel members who were surveyed, 19 responded to a questionnaire specifically designed to assess the potential areas of improvement within KECIP.

RESULTS: The majority of respondents favored maintaining the current member count and emphasized the need for a subcommittee. Opinions varied on issues such as the length of KECIP's term, the representation of vaccine manufacturers' perspectives, and the chairperson's role. However, there was a consensus on the importance of expertise, transparency, and fair proceedings within the committee.

CONCLUSION: This study underscores the pivotal role of KECIP in shaping national immunization policies, emphasizing the necessity for informed guidance amidst evolving vaccine science and emerging infectious diseases. Furthermore, it stressed the importance of enhancing KECIP's capacity to effectively address evolving public health challenges and maintain successful immunization programs in South Korea.},
}

Humans
Republic of Korea
*COVID-19/prevention & control
Surveys and Questionnaires
*Consensus
Immunization
Advisory Committees
SARS-CoV-2
Health Policy
COVID-19 Vaccines

@article {pmid38782749,
year = {2024},
author = {, and , and , },
title = {[Expert consensus on the clinical application of oral small-molecule antiviral drugs against COVID-19].},
journal = {Zhonghua yi xue za zhi},
volume = {104},
number = {20},
pages = {1812-1824},
doi = {10.3760/cma.j.cn112137-20240124-00177},
pmid = {38782749},
issn = {0376-2491},
support = {EKPG21-06//Emergency Key Program of Guangzhou Laboratory/ ; 0022/2021/A1//the Macao Science and Technology Development Fund/ ; 2021TQ060189//the Young Top Talent of Science and Technology Innovation Department of Guangdong Province/ ; ZYYCXTU-D-202201//National Administration of Traditional Chinese Medicine's Interdisciplinary Innovation Team Project/ ; },
mesh = {*Antiviral Agents/therapeutic use ; Humans ; *COVID-19 ; *SARS-CoV-2 ; *Pandemics ; Pneumonia, Viral/drug therapy ; COVID-19 Drug Treatment ; Coronavirus Infections/drug therapy ; Consensus ; Betacoronavirus ; Administration, Oral ; China ; Pregnancy ; },
abstract = {Although COVID-19 no longer constitutes a "public health emergency of international concern", which still has being spreading around the world at a low level. Small molecule drugs are the main antiviral treatment for novel coronavirus recommended in China. Although a variety of small-molecule antiviral drugs against COVID-19 have been listed in China, there is no specific drug recommendation for special populations. Society of Bacterial Infection and Resistance of Chinese Medical Association, together with the National Clinical Research Center for Respiratory Disease, and the National Center for Respiratory Medicine, organized domestic experts in various fields such as respiratory, virology, infection, critical care, emergency medicine and pharmacy to release Expert Consensus on the Clinical Application of Oral Small-Molecule Antiviral Drugs against COVID-19. The main content of this consensus includes the introduction of seven small-molecule antiviral drugs against COVID-19, focusing on the drug recommendations for 14 special groups such as the elderly, patients with complicated chronic diseases, tumor patients, pregnant women, and children, and providing suggestions for clinicians to standardize drug use.},
}

*Antiviral Agents/therapeutic use
Humans
*COVID-19
*SARS-CoV-2
*Pandemics
Pneumonia, Viral/drug therapy
COVID-19 Drug Treatment
Coronavirus Infections/drug therapy
Consensus
Betacoronavirus
Administration, Oral
China
Pregnancy

@article {pmid38228543,
year = {2024},
author = {, and , and , },
title = {[Expert consensus on vaccinations in adult patients with autoimmune rheumatic diseases in China (2023 Edition)].},
journal = {Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]},
volume = {58},
number = {1},
pages = {1-10},
doi = {10.3760/cma.j.cn112150-20231018-00274},
pmid = {38228543},
issn = {0253-9624},
mesh = {Adult ; Humans ; COVID-19 Vaccines ; Consensus ; Quality of Life ; Vaccination ; *Influenza Vaccines ; *Rheumatic Diseases ; *Respiratory Distress Syndrome ; },
abstract = {Vaccination is one of the critical tools to prevent infections among individuals with autoimmune rheumatic diseases (ARDs), ultimately improving the quality of life and reducing mortality. The incorporation of vaccination strategies into clinical decision-making processes has been recognized as pivotal. However, the absence of clinical guidelines and consensus on vaccination for ARDs patients still persists in China. Drawing from existing clinical evidence, this expert consensus encompasses eight prevalent vaccines: Influenza vaccine, pneumococcal polysaccharide vaccine, COVID-19 vaccine, herpes zoster vaccine, human papillomavirus vaccine, hepatitis A vaccine, hepatitis B vaccine, and rabies virus vaccine. This initiative aims to furnish highly practical technical directives for vaccination personnel and rheumatologists, thereby fostering standardized vaccination practices to combat infectious diseases among adult ARDs patients in China.},
}

Adult
Humans
COVID-19 Vaccines
Consensus
Quality of Life
Vaccination
*Influenza Vaccines
*Rheumatic Diseases
*Respiratory Distress Syndrome

@article {pmid38156914,
year = {2023},
author = {Wang, J and Shao, L and Liang, J and Wu, Q and Zhu, B and Deng, Q and Liu, Z and Liu, L and Wang, D and Yu, Z and Tan, X and Wang, F and Meng, J and Xu, X and Xia, Z and Li, Z and Wang, H and Wang, L and Wu, W and Xie, Q and Huang, X and Sun, Z and Zhang, Y and Zhou, H and Zhou, H and Yang, W and Ren, H and Liu, Z and Qiao, M and Tang, F and Qi, X and Wu, H and Deng, L and Gao, L and Zhang, H and Chen, P and Zhang, H and Zhang, X and Zhou, J and Chuanqing, TU and Guan, L and Yin, Q and Shu, R and Chen, F and He, M and Wang, Q and Guo, Z and , and , },
title = {Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2.},
journal = {Journal of cancer research and therapeutics},
volume = {19},
number = {6},
pages = {1495-1500},
doi = {10.4103/jcrt.JCRT_782_23},
pmid = {38156914},
issn = {1998-4138},
mesh = {Humans ; SARS-CoV-2 ; *COVID-19 ; Consensus ; *Hematologic Neoplasms/complications/therapy ; China/epidemiology ; },
abstract = {In December 2022, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became dominant in China due to its high infectivity and lower mortality rate. The risk of critical illness and mortality among patients with hematologic malignancies who contracted SARS-CoV-2 was particularly high. The aim of this study was to draft a consensus to facilitate effective treatments for these patients based on the type and severity of the disease. Following the outbreak of the novel coronavirus in China, a steering committee consisting of experienced hematologists was formed by the Specialized Committee of Oncology and Microecology of the Chinese Anti-Cancer Association. The expert group drafted a consensus on the management and intervention measures for different types of hematologic malignancies based on the clinical characteristics of the Omicron variant of the SARS-CoV-2 infection, along with relevant guidelines and literature. The expert group drafted independent recommendations on several important aspects based on the epidemiology of the Omicron variant in China and the unique vulnerability of patients with hematologic malignancies. These included prophylactic vaccinations for those with hematologic malignancies, the use of plasma from blood donors who recovered from the novel coronavirus infection, the establishment of negative pressure wards, the use of steady-state mobilization of peripheral blood hematopoietic stem cells, the provision of psychological support for patients and medical staff, and a focus on maintaining a healthy intestinal microecology.},
}

Humans
SARS-CoV-2
*COVID-19
Consensus
*Hematologic Neoplasms/complications/therapy
China/epidemiology

@article {pmid38044048,
year = {2023},
author = {, },
title = {[Expert consensus on the management of interstitial lung disease during the COVID-19 epidemic].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {46},
number = {12},
pages = {1204-1218},
doi = {10.3760/cma.j.cn112147-20230922-00187},
pmid = {38044048},
issn = {1001-0939},
support = {2022-PUMCH-B-108, 2022-PUMCH-A-130, 2022-PUMCH-C-069//National High Level Hospital Clinical Reseach Funding/ ; },
mesh = {Humans ; *COVID-19 ; *Coinfection ; COVID-19 Vaccines ; Consensus ; *Janus Kinase Inhibitors ; *Lung Diseases, Interstitial/therapy ; Immunosuppressive Agents ; Adrenal Cortex Hormones/therapeutic use ; Receptors, Interleukin-6 ; Biological Factors ; },
abstract = {Coronavirus disease 2019(COVID-19) is prevalent around the world, and pre-existing ILD is associated with increased severity and mortality of COVID-19. However, the current knowledge on the management strategy for COVID-19 patients with pre-existing interstitial lung disease (ILD) is very limited. There is still a need for consensus on treatments for these patients. In addition, ILD that occurs after the acute phase of COVID-19 (Post-acute Covid-19 ILD, PC-ILD) is also very common, and how to manage PC-ILD is also under debate. Therefore, a consensus was established by experts from the related disciplines in the field of ILD based on available scientific evidence and experience of the expert working group. This consensus elucidated 22 practical questions for practicing physicians, such as clinical characteristics, risk factors and treatment of COVID-19 patients with pre-existing ILD and PC-ILD patients. Finally, 15 recommendations were made regarding the diagnosis and management of COVID-19 patients with pre-existing ILD and PC-ILD patients. We hope to assist physicians in making appropriate decisions, thereby improving the management of COVID-19 with pre-existing ILD and PC-ILD.Recommendation 1: It is recommended to differentiate COVID-19 from ILD with acute/subacute onset based on duration, exposure history, symptoms and signs, chest high-resolution CT (HRCT) features, and laboratory tests.Recommendation 2: According to the guidelines on the diagnosis and treatment of new coronavirus pneumonia (version 10) issued by the National Health Commission of China on January 6[th], 2023, we recommended the following disease severity definition and management for the COVID-19 patients with pre-existing ILD.Recommendation 3: ILD is an independent risk factor for severe/critical COVID-19. We recommend antiviral treatment for COVID-19 patients with pre-existing ILD as early as possible after symptoms onset, ideally within 5 days.Recommendation 4: We recommend that the use of systemic corticosteroids in COVID-19 patients with pre-existing ILD who had no indications for corticosteroids therapy should follow the guidelines of COVID-19 for the general population. Those with pre-existing ILD who need to start or are already on systemic corticosteroids are recommended to start or continue corticosteroids if they develop COVID-19. The dose adjustment is based on the severity of COVID-19 with pre-existing ILD: For the patients with severe/critical COVID-19 with pre-existing ILD but no AE-ILD, the use of corticosteroids should follow the guidelines of COVID-19 in the general population; the patients with AE-ILD are recommended to follow the use of corticosteroids in AE-ILD.Recommendation 5: There is no evidence available for the use of interleukin-6 receptor blockers in COVID-19 patients with pre-existing ILD. Recommendations regarding interleukin-6 receptor blockers in COVID-19 patients with pre-existing ILD may follow the guideline of COVID-19 in the general population.Recommendation 6: There is no evidence to support the use of Janus kinase inhibitors in COVID-19 patients with pre-existing ILD. The use of Janus kinase inhibitors in COVID-19 patients with pre-existing ILD is recommended to follow the guideline of COVID-19 in the general population.Recommendation 7: For patients who have not started immunosuppressants/biological agents for pre-existing ILD at the time of COVID-19, delayed initiation of immunosuppressants/biological agents is recommended, if the risk of ILD progression in the short term is low. For patients who are already on immunosuppressants/biological agents, a multidisciplinary discussion with rheumatologists is recommended to weigh the benefits and risks of discontinuing immunosuppressants/biological agents. It is recommended to discontinue immunosuppressants/biological agents for pre-existing ILD in acute phase of COVID-19 unless short-term discontinuation affects control of underlying ILD or connective tissue disease.Recommendation 8: It is recommended that the COVID-19 patients with pre-existing ILD who are on anti-fibrotic medication should continue to take anti-fibrotic medication. For COVID-19 patients with newly diagnosed fibrotic ILD who need to start anti-fibrotic therapy, it is recommended to start anti-fibrotic treatment as early as possible.Recommendation 9: It is recommended to investigate and monitor co-infections and secondary infections in COVID-19 patients with pre-existing ILD, and to promptly prevent and treat co-infections and secondary infections such as bacteria, fungi, Pneumocystis jirovecii, and cytomegalovirus.Recommendation 10: Anticoagulation therapy for the COVID-19 patients with pre-existing ILD is recommended to be used in accordance with guideline of COVID-19 in general population.Recommendation 11: For COVID-19 patients with pre-existing ILD, we recommend follow-up at 4 weeks after recovery (non-hospitalized patients) or 4 weeks after discharge (hospitalized patients), and then the routine monitoring frequency for ILD once stable, i.e. every 3 to 6 months. Pulmonary function testing is a routine investigation. Chest HRCT is suggested when clinically indicated. Arterial blood gas analysis, echocardiography, CT pulmonary angiography, and blood examinations can be selected when necessary.Recommendation 12: Severe/critical COVID-19 survivors are the main target population for rehabilitation intervention. Rehabilitation therapy should be administered individualized.Recommendation 13: Healthcare providers should fully inform patients with pre-existing ILD about the benefits and risks of vaccination, and involve patients in a shared decision-making process to discuss whether or not to receive a COVID-19 vaccine.Recommendation 14: For PC-ILD patients with persistent or progressive respiratory symptoms, persistent interstitial lung abnormalities and lung function impairment following acute COVID-19 pneumonia, may be treated with glucocorticoids after exclusion of other causes such as infection.Recommendation 15: For PC-ILD patients who have recovered from severe/critical COVID-19, anti-fibrotic medications may be administered after discussing disease-and treatment-related factors with patients. The optimal timing and duration of anti-fibrotic treatment are still uncertain. We conditionally recommend against anti-fibrotic medications in patients who have recovered from mild or moderate COVID-19. This recommendation does not apply to patients with pre-existing fibrotic ILD.},
}

Humans
*COVID-19
*Coinfection
COVID-19 Vaccines
Consensus
*Janus Kinase Inhibitors
*Lung Diseases, Interstitial/therapy
Immunosuppressive Agents
Adrenal Cortex Hormones/therapeutic use
Receptors, Interleukin-6
Biological Factors

@article {pmid37805779,
year = {2023},
author = {, and , and , },
title = {[Expert consensus on the clinical treatment of burn patients complicated with Coronavirus infection (2023 version)].},
journal = {Zhonghua shao shang yu chuang mian xiu fu za zhi},
volume = {39},
number = {8},
pages = {701-712},
pmid = {37805779},
issn = {2097-1109},
support = {2021YFA1101100//National Key Research and Development Program of China/ ; cstc2019jcyj-cxttX0001//Innovation Group Science Foundation of Chongqing Natural Science Foundation/ ; },
mesh = {Humans ; Consensus ; *COVID-19 ; Delivery of Health Care ; China ; Burn Units ; },
abstract = {With China downgrading the management of Coronavirus infection (COVID-19) from Category A to Category B, a large number of COVID-19 patients have occurred in multiple waves across the country. Meanwhile, the long-term impact of Coronavirus on the body has gradually been noticed. However, the clinical treatment of burns complicated with COVID-19 is still a major challenge in Chinese burn centers. It is then essential to standardize the clinical treatment of such patients, improve the prognosis to the greatest extent, and provide valuable experiences for similar infectious diseases in future. Therefore, Chinese Burn Association, Burn Medicine Branch of China International Exchange and Promotion Association for Medical and Healthcare, and Editorial Committee of Chinese Journal of Burns and Wounds jointly initiated and organized multidisciplinary experts to develop this expert consensus based on the current medical evidence, clinical practice, and authoritative guidelines of other disciplines, in order to standardize the clinical treatment of burn patients complicated with COVID-19.},
}

Humans
Consensus
*COVID-19
Delivery of Health Care
China
Burn Units

@article {pmid37670643,
year = {2023},
author = {, and , and , and , },
title = {[Expert consensus on the diagnosis and management of Birt-Hogg-Dubé syndrome].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {46},
number = {9},
pages = {897-908},
doi = {10.3760/cma.j.cn112147-20230705-00362},
pmid = {37670643},
issn = {1001-0939},
support = {2022YFC2703901//National Key Reseach and Development Program of China/ ; 2021-I2M-1-003//CAMS Innovation Fund of Medical Sciences/ ; 2021szdzk05//Key Medical and Health Specialty Construction Project of Anhui Province/ ; 2021A1515011352, 2023A1515010308//Natural Science Foundation of Guangdong Province/ ; ZNSA-2020013//Independent Project Funding for Key Projects of Guangzhou Institute of Respiratory Health, Zhongnanshan Medical Foundation of Guangdong Province/ ; },
mesh = {Adult ; Female ; Pregnancy ; Humans ; *Birt-Hogg-Dube Syndrome ; COVID-19 Vaccines ; Consensus ; *Pneumothorax ; Prospective Studies ; *COVID-19 ; SARS-CoV-2 ; *Kidney Neoplasms ; COVID-19 Testing ; },
abstract = {Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disorder characterized by diffuse pulmonary cysts often leading to recurrent spontaneous pneumothorax, cutaneous fibrofolliculomas or trichodiscomas, and a variety of renal cell cancers. It is caused by pathogenic variants in the FLCN gene located on chromosome 17p11.2. Although an increasing number of patients with BHD syndrome are being recognized in China, the missed diagnosis and delayed diagnosis are still common. In addition, appropriate management is difficult for most of them. Pulmonary cysts and pneumothorax are the main presenting features, but skin and renal lesions appear to be less common in Chinese subjects than those reported from European and American countries. Therefore, the consensus is established by experts from the related disciplines to improve the diagnosis and management of BHD syndrome. This consensus consists of 15 recommendations related to BHD syndrome, including clinical assessments, diagnosis, differential diagnosis, treatment, follow-up, and family management. In particular, it provides revised diagnostic criteria based on the Chinese situation. We hope to promote scientific and clinical progress in this rare disease and improve the prognosis of the patients.Summary of recommendations[Recommendation 1] The folliculin (FLCN) gene is currently the only affirmative causative gene for Birt-Hogg-Dubé (BHD) syndrome, and the pedigree analysis of genetic testing of family members' samples can assist in the rapid identification of causative gene variants. The genetic testing methods, including Sanger sequencing, Multiplex Ligation-dependent Probe Amplification (MLPA), and Next-Generation Sequencing (NGS), can be chosen based on individual patient's care needs. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 2] Patients with BHD syndrome should undergo chest CT scan to evaluate cystic lesions in the lungs, and routine evaluation of the kidneys for tumor foci, using ultrasound, enhanced CT, or MR as appropriate. (43 experts voted; 43 in favor, 0 against, 0 abstention).[Recommendation 3] Clinicians should establish a diagnosis based on the appropriate clinical presentation and in conjunction with genetic test results and/or a family history of BHD syndrome. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 4] Lung histopathological biopsy is not recommended as the first choice for patients with suspected BHD syndrome based on clinical and pulmonary imaging manifestations. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 5] BHD syndrome should be particularly distinguished from other diffuse cystic lung diseases, such as lymphangioleiomyomatosis (LAM), lymphocyte interstitial pneumonia (LIP), pulmonary Langerhans cell histiocytosis (PLCH), etc. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 6] BHD syndrome is clinically rare and often involves multiple disciplines, such as respiratory and critical care medicine, radiology, pathology, thoracic surgery, urology, genetics, and dermatology, and multidisciplinary discussions are recommended to improve the diagnosis of BHD syndrome. (43 voting experts; 43 in favor, 0 against, 0 abstentions).[Recommendation 7] Patients with BHD syndrome should avoid smoking, and are recommended to be vaccinated with influenza, pneumococcal, and SARS-Cov-2 vaccines to prevent infections. (43 voting experts; 43 in favor, 0 against, 0 abstentions).[Recommendation 8] Air travel is not recommended for patients with BHD syndrome who have experienced pneumothorax until it has been recovered. (43 voting experts; 42 in favor, 0 against, 1 abstention).[Recommendation 9] In patients with BHD syndrome complicated by pneumothorax, early pleurodesis is recommended to reduce the risk of recurrence. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 10] Observation or topical treatment may be chosen for patients with BHD syndrome complicated by fibrofolliculoma or trichodiscoma. (43 voting experts; 42 in favor, 0 against, 1 abstention).[Recommendation 11] For patients with BHD syndrome complicated by renal tumors, annual abdominal MR examination is recommended when tumors are <1 cm in diameter; when tumors are 1-3 cm in diameter, abdominal MR examination at every 6 months or ablation surgery is recommended; when renal tumors are >3 cm in diameter, local excision of renal tumors with preservation of renal function is recommended. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 12] Patients with BHD syndrome are associated with significantly increased risks of kidney cancer, and routine screenings of kidney cancer during their lifetime are recommended. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 13] Couples with BHD syndrome are advised to undergo prenatal genetic counseling when preparing for pregnancy, to work with a prenatal diagnostician to assess genetic risk, and to discuss the feasibility of prenatal diagnosis during pregnancy. (43 experts voted; 43 in favor, 0 against, 0 abstention).[Recommendation 14] Family members of patients with BHD syndrome should receive health education, and FLCN gene testing is recommended for asymptomatic adults to rule out BHD syndrome in a timely manner. (43 voting experts; 43 in favor, 0 against, 0 abstention).[Recommendation 15] Improvements in the clinical diagnosis and treatment of BHD syndrome and overall management are needed. Due to the scarcity of effective therapeutic drugs, multicenter, prospective clinical trials are recommended. (43 experts voted; 43 in favor, 0 against, 0 abstention).},
}

Adult
Female
Pregnancy
Humans
*Birt-Hogg-Dube Syndrome
COVID-19 Vaccines
Consensus
*Pneumothorax
Prospective Studies
*COVID-19
SARS-CoV-2
*Kidney Neoplasms
COVID-19 Testing

@article {pmid37466079,
year = {2023},
author = {Tyo, MB and McCurry, MK},
title = {e-Delphi Study: Expert Consensus on the Needs and Resources Available to Family Caregivers of Individuals with Substance Use Disorder.},
journal = {Substance use & misuse},
volume = {58},
number = {12},
pages = {1560-1573},
doi = {10.1080/10826084.2023.2236203},
pmid = {37466079},
issn = {1532-2491},
mesh = {Humans ; Caregivers ; Consensus ; Delphi Technique ; Pandemics ; *COVID-19 ; *Substance-Related Disorders/therapy ; },
abstract = {Family caregivers of individuals with substance use disorder (SUD) experience a significant burden and have few evidence-based resources available. To obtain a consensus of expert views on the needs, and resources available, to family caregivers of individuals with SUD given the COVID-19 pandemic and other sociopolitical factors. Quantitative design using the Classic e-Delphi method of multiple iterations of questioning to reach a consensus among expert panelists. Purposive sampling was used to recruit a multidisciplinary, nationwide panel of SUD experts from professional contacts, professional organization list servers, websites relevant to support groups for family caregivers, flyers, and word of mouth. In round 1 panelists (n = 96) responded to open-ended questions about the support provided to family caregivers, and the additional needs of family caregivers. In subsequent rounds, the panel rated collated responses in terms of agreement (n = 54) and importance (n = 48). Thematic content analysis identified ten needs in the resources available to family caregivers. Consensus was obtained across thematic categories and the remaining items were ranked according to importance. Participatory-based SUD research that includes the expertise of healthcare providers, support leaders, and family caregivers is necessary to develop evidence-based interventions to increase caregiver resilience and facilitate coping. Several clear conclusions that address social and structural determinants of health emerged, including the need for increased access to healthcare and community services, more self-care strategies for families, and focused public advocacy to reduce SUD-related stigma.},
}

Humans
Caregivers
Consensus
Delphi Technique
Pandemics
*COVID-19
*Substance-Related Disorders/therapy

@article {pmid37438079,
year = {2023},
author = {, and , and , },
title = {[Expert Consensus on the prevention and treatment of indolent B-cell non-Hodgkin lymphoma with novel coronavirus infection].},
journal = {Zhonghua yi xue za zhi},
volume = {103},
number = {26},
pages = {1980-1985},
pmid = {37438079},
issn = {0376-2491},
mesh = {Humans ; *COVID-19 ; COVID-19 Vaccines ; Consensus ; SARS-CoV-2 ; *Lymphoma, B-Cell/therapy ; *Lymphoma, Non-Hodgkin/therapy ; },
abstract = {Indolent B-cell non-Hodgkin lymphoma (B-iNHL) is a group of mature B-cell lymphomas that develop slowly. It is characterized by low immune function and could be risky when complicated with novel coronavirus infection (COVID-19). In order to guide the prevention and treatment of B-iNHL combined with COVID-19, China Anti-Cancer Association Hematological malignancies Committee, the Chinese Society of Hematology Medical Association and Chinese Chronic lymphoproliferative Diseases Working Group formed consensus on COVID-19 vaccination, prognosis, treatment and follow-up of B-iNHL patients for clinician reference.},
}

Humans
*COVID-19
COVID-19 Vaccines
Consensus
SARS-CoV-2
*Lymphoma, B-Cell/therapy
*Lymphoma, Non-Hodgkin/therapy

@article {pmid37035881,
year = {2023},
author = {, and , },
title = {Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer.},
journal = {Zhongguo fei ai za zhi = Chinese journal of lung cancer},
volume = {26},
number = {3},
pages = {165-176},
pmid = {37035881},
issn = {1999-6187},
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; *Lung Neoplasms/complications/drug therapy ; Consensus ; Vaccination ; China/epidemiology ; },
abstract = {Corona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to "protect people's health and prevent severe cases". Patients with lung cancer who receive antitumor therapy have low immunity, and the risk of severe illness and death once infected is much higher than healthy people, so they are vulnerable to COVID-19 infection. At present, less attention has been paid to the prevention and treatment of COVID-19 infection in patients with lung cancer in domestic guidelines and consensus. Based on the published data in China and abroad, we proposed recommendations and formed expert consensus on the vaccination of COVID-19, the use of neutralizing antibodies and small molecule antiviral drugs for patients with lung cancer, for physician's reference.},
}

Humans
*COVID-19
SARS-CoV-2
*Lung Neoplasms/complications/drug therapy
Consensus
Vaccination
China/epidemiology

@article {pmid35353681,
year = {2022},
author = {Carrasco-Sánchez, FJ and Carretero-Anibarro, E and Gargallo, MÁ and Gómez-Huelgas, R and Merino-Torres, JF and Orozco-Beltrán, D and Pines Corrales, PJ and Ruiz Quintero, MA},
title = {Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19.},
journal = {Endocrinologia, diabetes y nutricion},
volume = {69},
number = {3},
pages = {209-218},
pmid = {35353681},
issn = {2530-0180},
mesh = {Humans ; *COVID-19 ; *Diabetes Mellitus, Type 2/complications/drug therapy ; *Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use ; Pandemics ; },
abstract = {BACKGROUND: This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.

MATERIALS AND METHODS: A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.

RESULTS: Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and the need for mechanical ventilation (evidence 2b).

CONCLUSIONS: The use of iDPP-4 appears to be safe in patients with COVID-19, and quality studies are needed to clarify their possible advantages further.},
}

Humans
*COVID-19
*Diabetes Mellitus, Type 2/complications/drug therapy
*Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use
Pandemics

@article {pmid41368508,
year = {2025},
author = {Kim, CG},
title = {Hospice and Palliative Care Response Policy During the Coronavirus Disease 2019 (COVID-19) Pandemic in South Korea.},
journal = {Journal of hospice and palliative care},
volume = {28},
number = {4},
pages = {138-151},
doi = {10.14475/jhpc.2025.28.4.138},
pmid = {41368508},
issn = {2765-3080},
abstract = {South Korea received international acclaim for its rapid response to the initial coronavirus disease 2019 (COVID-19) pandemic crisis through the "K-Quarantine" model, successfully managing it without closing its borders; however, terminally ill patients awaiting death in 19 public hospice facilities (83.4%/297 beds) had to vacate their beds to accommodate patients with COVID-19. This study examines and analyzed South Korea's hospice response policies during the pandemic. It draws on empirical data from domestic and international literature reviews and relevant websites. This study aimed to provide foundational data and policy recommendations for future pandemic preparedness. The findings revealed that, owing to the national response policy focused on infectious disease control and hospital bed allocation, 21 of the 88 inpatient hospice units in South Korea were closed, with their beds repurposed Therefore, hospice palliative care services became a "negotiable service" largely excluded from pandemic response policies. Strict visitation policies lowered hospice service utilization and disrupted service continuity. Emergency care support helped to mitigate care gaps; however, hospice care was limited in addressing patients' specialized needs, demonstrating structural fragmentation within the health and welfare systems. In conclusion, South Korea's hospice and palliative care response policy to the COVID-19 pandemic has failed to meet the essential goal of hospice palliative care: enhancing patient dignity and quality of life. To strengthen preparedness for future pandemics, designating specialized hospice institutions as essential health facilities, establishing infrastructure stabilization funds, developing a crisis-responsive payment systems, are essential.},
}

@article {pmid41368135,
year = {2025},
author = {Folorunsho, EF and Malabu, UH and Anderson, E and Malau-Aduli, BS},
title = {A Systematic Review of Emotional, Cognitive, and Logistical Factors Influencing Simulated Patient Performance in Simulation-Based Education.},
journal = {Advances in medical education and practice},
volume = {16},
number = {},
pages = {2229-2247},
doi = {10.2147/AMEP.S548904},
pmid = {41368135},
issn = {1179-7258},
abstract = {PURPOSE: Simulated patients (SPs) are critical to simulation-based education (SBE) in developing learners' clinical, communication, and professional skills. However, limited research has examined the factors influencing SP performance and consequent learning outcomes.

PATIENTS AND METHODS: We conducted a systematic review (2013-2025) using six databases, focusing on human SPs in healthcare education. Nineteen studies met the inclusion criteria and were analyzed using inductive thematic analysis. Study quality was assessed using the QATSDD tool.

RESULTS: Inductive thematic analysis identified three key domains influencing SP performance: emotional (anxiety, fulfillment), cognitive (task complexity, improvisation), and logistical (training, scheduling). SP involvement enhanced educational outcomes (empathy, communication, clinical reasoning) but was sometimes limited by SP fatigue, stress, or cognitive overload. Among the reviewed studies, 7 were high and 12 were of medium quality (no low-quality studies).

CONCLUSION: Authentic SP portrayals enhance student learning, but factors such as emotional strain and cognitive load can limit effectiveness. We recommend structured SP training, robust feedback mechanisms, and attention to SP cognitive and cultural challenges. Future research should prioritize long-term SP outcomes, measurement of SP cognitive load, and exploration of ethical and cultural dimensions of SP engagement.},
}

@article {pmid41366790,
year = {2025},
author = {Razi-Soofiyani, S and Saadat, YR and Vahed, SZ and Saghaleini, SH and Nakhjavani, MJ and Abediazar, S},
title = {Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations.},
journal = {Virology journal},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12985-025-03032-x},
pmid = {41366790},
issn = {1743-422X},
support = {77930//Tabriz University of Medical Sciences/ ; },
abstract = {Infection by SARS-CoV-2 has contributed to more than four million deaths worldwide. Based on clinical observations, it has been revealed that the virus can easily disturb the function of various organs in the body. Besides its main damage to the respiratory system, the extra-pulmonary manifestations are deemed to be common in affected patients even after COVID-19 vaccination. COVID-19 has been accompanied by various types of skin manifestations, including varicella-like exanthemas, dengue-like petechial rashes, or urticarial eruptions. However, not only have viral rashes been related to COVID-19, but also other types of skin symptoms that are reminiscent of a vascular disease, such as acro-ischaemic lesions. This literature review aims to provide information on various forms of COVID-19-induced vasculitis and vasculitis following vaccination. It has been hypothesized that various forms of vasculitis can be considered as pathological consequences following SARS-CoV-2 infection. Numerous suggested mechanisms are involved in vasculitis, including the deregulation of the immune system, increased activation of mastocyte, augmented production of proinflammatory cytokines, which in turn lead to indirect endothelial damage, complement system activation, recruitment of neutrophils, and deposition of immune complexes. Based on previous studies, the mRNA-based COVID-19 vaccine is much more implicated in relation to vasculitis. SARS-CoV-2 and COVID-19 vaccination lead to the onset and relapse of different types of vasculitis that should be clinically evaluated by exact monitoring.},
}

@article {pmid41366372,
year = {2025},
author = {Alqahtani, MA and Toloo, GS},
title = {Disaster management knowledge, education and training among Saudi paramedics a scoping review.},
journal = {BMC public health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12889-025-25218-2},
pmid = {41366372},
issn = {1471-2458},
abstract = {BACKGROUND AND AIM: Appropriate disaster knowledge, education and training are essential elements for adequate disaster preparedness. This is particularly evident for paramedics who are integral part of frontline disaster response teams. No reviews evaluated the published research on this subject within the Saudi context. The present review aimed to analyze the published studies on Saudi paramedics' knowledge, education and training in the context of disaster management.

METHODS: The present review was synthesized according 5-stage process: (1) Identification of the research question, (2) Identification of relevant studies, (3) Study selection, (4) Charting the data (5) Collating, summarizing and reporting the results.

RESULTS: Sixteen studies were included in final analysis. The vast majority of included studies (15, 93.8%) were published in last 6 years. The location of the included studies was Riyadh (8, 50.0%), Mecca (3, 19.0%), multiple provinces (3, 19.0%) and other provinces (2, 12.5%). Study design also varied with 9 studies (56.3%) following a descriptive design, 5 studies (31.3%) using mixed methods and 2 studies (12.5%) using a quasi-experimental design. The study sample included paramedics or paramedic students in 13 studies (81.3%) among other healthcare workers while only 3 studies (18.8%) studies were exclusively conducted on paramedic students. Thematic analysis of data extracted form included studies identified three themes: (1) Knowledge/awareness about COVID-19 pandemic preparedness; (2) Knowledge about other disasters and (3) Disaster education and training.

CONCLUSIONS: Research output from Saudi Arabia on paramedics' involvement in disaster knowledge, education and training has mostly emerged in the last six years and mainly focused on the two cities of Riyadh and Mecca. There a paucity of interventional and qualitative studies. Also, few studies exclusively included paramedics or paramedical students.},
}

@article {pmid41363008,
year = {2025},
author = {Yazdani, B and Sirous, H and Farzam, F and Ansarizadeh, S and Karimi Taheri, M and Pourmohammad-Hosseini, G and Noei, M and Daneshipour, K and Shakeri, D and Houshangi, M and Calderone, V and Brogi, S},
title = {In Silico Exploration of Potential Inhibitors Targeting SARS-CoV-2 Non-Structural Protein 15 (Nsp15): A Comprehensive Overview of Current Research.},
journal = {Chemical biology & drug design},
volume = {106},
number = {6},
pages = {e70218},
doi = {10.1111/cbdd.70218},
pmid = {41363008},
issn = {1747-0285},
support = {2402233//Isfahan University of Medical Sciences/ ; },
mesh = {*Viral Nonstructural Proteins/antagonists & inhibitors/metabolism/chemistry ; *Antiviral Agents/chemistry/pharmacology ; Humans ; SARS-CoV-2/drug effects ; Computer Simulation ; COVID-19 ; *Betacoronavirus/drug effects ; COVID-19 Drug Treatment ; Molecular Docking Simulation ; *Endoribonucleases/antagonists & inhibitors/metabolism/chemistry ; Protein Binding ; },
abstract = {The SARS-CoV-2 nonstructural protein 15 (Nsp15) is an endoribonuclease that plays a critical role in viral replication and immune evasion through its NendoU domain. The unique enzymatic mechanism of Nsp15 has attracted considerable attention as a potential therapeutic target, and the identification of its inhibitors could facilitate the development of novel antiviral agents against coronaviruses. Although biochemical and structural studies have provided important insights into Nsp15 function, no comprehensive review has yet focused on computational approaches applied to the discovery of Nsp15 inhibitors. Consequently, this study aims to address this gap by summarizing recent in silico research focused on the structure, function, and inhibition of Nsp15. Special attention is given to inhibitors derived from both natural and synthetic sources, as well as their binding interactions and predicted pharmacological potential. By integrating current computational findings, this review highlights novel prospects for the rational design of Nsp15-targeted therapeutics to combat SARS-CoV-2 and other related pathogenic coronaviruses.},
}

*Viral Nonstructural Proteins/antagonists & inhibitors/metabolism/chemistry
*Antiviral Agents/chemistry/pharmacology
Humans
SARS-CoV-2/drug effects
Computer Simulation
COVID-19
*Betacoronavirus/drug effects
COVID-19 Drug Treatment
Molecular Docking Simulation
*Endoribonucleases/antagonists & inhibitors/metabolism/chemistry
Protein Binding

@article {pmid41361900,
year = {2025},
author = {Vedlog Kveen, K and Lilier, K and Råberg Kjøllesdal, MK and Naranjo-Zolotov, M and Lapanun, P and Veiga, I and Dias, S and Overgaard, HJ and Bärnighausen, K},
title = {Public health messaging and community engagement during COVID-19: a rapid-review from the Greater Mekong Subregion.},
journal = {One health outlook},
volume = {7},
number = {1},
pages = {61},
pmid = {41361900},
issn = {2524-4655},
abstract = {BACKGROUND: The COVID-19 pandemic highlighted the importance of public health messaging and community engagement in reducing disease transmission. This rapid review analyzes these approaches in the Greater Mekong Subregion (GMS), a hotspot for emerging infectious diseases, to help inform future pandemic preparedness and response strategies.

METHODS: This rapid review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Checklist. We used Web of Science and PubMed databases. Articles were included if they addressed COVID-19-related public health messaging and/or community engagement initiatives, focused on countries within the GMS, were published in English between 2020 and 2024, and provided full-text access. Articles focusing on unrelated topics, such as vaccine development or adverse effects of the pandemic were excluded. Data extraction was performed using a calibrated data extraction sheet, with two researchers extracting and verifying the data.

RESULTS: After the screening process, 26 articles were included, and 24 were excluded. Three articles use qualitative methods, five articles use quantitative approaches, eleven articles are identified as descriptive and seven are literature reviews. In most countries the government employed a centralized strategy for streamlined and coherent communication using traditional media, social media and mobile applications. Vietnam demonstrated an innovative and inclusive approach to risk communication, leveraging creative approaches such as songs and slogans to disseminate messages. Thailand effectively utilized its pre-existing network of village health volunteers to inform community members, though marginalized groups remained hard to reach.

CONCLUSION: The GMS employed diverse public health messaging and community engagement strategies during COVID-19. Our findings emphasize the importance of adaptable and inclusive strategies to ensure equitable public health outcomes in future pandemics.},
}

@article {pmid41360485,
year = {2025},
author = {Anyikwa, CL},
title = {Global health and the dialectics of solidarity through Ubuntu and European perspectives.},
journal = {BMJ global health},
volume = {10},
number = {12},
pages = {},
pmid = {41360485},
issn = {2059-7908},
mesh = {Humans ; *Global Health ; COVID-19/epidemiology ; Europe ; SARS-CoV-2 ; *Social Responsibility ; Pandemics ; International Cooperation ; },
abstract = {The concept of solidarity plays a central role in shaping both African and European cultural responses to social and political challenges, although its interpretations diverge significantly. In African societies, solidarity is rooted in the relational philosophy of ubuntu, where individual identity is understood as inseparable from the community, emphasising collective well-being and mutual care. This is reflected in practices, such as community-based caregiving for the sick and elderly, traditional healing networks and shared child-rearing. In parts of West Africa, for example among the Igbo, co-wives may sleep over at the home of a bereaved wife to provide emotional support and boost morale during mourning.In contrast, European models of solidarity are often institutionalised and rights-based, focusing on balancing individual autonomy with collective welfare within legal frameworks. This paper explores these two distinct approaches to solidarity and examines their implications in global health, especially in the context of the COVID-19 pandemic and other global health crises. Ubuntu's emphasis on communal responsibility offers a valuable framework for addressing health inequities, suggesting that global health is a shared responsibility that transcends national borders and individual interests. Conversely, European solidarity, shaped by enlightenment principles and liberal democratic traditions, often prioritises individual rights and institutional mechanisms to ensure health equity. This dialectical exploration highlights the evolving nature of solidarity in a globalised world, where African and European models of solidarity are increasingly hybridised to address global health disparities. Drawing on examples such as the Ritshidze community-led HIV care monitoring initiative in South Africa, alongside international efforts like COVAX, this paper evaluates how solidarity, in both its African and European forms, can influence global health policy and collective action, promoting more inclusive and equitable health systems worldwide.},
}

Humans
*Global Health
COVID-19/epidemiology
Europe
SARS-CoV-2
*Social Responsibility
Pandemics
International Cooperation

@article {pmid41360478,
year = {2025},
author = {Zhou, W and Chen, C and Qi, J and Chen, M and Yuan, Z and Miao, J and Chen, J and Jiang, D and Yang, M and Du, Y and Cao, K and Wu, X and You, Y and Chen, D and Qu, R and Yang, S},
title = {Adherence to handwashing behaviour and its impact on the incidence and death of viral respiratory infectious diseases: a systematic review, meta-analysis and modelling study.},
journal = {BMJ global health},
volume = {10},
number = {12},
pages = {},
pmid = {41360478},
issn = {2059-7908},
mesh = {Humans ; *Hand Disinfection ; Incidence ; *COVID-19/prevention & control/mortality ; *Respiratory Tract Infections/prevention & control/mortality/epidemiology ; *Guideline Adherence/statistics & numerical data ; *Virus Diseases/mortality/prevention & control/epidemiology ; Pandemics ; SARS-CoV-2 ; Global Health ; },
abstract = {OBJECTIVES: Washing hands is considered an effective way for preventing viral respiratory infections. This study systematically investigated the global and regional adherence to hand-washing behaviour and its impact on the incidence and death of viral respiratory infectious diseases (VRIDs).

METHODS: In our systematic review and meta-analysis, we searched PubMed, Embase, Web of Science and Scopus for related studies. We included observational studies with raw data of adherence to handwashing (rates of acceptability of handwashing, daily habitual handwashing and key-moment handwashing) during VRID pandemics/epidemics. Pooled rates and effect of handwashing were calculated by random-effects model and generalised linear model.

RESULTS: We analysed 108 articles, generating 227 datasets. During VRID epidemics/pandemics, the global pooled rate of daily handwashing was 72.23% (95% CI 66.95% to 76.95%). The lowest rate was observed in Africa (pooled rate 59.46%, 95% CI 50.73% to 67.68%) and among public transportation workers (18.15%, 95% CI 6.54% to 41.26%). Global pooled rate of key moment handwashing was 65.11% (95% CI 59.74% to 70.28%), with the lowest rate being after handshaking (36.40%, 95% CI 18.49% to 56.52%) and among the elderly (22.86%, 95% CI 16.77% to 29.58%) and was higher during the COVID-19 pandemic than the 2009 H1N1 pandemic (72.02% vs 31.33%). The pooled rate of global acceptability of handwashing was 90.01% (95% CI 83.73% to 94.05%). Key-moment handwashing was associated with a reduction in COVID-19 incidence (β=-151.1, p=0.010), COVID-19 mortality (β=-0.066, p<0.001) and other COVID-19 related deaths (β=-0.112, p<0.001).

CONCLUSION: During the VRID epidemics/pandemics, the handwashing behaviour adherence was relatively low. Health education efforts targeting public transportation workers and the elderly should be intensified. Augmented key-moment handwashing adherence potentially led to a significant reduction of the incidence and death of VRIDs.

PROSPERO REGISTRATION NUMBER: CRD42024499090.},
}

Humans
*Hand Disinfection
Incidence
*COVID-19/prevention & control/mortality
*Respiratory Tract Infections/prevention & control/mortality/epidemiology
*Guideline Adherence/statistics & numerical data
*Virus Diseases/mortality/prevention & control/epidemiology
Pandemics
SARS-CoV-2
Global Health

@article {pmid41360360,
year = {2025},
author = {Pillay, TS and Rampul, A and Subramoney, EL and van Deventer, BS and van Niekerk, C and Gwiliza, S},
title = {The double-edged role of point-of-care testing in modern medicine.},
journal = {Clinica chimica acta; international journal of clinical chemistry},
volume = {},
number = {},
pages = {120770},
doi = {10.1016/j.cca.2025.120770},
pmid = {41360360},
issn = {1873-3492},
abstract = {Point-of-care testing (POCT) has emerged as a transformative force in clinical diagnostics, enabling rapid, near-patient testing that can expedite decision-making, improve patient outcomes, and expand access to care. This review critically examines the double-edged nature of POCT, balancing its clear clinical and operational advantages against persistent challenges of accuracy, quality assurance, governance, and cost-effectiveness. The scope of POCT technologies ranges from simple lateral-flow assays to advanced molecular platforms, increasingly integrated with digital health ecosystems. Their clinical utility is evident in emergency medicine, chronic disease management, and resource-limited settings, where timely results reduce delays, hospital stays, and downstream complications, while supporting personalized and preventive care. The COVID-19 pandemic further highlighted the flexibility and scalability of POCT during public health emergencies. However, these benefits are countered by risks of variable analytical performance, inadequate training of non-laboratory operators, fragmented data integration, and economic trade-offs from high per-test costs and potential overuse. Governance frameworks-anchored in ISO 22870 (and now ISO 15189:2022), rigorous quality management, connectivity solutions, and multidisciplinary oversight-are essential to ensuring safe, effective, and sustainable implementation. Successful programs demonstrate that strong laboratory leadership, continuous training, and robust data integration mitigate risks while maximizing impact. Ultimately, POCT should be viewed not as a replacement but as a complement to central laboratory services, whose value is realized only through thoughtful deployment and governance. With advancing technology and improved oversight, POCT can be harnessed as a powerful adjunct in modern healthcare, turning its double-edged potential into a precise tool for patient-centered diagnostics.},
}

@article {pmid41359142,
year = {2025},
author = {Dikamu, M and Syraji, Y and Pr, J and K, G and Raza, A and Ezez, D},
title = {Nanotechnology in COVID-19 prevention, diagnosis, and treatment: a comprehensive review.},
journal = {Discover nano},
volume = {20},
number = {1},
pages = {225},
pmid = {41359142},
issn = {2731-9229},
abstract = {The worst of the COVID-19 (coronavirus disease 2019) pandemic may be over, but its impact continues to be felt worldwide. During the outbreak, medical regulatory authorities introduced several principles for outbreak control, with the World Health Organization emphasizing three key strategies: prevention, early detection, and treatment. In this context, technological advancements have played a critical role, particularly nanotechnology, which has emerged as a promising platform for medical innovation. Its applications span multiple sectors, including healthcare, environmental protection, and diagnostics. These applications offer unmatched potential to enhance personal protective equipment, develop antiviral surface coatings, and engineer rapid point-of-care diagnostics. Nanotechnology contributed significantly to combating COVID-19, enhancing prevention through nanofiber-enhanced masks and nanoparticle-based disinfectants; facilitating diagnosis via gold nanoparticles (AuNPs) and magnetic nanoparticle biosensors, quantum dots, and artificial intelligence-integrated nanosensors; and supporting treatment efforts through lipid nanoparticle (LNP) vaccines, virus-like particles, and targeted drug delivery systems. We highlight key nanomaterials such as silver nanoparticles, copper nanoparticles, AuNPs, zinc oxide nanoparticles, and selenium nanoparticles, alongside advanced formulations like LNPs and polymeric nanocarriers, exploring their mechanisms of viral inactivation, sensitive detection, and controlled delivery of therapeutics. Furthermore, this review addresses critical regulatory and translational challenges and post-pandemic adaptations of nanotechnologies for emerging viral threats.},
}

@article {pmid41359099,
year = {2025},
author = {Ramanan, RS and Kesavan, KV and Ravikumar, V},
title = {Pulmonary fibrosis in post-COVID-19: epithelial-mesenchymal transition as a key mechanism and target for therapy.},
journal = {Inflammopharmacology},
volume = {},
number = {},
pages = {},
pmid = {41359099},
issn = {1568-5608},
support = {VIR/COVID-19/6/2021/ECD-I//Indian Council of Medical Research/ ; },
abstract = {Pulmonary fibrosis is a serious threat to global health, especially in after math of covid-19 infection, eventually results in fibrotic remodeling and organ damage. This SARS-CoV 2 induced fibrosis initiates cascade of proinflammatory responses such as cytokine release. EMT (Epithelial-mesenchymal transition) is a central event in post COVID 19 pulmonary fibrosis which is characterized by the accumulation of stimulated fibroblast and myoblast, finally epithelial morphology changed to mesenchymal traits. This transformation is marked by the loss of intercellular adhesion and polarity. A study of SARS-CoV 2 pathogenesis and EMT can provide insights to pulmonary fibrosis. Hence identification of biomarkers of EMT activation helps early diagnosis and determination of therapeutic approaches against pathogenesis. This review focusing on the mechanism of post-covid 19 pulmonary fibrosis through EMT with a special importance to TGF-β/Smad, NF-κB pathways and oxidative stress. Previous studies marked the EMT induced fibronectin, collagen deposition that can potentially disrupt lung structure and its function. SARS CoV 2 infection can trigger Hyper activation of profibrotic pathways like TGF-β/Smad, NF-κB pathways that maintain EMT via downregulation of E-Cadherin and upregulation of vimentin, fibronectin and α-SMA. SARS-CoV spike-protein binds to AEC-2 cells initiates cytokine storm followed by amplified NF-κB pathway, and oxidative stress. Elevated activation of this pathway increases Snail, Slug, Twist expression that leads to EMT. Moreover, increased ROS production creates fibrotic environment in lung. This review examined the mechanism behind the pulmonary fibrosis by analyzing interplay between the SARS-CoV 2 infection and EMT, providing effective therapeutic strategies to prevent EMT.},
}

@article {pmid41358652,
year = {2025},
author = {Gadsby, E and King, E and Bell, M and Wong, G and Kendall, S},
title = {Health visiting in the UK in light of the COVID-19 pandemic experience (RReHOPE): study synopsis.},
journal = {Health and social care delivery research},
volume = {13},
number = {42},
pages = {1-28},
doi = {10.3310/GJEG0402},
pmid = {41358652},
issn = {2755-0079},
mesh = {Humans ; *COVID-19/epidemiology ; United Kingdom/epidemiology ; SARS-CoV-2 ; Pandemics ; Delivery of Health Care/organization & administration ; },
abstract = {BACKGROUND: The COVID-19 pandemic interrupted and, in some cases, transformed the way health visiting teams work, the way they interact with families and children and with the wider community and other service providers. Health visiting services are organised, delivered and experienced differently in different places, with little evidence to suggest what works best, for whom and in what contexts.

OBJECTIVE: To synthesise the evidence on changes during the pandemic to identify the potential for improving health visiting services and their delivery in the United Kingdom.

METHODS: This realist review engaged professional stakeholders (N = 28) and those caring for babies during the pandemic (N = 6) throughout the process. We searched five electronic databases for publications on health visiting during the COVID-19 pandemic from October 2022 to April 2023. This was followed by citation searching and review of organisational websites. Programme theory was iteratively refined through discussions with the team, professional stakeholders and people with lived experience and was translated into key findings and recommendations.

RESULTS: One hundred and eighteen documents informed this review; most focused on health visiting in England (56%) or the United Kingdom (34%), with relatively few from Wales (6%), Scotland (3%) and Northern Ireland (1%). Documents highlighted the widespread, uneven and lasting impact of the COVID-19 pandemic on babies and families. Findings revealed significant concerns expressed by both families and practitioners and corresponding actions taken by health visiting services. These concerns and responses emphasised the flexibility and resourcefulness of health visitors, the vital role of trusting relationships between health visitors and families and the importance of holistic assessments for early intervention. Changes in service delivery were varied and were not always evaluated or sustainable. While the data illuminated some of the hidden complexities of health visiting practice, limited evidence was found on decision-making at organisational and managerial levels during the pandemic response.

EVIDENCE LIMITATIONS: Included papers were predominantly from an advocacy or practitioner perspective, and few focused on health visiting in Scotland, Wales and Northern Ireland. Our focus on the universal health visiting pathways meant that documents pertaining to additional support received by the most vulnerable families might have been excluded. Experiences of Black, Asian and minority ethnic families and staff were illustrated in several papers.

CONCLUSIONS: The COVID-19 pandemic highlighted the essential role of health visitors in safeguarding child and family well-being in the United Kingdom. While digital adaptations provide necessary continuity, face-to-face interactions remain essential for effective health visiting. The crisis exposed pre-existing workforce pressures and inconsistencies in service provision, emphasising the need for adequate support and funding. Policy-makers must recognise the complexity of health visiting and ensure sustained investment in universal home visiting services. Future resilience requires a realistic understanding of health visitors' work, integration into broader child health policies and enhanced interagency collaboration to address inequalities and improve long-term public health outcomes.

FUTURE WORK: Our implications for policy-makers will be translated into reflexive questions to prompt critical thinking about health visiting services in local areas. The small number of documents from countries outside England highlights this as a key area for future research.

FUNDING: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme as award number NIHR134986.},
}

Humans
*COVID-19/epidemiology
United Kingdom/epidemiology
SARS-CoV-2
Pandemics
Delivery of Health Care/organization & administration